#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Altered brainstem responses to modafinil in schizophrenia: implications for adjunctive treatment of cognition
#Text=Candidate pro-cognitive drugs for schizophrenia targeting several neurochemical systems have consistently failed to demonstrate robust efficacy.
1-1	0-7	Altered	_	
1-2	8-17	brainstem	_	
1-3	18-27	responses	_	
1-4	28-30	to	_	
1-5	31-40	modafinil	_	
1-6	41-43	in	_	
1-7	44-57	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
1-8	57-58	:	_	
1-9	59-71	implications	_	
1-10	72-75	for	_	
1-11	76-86	adjunctive	_	
1-12	87-96	treatment	_	
1-13	97-99	of	_	
1-14	100-109	cognition	_	
1-15	110-119	Candidate	_	
1-16	120-133	pro-cognitive	_	
1-17	134-139	drugs	_	
1-18	140-143	for	_	
1-19	144-157	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
1-20	158-167	targeting	_	
1-21	168-175	several	_	
1-22	176-189	neurochemical	_	
1-23	190-197	systems	_	
1-24	198-202	have	_	
1-25	203-215	consistently	_	
1-26	216-222	failed	_	
1-27	223-225	to	_	
1-28	226-237	demonstrate	_	
1-29	238-244	robust	_	
1-30	245-253	efficacy	_	
1-31	253-254	.	_	

#Text=It remains untested whether concurrent antipsychotic medications exert pharmacodynamic interactions that mitigate pro-cognitive action in patients.
2-1	255-257	It	_	
2-2	258-265	remains	_	
2-3	266-274	untested	_	
2-4	275-282	whether	_	
2-5	283-293	concurrent	_	
2-6	294-307	antipsychotic	_	
2-7	308-319	medications	_	
2-8	320-325	exert	_	
2-9	326-341	pharmacodynamic	_	
2-10	342-354	interactions	_	
2-11	355-359	that	_	
2-12	360-368	mitigate	_	
2-13	369-382	pro-cognitive	_	
2-14	383-389	action	_	
2-15	390-392	in	_	
2-16	393-401	patients	_	
2-17	401-402	.	_	

#Text=We used functional MRI (fMRI) in a randomized, double-blind, placebo-controlled within-subject crossover test of single-dose modafinil effects in 27 medicated schizophrenia patients, interrogating brainstem regions where catecholamine systems arise to innervate the cortex, to link cellular and systems-level models of cognitive control.
3-1	403-405	We	_	
3-2	406-410	used	_	
3-3	411-421	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[1]	
3-4	422-425	MRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[1]	
3-5	426-427	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[1]	
3-6	427-431	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[1]	
3-7	431-432	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[1]	
3-8	433-435	in	_	
3-9	436-437	a	_	
3-10	438-448	randomized	_	
3-11	448-449	,	_	
3-12	450-462	double-blind	_	
3-13	462-463	,	_	
3-14	464-482	placebo-controlled	_	
3-15	483-497	within-subject	_	
3-16	498-507	crossover	_	
3-17	508-512	test	_	
3-18	513-515	of	_	
3-19	516-527	single-dose	_	
3-20	528-537	modafinil	_	
3-21	538-545	effects	_	
3-22	546-548	in	_	
3-23	549-551	27	_	
3-24	552-561	medicated	_	
3-25	562-575	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
3-26	576-584	patients	_	
3-27	584-585	,	_	
3-28	586-599	interrogating	_	
3-29	600-609	brainstem	_	
3-30	610-617	regions	_	
3-31	618-623	where	_	
3-32	624-637	catecholamine	_	
3-33	638-645	systems	_	
3-34	646-651	arise	_	
3-35	652-654	to	_	
3-36	655-664	innervate	_	
3-37	665-668	the	_	
3-38	669-675	cortex	_	
3-39	675-676	,	_	
3-40	677-679	to	_	
3-41	680-684	link	_	
3-42	685-693	cellular	_	
3-43	694-697	and	_	
3-44	698-711	systems-level	_	
3-45	712-718	models	_	
3-46	719-721	of	_	
3-47	722-731	cognitive	_	
3-48	732-739	control	_	
3-49	739-740	.	_	

#Text=Modafinil effects were evaluated both within this patient group and compared to a healthy subject group.
4-1	741-750	Modafinil	_	
4-2	751-758	effects	_	
4-3	759-763	were	_	
4-4	764-773	evaluated	_	
4-5	774-778	both	_	
4-6	779-785	within	_	
4-7	786-790	this	_	
4-8	791-798	patient	_	
4-9	799-804	group	_	
4-10	805-808	and	_	
4-11	809-817	compared	_	
4-12	818-820	to	_	
4-13	821-822	a	_	
4-14	823-830	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[2]	
4-15	831-838	subject	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[2]	
4-16	839-844	group	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[2]	
4-17	844-845	.	_	

#Text=Modafinil modulated activity in the locus coeruleus (LC) and ventral tegmental area (VTA) in the patient group.
5-1	846-855	Modafinil	_	
5-2	856-865	modulated	_	
5-3	866-874	activity	_	
5-4	875-877	in	_	
5-5	878-881	the	_	
5-6	882-887	locus	_	
5-7	888-897	coeruleus	_	
5-8	898-899	(	_	
5-9	899-901	LC	_	
5-10	901-902	)	_	
5-11	903-906	and	_	
5-12	907-914	ventral	_	
5-13	915-924	tegmental	_	
5-14	925-929	area	_	
5-15	930-931	(	_	
5-16	931-934	VTA	_	
5-17	934-935	)	_	
5-18	936-938	in	_	
5-19	939-942	the	_	
5-20	943-950	patient	_	
5-21	951-956	group	_	
5-22	956-957	.	_	

#Text=However, compared to the healthy comparison group, these effects were altered as a function of task demands: the control-independent drug effect on deactivation was relatively attenuated (shallower) in the LC and exaggerated (deeper) in the VTA; in contrast, again compared to the comparison group, the control-related drug effects on positive activation were attenuated in LC, VTA and the cortical cognitive control network.
6-1	958-965	However	_	
6-2	965-966	,	_	
6-3	967-975	compared	_	
6-4	976-978	to	_	
6-5	979-982	the	_	
6-6	983-990	healthy	_	
6-7	991-1001	comparison	_	
6-8	1002-1007	group	_	
6-9	1007-1008	,	_	
6-10	1009-1014	these	_	
6-11	1015-1022	effects	_	
6-12	1023-1027	were	_	
6-13	1028-1035	altered	_	
6-14	1036-1038	as	_	
6-15	1039-1040	a	_	
6-16	1041-1049	function	_	
6-17	1050-1052	of	_	
6-18	1053-1057	task	_	
6-19	1058-1065	demands	_	
6-20	1065-1066	:	_	
6-21	1067-1070	the	_	
6-22	1071-1090	control-independent	_	
6-23	1091-1095	drug	_	
6-24	1096-1102	effect	_	
6-25	1103-1105	on	_	
6-26	1106-1118	deactivation	_	
6-27	1119-1122	was	_	
6-28	1123-1133	relatively	_	
6-29	1134-1144	attenuated	_	
6-30	1145-1146	(	_	
6-31	1146-1155	shallower	_	
6-32	1155-1156	)	_	
6-33	1157-1159	in	_	
6-34	1160-1163	the	_	
6-35	1164-1166	LC	_	
6-36	1167-1170	and	_	
6-37	1171-1182	exaggerated	_	
6-38	1183-1184	(	_	
6-39	1184-1190	deeper	_	
6-40	1190-1191	)	_	
6-41	1192-1194	in	_	
6-42	1195-1198	the	_	
6-43	1199-1202	VTA	_	
6-44	1202-1203	;	_	
6-45	1204-1206	in	_	
6-46	1207-1215	contrast	_	
6-47	1215-1216	,	_	
6-48	1217-1222	again	_	
6-49	1223-1231	compared	_	
6-50	1232-1234	to	_	
6-51	1235-1238	the	_	
6-52	1239-1249	comparison	_	
6-53	1250-1255	group	_	
6-54	1255-1256	,	_	
6-55	1257-1260	the	_	
6-56	1261-1276	control-related	_	
6-57	1277-1281	drug	_	
6-58	1282-1289	effects	_	
6-59	1290-1292	on	_	
6-60	1293-1301	positive	_	
6-61	1302-1312	activation	_	
6-62	1313-1317	were	_	
6-63	1318-1328	attenuated	_	
6-64	1329-1331	in	_	
6-65	1332-1334	LC	_	
6-66	1334-1335	,	_	
6-67	1336-1339	VTA	_	
6-68	1340-1343	and	_	
6-69	1344-1347	the	_	
6-70	1348-1356	cortical	_	
6-71	1357-1366	cognitive	_	
6-72	1367-1374	control	_	
6-73	1375-1382	network	_	
6-74	1382-1383	.	_	

#Text=These altered effects in the LC and VTA were significantly and specifically associated with the degree of antagonism of alpha-2 adrenergic and dopamine-2 receptors, respectively, by concurrently prescribed antipsychotics.
7-1	1384-1389	These	_	
7-2	1390-1397	altered	_	
7-3	1398-1405	effects	_	
7-4	1406-1408	in	_	
7-5	1409-1412	the	_	
7-6	1413-1415	LC	_	
7-7	1416-1419	and	_	
7-8	1420-1423	VTA	_	
7-9	1424-1428	were	_	
7-10	1429-1442	significantly	_	
7-11	1443-1446	and	_	
7-12	1447-1459	specifically	_	
7-13	1460-1470	associated	_	
7-14	1471-1475	with	_	
7-15	1476-1479	the	_	
7-16	1480-1486	degree	_	
7-17	1487-1489	of	_	
7-18	1490-1500	antagonism	_	
7-19	1501-1503	of	_	
7-20	1504-1509	alpha	_	
7-21	1509-1510	-	_	
7-22	1510-1511	2	_	
7-23	1512-1522	adrenergic	_	
7-24	1523-1526	and	_	
7-25	1527-1535	dopamine	_	
7-26	1535-1536	-	_	
7-27	1536-1537	2	_	
7-28	1538-1547	receptors	_	
7-29	1547-1548	,	_	
7-30	1549-1561	respectively	_	
7-31	1561-1562	,	_	
7-32	1563-1565	by	_	
7-33	1566-1578	concurrently	_	
7-34	1579-1589	prescribed	_	
7-35	1590-1604	antipsychotics	_	
7-36	1604-1605	.	_	

#Text=These sources of evidence suggest interacting effects on catecholamine neurons of chronic antipsychotic treatment, which respectively increase and decrease sustained neuronal activity in LC and VTA.
8-1	1606-1611	These	_	
8-2	1612-1619	sources	_	
8-3	1620-1622	of	_	
8-4	1623-1631	evidence	_	
8-5	1632-1639	suggest	_	
8-6	1640-1651	interacting	_	
8-7	1652-1659	effects	_	
8-8	1660-1662	on	_	
8-9	1663-1676	catecholamine	_	
8-10	1677-1684	neurons	_	
8-11	1685-1687	of	_	
8-12	1688-1695	chronic	_	
8-13	1696-1709	antipsychotic	_	
8-14	1710-1719	treatment	_	
8-15	1719-1720	,	_	
8-16	1721-1726	which	_	
8-17	1727-1739	respectively	_	
8-18	1740-1748	increase	_	
8-19	1749-1752	and	_	
8-20	1753-1761	decrease	_	
8-21	1762-1771	sustained	_	
8-22	1772-1780	neuronal	_	
8-23	1781-1789	activity	_	
8-24	1790-1792	in	_	
8-25	1793-1795	LC	_	
8-26	1796-1799	and	_	
8-27	1800-1803	VTA	_	
8-28	1803-1804	.	_	

#Text=This is the first direct evidence in a clinical population to suggest that antipsychotic medications alter catecholamine neuronal activity to mitigate pro-cognitive drug action on cortical circuits.
9-1	1805-1809	This	_	
9-2	1810-1812	is	_	
9-3	1813-1816	the	_	
9-4	1817-1822	first	_	
9-5	1823-1829	direct	_	
9-6	1830-1838	evidence	_	
9-7	1839-1841	in	_	
9-8	1842-1843	a	_	
9-9	1844-1852	clinical	_	
9-10	1853-1863	population	_	
9-11	1864-1866	to	_	
9-12	1867-1874	suggest	_	
9-13	1875-1879	that	_	
9-14	1880-1893	antipsychotic	_	
9-15	1894-1905	medications	_	
9-16	1906-1911	alter	_	
9-17	1912-1925	catecholamine	_	
9-18	1926-1934	neuronal	_	
9-19	1935-1943	activity	_	
9-20	1944-1946	to	_	
9-21	1947-1955	mitigate	_	
9-22	1956-1969	pro-cognitive	_	
9-23	1970-1974	drug	_	
9-24	1975-1981	action	_	
9-25	1982-1984	on	_	
9-26	1985-1993	cortical	_	
9-27	1994-2002	circuits	_	
9-28	2002-2003	.	_	

#Text=Introduction
#Text=Schizophrenia is a common, severe, high-impact disorder with cognitive deficits representing a critical determinant of clinical outcome.
10-1	2004-2016	Introduction	_	
10-2	2017-2030	Schizophrenia	_	
10-3	2031-2033	is	_	
10-4	2034-2035	a	_	
10-5	2036-2042	common	_	
10-6	2042-2043	,	_	
10-7	2044-2050	severe	_	
10-8	2050-2051	,	_	
10-9	2052-2063	high-impact	_	
10-10	2064-2072	disorder	_	
10-11	2073-2077	with	_	
10-12	2078-2087	cognitive	_	
10-13	2088-2096	deficits	_	
10-14	2097-2109	representing	_	
10-15	2110-2111	a	_	
10-16	2112-2120	critical	_	
10-17	2121-2132	determinant	_	
10-18	2133-2135	of	_	
10-19	2136-2144	clinical	_	
10-20	2145-2152	outcome	_	
10-21	2152-2153	.	_	

#Text=Cognitive impairment is particularly important among processes that are highly dependent on cortical networks operated by the prefrontal cortex (PFC).
11-1	2154-2163	Cognitive	_	
11-2	2164-2174	impairment	_	
11-3	2175-2177	is	_	
11-4	2178-2190	particularly	_	
11-5	2191-2200	important	_	
11-6	2201-2206	among	_	
11-7	2207-2216	processes	_	
11-8	2217-2221	that	_	
11-9	2222-2225	are	_	
11-10	2226-2232	highly	_	
11-11	2233-2242	dependent	_	
11-12	2243-2245	on	_	
11-13	2246-2254	cortical	_	
11-14	2255-2263	networks	_	
11-15	2264-2272	operated	_	
11-16	2273-2275	by	_	
11-17	2276-2279	the	_	
11-18	2280-2290	prefrontal	_	
11-19	2291-2297	cortex	_	
11-20	2298-2299	(	_	
11-21	2299-2302	PFC	_	
11-22	2302-2303	)	_	
11-23	2303-2304	.	_	

#Text=Presently, there is no established treatment for cognitive impairment in schizophrenia, and therefore, advances in this research area have the potential to alleviate a considerable global illness burden.
12-1	2305-2314	Presently	_	
12-2	2314-2315	,	_	
12-3	2316-2321	there	_	
12-4	2322-2324	is	_	
12-5	2325-2327	no	_	
12-6	2328-2339	established	_	
12-7	2340-2349	treatment	_	
12-8	2350-2353	for	_	
12-9	2354-2363	cognitive	_	
12-10	2364-2374	impairment	_	
12-11	2375-2377	in	_	
12-12	2378-2391	schizophrenia	_	
12-13	2391-2392	,	_	
12-14	2393-2396	and	_	
12-15	2397-2406	therefore	_	
12-16	2406-2407	,	_	
12-17	2408-2416	advances	_	
12-18	2417-2419	in	_	
12-19	2420-2424	this	_	
12-20	2425-2433	research	_	
12-21	2434-2438	area	_	
12-22	2439-2443	have	_	
12-23	2444-2447	the	_	
12-24	2448-2457	potential	_	
12-25	2458-2460	to	_	
12-26	2461-2470	alleviate	_	
12-27	2471-2472	a	_	
12-28	2473-2485	considerable	_	
12-29	2486-2492	global	_	
12-30	2493-2500	illness	_	
12-31	2501-2507	burden	_	
12-32	2507-2508	.	_	

#Text=Two major candidate neural targets for the remediation of PFC dysfunction in schizophrenia are the catecholamine systems arising from the pontine locus coeruleus (LC) and midbrain ventral tegmental area (VTA), which use norepinephrine (NE) and dopamine (DA) respectively as neurotransmitters.
13-1	2509-2512	Two	_	
13-2	2513-2518	major	_	
13-3	2519-2528	candidate	_	
13-4	2529-2535	neural	_	
13-5	2536-2543	targets	_	
13-6	2544-2547	for	_	
13-7	2548-2551	the	_	
13-8	2552-2563	remediation	_	
13-9	2564-2566	of	_	
13-10	2567-2570	PFC	_	
13-11	2571-2582	dysfunction	_	
13-12	2583-2585	in	_	
13-13	2586-2599	schizophrenia	_	
13-14	2600-2603	are	_	
13-15	2604-2607	the	_	
13-16	2608-2621	catecholamine	_	
13-17	2622-2629	systems	_	
13-18	2630-2637	arising	_	
13-19	2638-2642	from	_	
13-20	2643-2646	the	_	
13-21	2647-2654	pontine	_	
13-22	2655-2660	locus	_	
13-23	2661-2670	coeruleus	_	
13-24	2671-2672	(	_	
13-25	2672-2674	LC	_	
13-26	2674-2675	)	_	
13-27	2676-2679	and	_	
13-28	2680-2688	midbrain	_	
13-29	2689-2696	ventral	_	
13-30	2697-2706	tegmental	_	
13-31	2707-2711	area	_	
13-32	2712-2713	(	_	
13-33	2713-2716	VTA	_	
13-34	2716-2717	)	_	
13-35	2717-2718	,	_	
13-36	2719-2724	which	_	
13-37	2725-2728	use	_	
13-38	2729-2743	norepinephrine	_	
13-39	2744-2745	(	_	
13-40	2745-2747	NE	_	
13-41	2747-2748	)	_	
13-42	2749-2752	and	_	
13-43	2753-2761	dopamine	_	
13-44	2762-2763	(	_	
13-45	2763-2765	DA	_	
13-46	2765-2766	)	_	
13-47	2767-2779	respectively	_	
13-48	2780-2782	as	_	
13-49	2783-2800	neurotransmitters	_	
13-50	2800-2801	.	_	

#Text=These systems project widely throughout the cortex, and are well-suited to modulate widely-distributed neural networks such as those engaged by the PFC during higher-order cognition.
14-1	2802-2807	These	_	
14-2	2808-2815	systems	_	
14-3	2816-2823	project	_	
14-4	2824-2830	widely	_	
14-5	2831-2841	throughout	_	
14-6	2842-2845	the	_	
14-7	2846-2852	cortex	_	
14-8	2852-2853	,	_	
14-9	2854-2857	and	_	
14-10	2858-2861	are	_	
14-11	2862-2873	well-suited	_	
14-12	2874-2876	to	_	
14-13	2877-2885	modulate	_	
14-14	2886-2904	widely-distributed	_	
14-15	2905-2911	neural	_	
14-16	2912-2920	networks	_	
14-17	2921-2925	such	_	
14-18	2926-2928	as	_	
14-19	2929-2934	those	_	
14-20	2935-2942	engaged	_	
14-21	2943-2945	by	_	
14-22	2946-2949	the	_	
14-23	2950-2953	PFC	_	
14-24	2954-2960	during	_	
14-25	2961-2973	higher-order	_	
14-26	2974-2983	cognition	_	
14-27	2983-2984	.	_	

#Text=Indeed, there is ample evidence in both animal models and humans that NE and DA strongly modulate PFC neurons, PFC-operated networks, and PFC-dependent cognitive processes such as working memory and cognitive control.
#Text=a Cellular model of modafinil action on LC-NE neuron, indicating how NET inhibition (red Xs on schematic neuron in second row) by modafinil increases NE at the cell-body α2 autoreceptor, leading to moderately-slowed tonic discharge rate, and increased NE release (via both enhanced task-related discharge and terminal NET inhibition). b Hypothetical model of inverted-U curve relating control-related catecholamine cell activity to tonic activity, and the relative effects of NET inhibition by modafinil in healthy subjects (HC) vs. subjects with schizophrenia (SZ).
15-1	2985-2991	Indeed	_	
15-2	2991-2992	,	_	
15-3	2993-2998	there	_	
15-4	2999-3001	is	_	
15-5	3002-3007	ample	_	
15-6	3008-3016	evidence	_	
15-7	3017-3019	in	_	
15-8	3020-3024	both	_	
15-9	3025-3031	animal	_	
15-10	3032-3038	models	_	
15-11	3039-3042	and	_	
15-12	3043-3049	humans	_	
15-13	3050-3054	that	_	
15-14	3055-3057	NE	_	
15-15	3058-3061	and	_	
15-16	3062-3064	DA	_	
15-17	3065-3073	strongly	_	
15-18	3074-3082	modulate	_	
15-19	3083-3086	PFC	_	
15-20	3087-3094	neurons	_	
15-21	3094-3095	,	_	
15-22	3096-3108	PFC-operated	_	
15-23	3109-3117	networks	_	
15-24	3117-3118	,	_	
15-25	3119-3122	and	_	
15-26	3123-3136	PFC-dependent	_	
15-27	3137-3146	cognitive	_	
15-28	3147-3156	processes	_	
15-29	3157-3161	such	_	
15-30	3162-3164	as	_	
15-31	3165-3172	working	_	
15-32	3173-3179	memory	_	
15-33	3180-3183	and	_	
15-34	3184-3193	cognitive	_	
15-35	3194-3201	control	_	
15-36	3201-3202	.	_	
15-37	3203-3204	a	_	
15-38	3205-3213	Cellular	_	
15-39	3214-3219	model	_	
15-40	3220-3222	of	_	
15-41	3223-3232	modafinil	_	
15-42	3233-3239	action	_	
15-43	3240-3242	on	_	
15-44	3243-3248	LC-NE	_	
15-45	3249-3255	neuron	_	
15-46	3255-3256	,	_	
15-47	3257-3267	indicating	_	
15-48	3268-3271	how	_	
15-49	3272-3275	NET	_	
15-50	3276-3286	inhibition	_	
15-51	3287-3288	(	_	
15-52	3288-3291	red	_	
15-53	3292-3294	Xs	_	
15-54	3295-3297	on	_	
15-55	3298-3307	schematic	_	
15-56	3308-3314	neuron	_	
15-57	3315-3317	in	_	
15-58	3318-3324	second	_	
15-59	3325-3328	row	_	
15-60	3328-3329	)	_	
15-61	3330-3332	by	_	
15-62	3333-3342	modafinil	_	
15-63	3343-3352	increases	_	
15-64	3353-3355	NE	_	
15-65	3356-3358	at	_	
15-66	3359-3362	the	_	
15-67	3363-3372	cell-body	_	
15-68	3373-3375	α2	_	
15-69	3376-3388	autoreceptor	_	
15-70	3388-3389	,	_	
15-71	3390-3397	leading	_	
15-72	3398-3400	to	_	
15-73	3401-3418	moderately-slowed	_	
15-74	3419-3424	tonic	_	
15-75	3425-3434	discharge	_	
15-76	3435-3439	rate	_	
15-77	3439-3440	,	_	
15-78	3441-3444	and	_	
15-79	3445-3454	increased	_	
15-80	3455-3457	NE	_	
15-81	3458-3465	release	_	
15-82	3466-3467	(	_	
15-83	3467-3470	via	_	
15-84	3471-3475	both	_	
15-85	3476-3484	enhanced	_	
15-86	3485-3497	task-related	_	
15-87	3498-3507	discharge	_	
15-88	3508-3511	and	_	
15-89	3512-3520	terminal	_	
15-90	3521-3524	NET	_	
15-91	3525-3535	inhibition	_	
15-92	3535-3536	)	_	
15-93	3536-3537	.	_	
15-94	3538-3539	b	_	
15-95	3540-3552	Hypothetical	_	
15-96	3553-3558	model	_	
15-97	3559-3561	of	_	
15-98	3562-3572	inverted-U	_	
15-99	3573-3578	curve	_	
15-100	3579-3587	relating	_	
15-101	3588-3603	control-related	_	
15-102	3604-3617	catecholamine	_	
15-103	3618-3622	cell	_	
15-104	3623-3631	activity	_	
15-105	3632-3634	to	_	
15-106	3635-3640	tonic	_	
15-107	3641-3649	activity	_	
15-108	3649-3650	,	_	
15-109	3651-3654	and	_	
15-110	3655-3658	the	_	
15-111	3659-3667	relative	_	
15-112	3668-3675	effects	_	
15-113	3676-3678	of	_	
15-114	3679-3682	NET	_	
15-115	3683-3693	inhibition	_	
15-116	3694-3696	by	_	
15-117	3697-3706	modafinil	_	
15-118	3707-3709	in	_	
15-119	3710-3717	healthy	_	
15-120	3718-3726	subjects	_	
15-121	3727-3728	(	_	
15-122	3728-3730	HC	_	
15-123	3730-3731	)	_	
15-124	3732-3734	vs	_	
15-125	3734-3735	.	_	
15-126	3736-3744	subjects	_	
15-127	3745-3749	with	_	
15-128	3750-3763	schizophrenia	_	
15-129	3764-3765	(	_	
15-130	3765-3767	SZ	_	
15-131	3767-3768	)	_	
15-132	3768-3769	.	_	

#Text=The present results suggest that compared to HC, the SZ group exhibits relatively less control-independent deactivation in the LC (blue), relatively greater control-independent deactivation in the VTA (blue), and less control-related positive activation in both LC and VTA (red).
16-1	3770-3773	The	_	
16-2	3774-3781	present	_	
16-3	3782-3789	results	_	
16-4	3790-3797	suggest	_	
16-5	3798-3802	that	_	
16-6	3803-3811	compared	_	
16-7	3812-3814	to	_	
16-8	3815-3817	HC	_	
16-9	3817-3818	,	_	
16-10	3819-3822	the	_	
16-11	3823-3825	SZ	_	
16-12	3826-3831	group	_	
16-13	3832-3840	exhibits	_	
16-14	3841-3851	relatively	_	
16-15	3852-3856	less	_	
16-16	3857-3876	control-independent	_	
16-17	3877-3889	deactivation	_	
16-18	3890-3892	in	_	
16-19	3893-3896	the	_	
16-20	3897-3899	LC	_	
16-21	3900-3901	(	_	
16-22	3901-3905	blue	_	
16-23	3905-3906	)	_	
16-24	3906-3907	,	_	
16-25	3908-3918	relatively	_	
16-26	3919-3926	greater	_	
16-27	3927-3946	control-independent	_	
16-28	3947-3959	deactivation	_	
16-29	3960-3962	in	_	
16-30	3963-3966	the	_	
16-31	3967-3970	VTA	_	
16-32	3971-3972	(	_	
16-33	3972-3976	blue	_	
16-34	3976-3977	)	_	
16-35	3977-3978	,	_	
16-36	3979-3982	and	_	
16-37	3983-3987	less	_	
16-38	3988-4003	control-related	_	
16-39	4004-4012	positive	_	
16-40	4013-4023	activation	_	
16-41	4024-4026	in	_	
16-42	4027-4031	both	_	
16-43	4032-4034	LC	_	
16-44	4035-4038	and	_	
16-45	4039-4042	VTA	_	
16-46	4043-4044	(	_	
16-47	4044-4047	red	_	
16-48	4047-4048	)	_	
16-49	4048-4049	.	_	

#Text=Figures modified from Invernizzi and Garattini, 2004, and Aston-Jones and Cohen, 
#Text=Models of catecholamine neuronal activity suggest that optimization of cortical networks and cognition arises from robust catecholamine neuronal responses to task-relevant information.
17-1	4050-4057	Figures	_	
17-2	4058-4066	modified	_	
17-3	4067-4071	from	_	
17-4	4072-4082	Invernizzi	_	
17-5	4083-4086	and	_	
17-6	4087-4096	Garattini	_	
17-7	4096-4097	,	_	
17-8	4098-4102	2004	_	
17-9	4102-4103	,	_	
17-10	4104-4107	and	_	
17-11	4108-4119	Aston-Jones	_	
17-12	4120-4123	and	_	
17-13	4124-4129	Cohen	_	
17-14	4129-4130	,	_	
17-15	4132-4138	Models	_	
17-16	4139-4141	of	_	
17-17	4142-4155	catecholamine	_	
17-18	4156-4164	neuronal	_	
17-19	4165-4173	activity	_	
17-20	4174-4181	suggest	_	
17-21	4182-4186	that	_	
17-22	4187-4199	optimization	_	
17-23	4200-4202	of	_	
17-24	4203-4211	cortical	_	
17-25	4212-4220	networks	_	
17-26	4221-4224	and	_	
17-27	4225-4234	cognition	_	
17-28	4235-4241	arises	_	
17-29	4242-4246	from	_	
17-30	4247-4253	robust	_	
17-31	4254-4267	catecholamine	_	
17-32	4268-4276	neuronal	_	
17-33	4277-4286	responses	_	
17-34	4287-4289	to	_	
17-35	4290-4303	task-relevant	_	
17-36	4304-4315	information	_	
17-37	4315-4316	.	_	

#Text=These responses in turn require a moderate level of tonic, background activity, which tends to be a function of behavioral state (see inverted-U-shaped curve in Fig. 1b).
18-1	4317-4322	These	_	
18-2	4323-4332	responses	_	
18-3	4333-4335	in	_	
18-4	4336-4340	turn	_	
18-5	4341-4348	require	_	
18-6	4349-4350	a	_	
18-7	4351-4359	moderate	_	
18-8	4360-4365	level	_	
18-9	4366-4368	of	_	
18-10	4369-4374	tonic	_	
18-11	4374-4375	,	_	
18-12	4376-4386	background	_	
18-13	4387-4395	activity	_	
18-14	4395-4396	,	_	
18-15	4397-4402	which	_	
18-16	4403-4408	tends	_	
18-17	4409-4411	to	_	
18-18	4412-4414	be	_	
18-19	4415-4416	a	_	
18-20	4417-4425	function	_	
18-21	4426-4428	of	_	
18-22	4429-4439	behavioral	_	
18-23	4440-4445	state	_	
18-24	4446-4447	(	_	
18-25	4447-4450	see	_	
18-26	4451-4468	inverted-U-shaped	_	
18-27	4469-4474	curve	_	
18-28	4475-4477	in	_	
18-29	4478-4481	Fig	_	
18-30	4481-4482	.	_	
18-31	4483-4485	1b	_	
18-32	4485-4486	)	_	
18-33	4486-4487	.	_	

#Text=Computational modeling suggests that modest slowing of tonic background activity of catecholamine neurons may be ideal for enhancing their responsiveness to task-relevant stimuli.
19-1	4488-4501	Computational	_	
19-2	4502-4510	modeling	_	
19-3	4511-4519	suggests	_	
19-4	4520-4524	that	_	
19-5	4525-4531	modest	_	
19-6	4532-4539	slowing	_	
19-7	4540-4542	of	_	
19-8	4543-4548	tonic	_	
19-9	4549-4559	background	_	
19-10	4560-4568	activity	_	
19-11	4569-4571	of	_	
19-12	4572-4585	catecholamine	_	
19-13	4586-4593	neurons	_	
19-14	4594-4597	may	_	
19-15	4598-4600	be	_	
19-16	4601-4606	ideal	_	
19-17	4607-4610	for	_	
19-18	4611-4620	enhancing	_	
19-19	4621-4626	their	_	
19-20	4627-4641	responsiveness	_	
19-21	4642-4644	to	_	
19-22	4645-4658	task-relevant	_	
19-23	4659-4666	stimuli	_	
19-24	4666-4667	.	_	

#Text=This can be achieved pharmacologically with moderate inhibition of plasma-membrane catecholamine transport, which increases catecholamine-mediated activation of inhibitory cell-body autoreceptors (Fig. 1a).
20-1	4668-4672	This	_	
20-2	4673-4676	can	_	
20-3	4677-4679	be	_	
20-4	4680-4688	achieved	_	
20-5	4689-4706	pharmacologically	_	
20-6	4707-4711	with	_	
20-7	4712-4720	moderate	_	
20-8	4721-4731	inhibition	_	
20-9	4732-4734	of	_	
20-10	4735-4750	plasma-membrane	_	
20-11	4751-4764	catecholamine	_	
20-12	4765-4774	transport	_	
20-13	4774-4775	,	_	
20-14	4776-4781	which	_	
20-15	4782-4791	increases	_	
20-16	4792-4814	catecholamine-mediated	_	
20-17	4815-4825	activation	_	
20-18	4826-4828	of	_	
20-19	4829-4839	inhibitory	_	
20-20	4840-4849	cell-body	_	
20-21	4850-4863	autoreceptors	_	
20-22	4864-4865	(	_	
20-23	4865-4868	Fig	_	
20-24	4868-4869	.	_	
20-25	4870-4872	1a	_	
20-26	4872-4873	)	_	
20-27	4873-4874	.	_	

#Text=We have previously shown that modafinil, a low-potency inhibitor of transporters for NE (NET) and DA (DAT) (reviewed in ref.) modulates the LC and the cortical network subserving cognitive control, in a manner consistent with this cellular model of pro-cognitive action.
21-1	4875-4877	We	_	
21-2	4878-4882	have	_	
21-3	4883-4893	previously	_	
21-4	4894-4899	shown	_	
21-5	4900-4904	that	_	
21-6	4905-4914	modafinil	_	
21-7	4914-4915	,	_	
21-8	4916-4917	a	_	
21-9	4918-4929	low-potency	_	
21-10	4930-4939	inhibitor	_	
21-11	4940-4942	of	_	
21-12	4943-4955	transporters	_	
21-13	4956-4959	for	_	
21-14	4960-4962	NE	_	
21-15	4963-4964	(	_	
21-16	4964-4967	NET	_	
21-17	4967-4968	)	_	
21-18	4969-4972	and	_	
21-19	4973-4975	DA	_	
21-20	4976-4977	(	_	
21-21	4977-4980	DAT	_	
21-22	4980-4981	)	_	
21-23	4982-4983	(	_	
21-24	4983-4991	reviewed	_	
21-25	4992-4994	in	_	
21-26	4995-4998	ref	_	
21-27	4998-4999	.	_	
21-28	4999-5000	)	_	
21-29	5001-5010	modulates	_	
21-30	5011-5014	the	_	
21-31	5015-5017	LC	_	
21-32	5018-5021	and	_	
21-33	5022-5025	the	_	
21-34	5026-5034	cortical	_	
21-35	5035-5042	network	_	
21-36	5043-5053	subserving	_	
21-37	5054-5063	cognitive	_	
21-38	5064-5071	control	_	
21-39	5071-5072	,	_	
21-40	5073-5075	in	_	
21-41	5076-5077	a	_	
21-42	5078-5084	manner	_	
21-43	5085-5095	consistent	_	
21-44	5096-5100	with	_	
21-45	5101-5105	this	_	
21-46	5106-5114	cellular	_	
21-47	5115-5120	model	_	
21-48	5121-5123	of	_	
21-49	5124-5137	pro-cognitive	_	
21-50	5138-5144	action	_	
21-51	5144-5145	.	_	

#Text=This mechanism therefore serves as an important model for the pharmacological modulation of PFC-based networks to remediate cognition in schizophrenia, and could form the basis for modafinil effects on brain function and cognition observed in other studies of schizophrenia.
22-1	5146-5150	This	_	
22-2	5151-5160	mechanism	_	
22-3	5161-5170	therefore	_	
22-4	5171-5177	serves	_	
22-5	5178-5180	as	_	
22-6	5181-5183	an	_	
22-7	5184-5193	important	_	
22-8	5194-5199	model	_	
22-9	5200-5203	for	_	
22-10	5204-5207	the	_	
22-11	5208-5223	pharmacological	_	
22-12	5224-5234	modulation	_	
22-13	5235-5237	of	_	
22-14	5238-5247	PFC-based	_	
22-15	5248-5256	networks	_	
22-16	5257-5259	to	_	
22-17	5260-5269	remediate	_	
22-18	5270-5279	cognition	_	
22-19	5280-5282	in	_	
22-20	5283-5296	schizophrenia	_	
22-21	5296-5297	,	_	
22-22	5298-5301	and	_	
22-23	5302-5307	could	_	
22-24	5308-5312	form	_	
22-25	5313-5316	the	_	
22-26	5317-5322	basis	_	
22-27	5323-5326	for	_	
22-28	5327-5336	modafinil	_	
22-29	5337-5344	effects	_	
22-30	5345-5347	on	_	
22-31	5348-5353	brain	_	
22-32	5354-5362	function	_	
22-33	5363-5366	and	_	
22-34	5367-5376	cognition	_	
22-35	5377-5385	observed	_	
22-36	5386-5388	in	_	
22-37	5389-5394	other	_	
22-38	5395-5402	studies	_	
22-39	5403-5405	of	_	
22-40	5406-5419	schizophrenia	_	
22-41	5419-5420	.	_	

#Text=Despite the intense interest and resources that the scientific, clinical, regulatory communities and industry have dedicated to cognition in schizophrenia, to date numerous pharmacological strategies (targeting a wide range of neurochemical systems) have shown minimal or inconsistent efficacy in clinical trials.
23-1	5421-5428	Despite	_	
23-2	5429-5432	the	_	
23-3	5433-5440	intense	_	
23-4	5441-5449	interest	_	
23-5	5450-5453	and	_	
23-6	5454-5463	resources	_	
23-7	5464-5468	that	_	
23-8	5469-5472	the	_	
23-9	5473-5483	scientific	_	
23-10	5483-5484	,	_	
23-11	5485-5493	clinical	_	
23-12	5493-5494	,	_	
23-13	5495-5505	regulatory	_	
23-14	5506-5517	communities	_	
23-15	5518-5521	and	_	
23-16	5522-5530	industry	_	
23-17	5531-5535	have	_	
23-18	5536-5545	dedicated	_	
23-19	5546-5548	to	_	
23-20	5549-5558	cognition	_	
23-21	5559-5561	in	_	
23-22	5562-5575	schizophrenia	_	
23-23	5575-5576	,	_	
23-24	5577-5579	to	_	
23-25	5580-5584	date	_	
23-26	5585-5593	numerous	_	
23-27	5594-5609	pharmacological	_	
23-28	5610-5620	strategies	_	
23-29	5621-5622	(	_	
23-30	5622-5631	targeting	_	
23-31	5632-5633	a	_	
23-32	5634-5638	wide	_	
23-33	5639-5644	range	_	
23-34	5645-5647	of	_	
23-35	5648-5661	neurochemical	_	
23-36	5662-5669	systems	_	
23-37	5669-5670	)	_	
23-38	5671-5675	have	_	
23-39	5676-5681	shown	_	
23-40	5682-5689	minimal	_	
23-41	5690-5692	or	_	
23-42	5693-5705	inconsistent	_	
23-43	5706-5714	efficacy	_	
23-44	5715-5717	in	_	
23-45	5718-5726	clinical	_	
23-46	5727-5733	trials	_	
23-47	5733-5734	.	_	

#Text=One important and under-addressed factor driving these results could be that antipsychotic medications mitigate the impact of candidate pro-cognitive agents through pharmacodynamic mechanisms.
24-1	5735-5738	One	_	
24-2	5739-5748	important	_	
24-3	5749-5752	and	_	
24-4	5753-5768	under-addressed	_	
24-5	5769-5775	factor	_	
24-6	5776-5783	driving	_	
24-7	5784-5789	these	_	
24-8	5790-5797	results	_	
24-9	5798-5803	could	_	
24-10	5804-5806	be	_	
24-11	5807-5811	that	_	
24-12	5812-5825	antipsychotic	_	
24-13	5826-5837	medications	_	
24-14	5838-5846	mitigate	_	
24-15	5847-5850	the	_	
24-16	5851-5857	impact	_	
24-17	5858-5860	of	_	
24-18	5861-5870	candidate	_	
24-19	5871-5884	pro-cognitive	_	
24-20	5885-5891	agents	_	
24-21	5892-5899	through	_	
24-22	5900-5915	pharmacodynamic	_	
24-23	5916-5926	mechanisms	_	
24-24	5926-5927	.	_	

#Text=For example, antipsychotics exert strong effects that decrease neuronal activity in VTA-DA neurons while increasing tonic activity in LC-NE neurons.
25-1	5928-5931	For	_	
25-2	5932-5939	example	_	
25-3	5939-5940	,	_	
25-4	5941-5955	antipsychotics	_	
25-5	5956-5961	exert	_	
25-6	5962-5968	strong	_	
25-7	5969-5976	effects	_	
25-8	5977-5981	that	_	
25-9	5982-5990	decrease	_	
25-10	5991-5999	neuronal	_	
25-11	6000-6008	activity	_	
25-12	6009-6011	in	_	
25-13	6012-6018	VTA-DA	_	
25-14	6019-6026	neurons	_	
25-15	6027-6032	while	_	
25-16	6033-6043	increasing	_	
25-17	6044-6049	tonic	_	
25-18	6050-6058	activity	_	
25-19	6059-6061	in	_	
25-20	6062-6067	LC-NE	_	
25-21	6068-6075	neurons	_	
25-22	6075-6076	.	_	

#Text=These effects would then alter the responses of these brain areas to candidate agents that modulate catecholamine systems.
26-1	6077-6082	These	_	
26-2	6083-6090	effects	_	
26-3	6091-6096	would	_	
26-4	6097-6101	then	_	
26-5	6102-6107	alter	_	
26-6	6108-6111	the	_	
26-7	6112-6121	responses	_	
26-8	6122-6124	of	_	
26-9	6125-6130	these	_	
26-10	6131-6136	brain	_	
26-11	6137-6142	areas	_	
26-12	6143-6145	to	_	
26-13	6146-6155	candidate	_	
26-14	6156-6162	agents	_	
26-15	6163-6167	that	_	
26-16	6168-6176	modulate	_	
26-17	6177-6190	catecholamine	_	
26-18	6191-6198	systems	_	
26-19	6198-6199	.	_	

#Text=Interactions with concurrent antipsychotics could occur regardless of the neurochemical system targeted by a given pro-cognitive agent, due to the highly interacting nature of neurotransmitter systems in the brain, where biogenic amines mutually influence each other as well as amino acid neurotransmission.
27-1	6200-6212	Interactions	_	
27-2	6213-6217	with	_	
27-3	6218-6228	concurrent	_	
27-4	6229-6243	antipsychotics	_	
27-5	6244-6249	could	_	
27-6	6250-6255	occur	_	
27-7	6256-6266	regardless	_	
27-8	6267-6269	of	_	
27-9	6270-6273	the	_	
27-10	6274-6287	neurochemical	_	
27-11	6288-6294	system	_	
27-12	6295-6303	targeted	_	
27-13	6304-6306	by	_	
27-14	6307-6308	a	_	
27-15	6309-6314	given	_	
27-16	6315-6328	pro-cognitive	_	
27-17	6329-6334	agent	_	
27-18	6334-6335	,	_	
27-19	6336-6339	due	_	
27-20	6340-6342	to	_	
27-21	6343-6346	the	_	
27-22	6347-6353	highly	_	
27-23	6354-6365	interacting	_	
27-24	6366-6372	nature	_	
27-25	6373-6375	of	_	
27-26	6376-6392	neurotransmitter	_	
27-27	6393-6400	systems	_	
27-28	6401-6403	in	_	
27-29	6404-6407	the	_	
27-30	6408-6413	brain	_	
27-31	6413-6414	,	_	
27-32	6415-6420	where	_	
27-33	6421-6429	biogenic	_	
27-34	6430-6436	amines	_	
27-35	6437-6445	mutually	_	
27-36	6446-6455	influence	_	
27-37	6456-6460	each	_	
27-38	6461-6466	other	_	
27-39	6467-6469	as	_	
27-40	6470-6474	well	_	
27-41	6475-6477	as	_	
27-42	6478-6483	amino	_	
27-43	6484-6488	acid	_	
27-44	6489-6506	neurotransmission	_	
27-45	6506-6507	.	_	

#Text=We therefore adopted an experimental medicine approach, using fMRI to support a mechanistic, model-driven investigation of drug action on modulation of large-scale neural systems that support complex cognition.
28-1	6508-6510	We	_	
28-2	6511-6520	therefore	_	
28-3	6521-6528	adopted	_	
28-4	6529-6531	an	_	
28-5	6532-6544	experimental	_	
28-6	6545-6553	medicine	_	
28-7	6554-6562	approach	_	
28-8	6562-6563	,	_	
28-9	6564-6569	using	_	
28-10	6570-6574	fMRI	_	
28-11	6575-6577	to	_	
28-12	6578-6585	support	_	
28-13	6586-6587	a	_	
28-14	6588-6599	mechanistic	_	
28-15	6599-6600	,	_	
28-16	6601-6613	model-driven	_	
28-17	6614-6627	investigation	_	
28-18	6628-6630	of	_	
28-19	6631-6635	drug	_	
28-20	6636-6642	action	_	
28-21	6643-6645	on	_	
28-22	6646-6656	modulation	_	
28-23	6657-6659	of	_	
28-24	6660-6671	large-scale	_	
28-25	6672-6678	neural	_	
28-26	6679-6686	systems	_	
28-27	6687-6691	that	_	
28-28	6692-6699	support	_	
28-29	6700-6707	complex	_	
28-30	6708-6717	cognition	_	
28-31	6717-6718	.	_	

#Text=We tested modafinil modulatory effects on the LC, VTA and cortical networks during cognitive performance in schizophrenia, integrating both cellular and systems-level neurobiological models.
29-1	6719-6721	We	_	
29-2	6722-6728	tested	_	
29-3	6729-6738	modafinil	_	
29-4	6739-6749	modulatory	_	
29-5	6750-6757	effects	_	
29-6	6758-6760	on	_	
29-7	6761-6764	the	_	
29-8	6765-6767	LC	_	
29-9	6767-6768	,	_	
29-10	6769-6772	VTA	_	
29-11	6773-6776	and	_	
29-12	6777-6785	cortical	_	
29-13	6786-6794	networks	_	
29-14	6795-6801	during	_	
29-15	6802-6811	cognitive	_	
29-16	6812-6823	performance	_	
29-17	6824-6826	in	_	
29-18	6827-6840	schizophrenia	_	
29-19	6840-6841	,	_	
29-20	6842-6853	integrating	_	
29-21	6854-6858	both	_	
29-22	6859-6867	cellular	_	
29-23	6868-6871	and	_	
29-24	6872-6885	systems-level	_	
29-25	6886-6901	neurobiological	_	
29-26	6902-6908	models	_	
29-27	6908-6909	.	_	

#Text=We report novel evidence that the catecholamine modulatory effects of modafinil are observable in schizophrenia in support of cognition, yet critically, these effects are altered in a pattern consistent with the actions of concurrent antipsychotic medications.
30-1	6910-6912	We	_	
30-2	6913-6919	report	_	
30-3	6920-6925	novel	_	
30-4	6926-6934	evidence	_	
30-5	6935-6939	that	_	
30-6	6940-6943	the	_	
30-7	6944-6957	catecholamine	_	
30-8	6958-6968	modulatory	_	
30-9	6969-6976	effects	_	
30-10	6977-6979	of	_	
30-11	6980-6989	modafinil	_	
30-12	6990-6993	are	_	
30-13	6994-7004	observable	_	
30-14	7005-7007	in	_	
30-15	7008-7021	schizophrenia	_	
30-16	7022-7024	in	_	
30-17	7025-7032	support	_	
30-18	7033-7035	of	_	
30-19	7036-7045	cognition	_	
30-20	7045-7046	,	_	
30-21	7047-7050	yet	_	
30-22	7051-7061	critically	_	
30-23	7061-7062	,	_	
30-24	7063-7068	these	_	
30-25	7069-7076	effects	_	
30-26	7077-7080	are	_	
30-27	7081-7088	altered	_	
30-28	7089-7091	in	_	
30-29	7092-7093	a	_	
30-30	7094-7101	pattern	_	
30-31	7102-7112	consistent	_	
30-32	7113-7117	with	_	
30-33	7118-7121	the	_	
30-34	7122-7129	actions	_	
30-35	7130-7132	of	_	
30-36	7133-7143	concurrent	_	
30-37	7144-7157	antipsychotic	_	
30-38	7158-7169	medications	_	
30-39	7169-7170	.	_	

#Text=Subjects and methods
#Text=Subjects/overview of procedures
#Text=The study was set in the University of California—Davis Medical Center from February 2007 to July 2010.
31-1	7171-7179	Subjects	http://www.case.edu/ProvCaRe/provcare#StudyMethod[3]	
31-2	7180-7183	and	http://www.case.edu/ProvCaRe/provcare#StudyMethod[3]	
31-3	7184-7191	methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod[3]	
31-4	7192-7200	Subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
31-5	7200-7201	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
31-6	7201-7209	overview	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
31-7	7210-7212	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
31-8	7213-7223	procedures	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
31-9	7224-7227	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
31-10	7228-7233	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
31-11	7234-7237	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
31-12	7238-7241	set	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
31-13	7242-7244	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
31-14	7245-7248	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
31-15	7249-7259	University	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
31-16	7260-7262	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
31-17	7263-7279	California—Davis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
31-18	7280-7287	Medical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
31-19	7288-7294	Center	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
31-20	7295-7299	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
31-21	7300-7308	February	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
31-22	7309-7313	2007	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
31-23	7314-7316	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
31-24	7317-7321	July	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
31-25	7322-7326	2010	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
31-26	7326-7327	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	

#Text=The ClinicalTrials.gov identifier is NCT00423943.
32-1	7328-7331	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
32-2	7332-7350	ClinicalTrials.gov	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
32-3	7351-7361	identifier	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
32-4	7362-7364	is	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
32-5	7365-7376	NCT00423943	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
32-6	7376-7377	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	

#Text=All procedures were approved by the UCD Institutional Review Board.
33-1	7378-7381	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
33-2	7382-7392	procedures	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
33-3	7393-7397	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
33-4	7398-7406	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
33-5	7407-7409	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
33-6	7410-7413	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
33-7	7414-7417	UCD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
33-8	7418-7431	Institutional	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
33-9	7432-7438	Review	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
33-10	7439-7444	Board	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
33-11	7444-7445	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	

#Text=All subjects provided informed consent for all procedures, and received remuneration for procedures, and the study was concluded at the end of the funding award period.
34-1	7446-7449	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
34-2	7450-7458	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
34-3	7459-7467	provided	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
34-4	7468-7476	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
34-5	7477-7484	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
34-6	7485-7488	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
34-7	7489-7492	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
34-8	7493-7503	procedures	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
34-9	7503-7504	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
34-10	7505-7508	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
34-11	7509-7517	received	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
34-12	7518-7530	remuneration	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
34-13	7531-7534	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
34-14	7535-7545	procedures	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
34-15	7545-7546	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
34-16	7547-7550	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
34-17	7551-7554	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
34-18	7555-7560	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
34-19	7561-7564	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
34-20	7565-7574	concluded	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
34-21	7575-7577	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
34-22	7578-7581	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
34-23	7582-7585	end	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
34-24	7586-7588	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
34-25	7589-7592	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
34-26	7593-7600	funding	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
34-27	7601-7606	award	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
34-28	7607-7613	period	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
34-29	7613-7614	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	

#Text=There were no changes to the methods or outcomes after trial commencement.
35-1	7615-7620	There	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
35-2	7621-7625	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
35-3	7626-7628	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
35-4	7629-7636	changes	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
35-5	7637-7639	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
35-6	7640-7643	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
35-7	7644-7651	methods	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
35-8	7652-7654	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
35-9	7655-7663	outcomes	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
35-10	7664-7669	after	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
35-11	7670-7675	trial	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
35-12	7676-7688	commencement	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
35-13	7688-7689	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	

#Text=Subjects were all outpatients, recruited from the community and our research clinic at UCD, and were included if they were aged 18–50 years, and lacked the following history: neurological illness, including head injury with loss of consciousness, uncorrectable visual or peripheral motor disturbance; full-scale IQ < 70 (by Wechsler Abbreviated Scale of Intelligence: WASI); known intolerance to modafinil; active substance abuse within 6 months of study; uncontrolled medical illness; incompatability with MRI procedures.
36-1	7690-7698	Subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-2	7699-7703	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-3	7704-7707	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-4	7708-7719	outpatients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-5	7719-7720	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-6	7721-7730	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-7	7731-7735	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-8	7736-7739	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-9	7740-7749	community	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-10	7750-7753	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-11	7754-7757	our	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-12	7758-7766	research	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-13	7767-7773	clinic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-14	7774-7776	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-15	7777-7780	UCD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-16	7780-7781	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-17	7782-7785	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-18	7786-7790	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-19	7791-7799	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-20	7800-7802	if	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-21	7803-7807	they	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-22	7808-7812	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-23	7813-7817	aged	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-24	7818-7820	18	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-25	7820-7821	–	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-26	7821-7823	50	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-27	7824-7829	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-28	7829-7830	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-29	7831-7834	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-30	7835-7841	lacked	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-31	7842-7845	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-32	7846-7855	following	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-33	7856-7863	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-34	7863-7864	:	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-35	7865-7877	neurological	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-36	7878-7885	illness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-37	7885-7886	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-38	7887-7896	including	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-39	7897-7901	head	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-40	7902-7908	injury	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-41	7909-7913	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-42	7914-7918	loss	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-43	7919-7921	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-44	7922-7935	consciousness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-45	7935-7936	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-46	7937-7950	uncorrectable	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-47	7951-7957	visual	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-48	7958-7960	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-49	7961-7971	peripheral	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-50	7972-7977	motor	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-51	7978-7989	disturbance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-52	7989-7990	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-53	7991-8001	full-scale	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-54	8002-8004	IQ	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-55	8005-8006	<	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-56	8007-8009	70	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-57	8010-8011	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-58	8011-8013	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-59	8014-8022	Wechsler	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-60	8023-8034	Abbreviated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-61	8035-8040	Scale	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-62	8041-8043	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-63	8044-8056	Intelligence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-64	8056-8057	:	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-65	8058-8062	WASI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-66	8062-8063	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-67	8063-8064	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-68	8065-8070	known	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-69	8071-8082	intolerance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-70	8083-8085	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-71	8086-8095	modafinil	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-72	8095-8096	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-73	8097-8103	active	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-74	8104-8113	substance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-75	8114-8119	abuse	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-76	8120-8126	within	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-77	8127-8128	6	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-78	8129-8135	months	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-79	8136-8138	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-80	8139-8144	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-81	8144-8145	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-82	8146-8158	uncontrolled	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-83	8159-8166	medical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-84	8167-8174	illness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-85	8174-8175	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-86	8176-8191	incompatability	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-87	8192-8196	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-88	8197-8200	MRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-89	8201-8211	procedures	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-90	8211-8212	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	

#Text=All patients were evaluated by structured diagnostic interview, using the SCID-I with DSM-IV-TR criteria, and all assigned a 295.X diagnosis.
37-1	8213-8216	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
37-2	8217-8225	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
37-3	8226-8230	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
37-4	8231-8240	evaluated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
37-5	8241-8243	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
37-6	8244-8254	structured	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
37-7	8255-8265	diagnostic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
37-8	8266-8275	interview	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
37-9	8275-8276	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
37-10	8277-8282	using	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
37-11	8283-8286	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
37-12	8287-8293	SCID-I	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders[5]	
37-13	8294-8298	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
37-14	8299-8308	DSM-IV-TR	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
37-15	8309-8317	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
37-16	8317-8318	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
37-17	8319-8322	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
37-18	8323-8326	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
37-19	8327-8335	assigned	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
37-20	8336-8337	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
37-21	8338-8341	295	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
37-22	8341-8342	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
37-23	8342-8343	X	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
37-24	8344-8353	diagnosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
37-25	8353-8354	.	_	

#Text=Each subject completed a double-blind, placebo-controlled crossover study of modafinil (single oral dose 200 mg) effects on neural activity measured by fMRI during cognitive control task performance.
38-1	8355-8359	Each	_	
38-2	8360-8367	subject	_	
38-3	8368-8377	completed	_	
38-4	8378-8379	a	_	
38-5	8380-8392	double-blind	_	
38-6	8392-8393	,	_	
38-7	8394-8412	placebo-controlled	_	
38-8	8413-8422	crossover	_	
38-9	8423-8428	study	_	
38-10	8429-8431	of	_	
38-11	8432-8441	modafinil	_	
38-12	8442-8443	(	_	
38-13	8443-8449	single	_	
38-14	8450-8454	oral	_	
38-15	8455-8459	dose	_	
38-16	8460-8463	200	_	
38-17	8464-8466	mg	_	
38-18	8466-8467	)	_	
38-19	8468-8475	effects	_	
38-20	8476-8478	on	_	
38-21	8479-8485	neural	_	
38-22	8486-8494	activity	_	
38-23	8495-8503	measured	_	
38-24	8504-8506	by	_	
38-25	8507-8511	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
38-26	8512-8518	during	_	
38-27	8519-8528	cognitive	_	
38-28	8529-8536	control	_	
38-29	8537-8541	task	_	
38-30	8542-8553	performance	_	
38-31	8553-8554	.	_	

#Text=BOLD signal change measured by fMRI during the cognitive task was the primary outcome measure, and task performance was the secondary outcome measure.
39-1	8555-8559	BOLD	_	
39-2	8560-8566	signal	_	
39-3	8567-8573	change	_	
39-4	8574-8582	measured	_	
39-5	8583-8585	by	_	
39-6	8586-8590	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
39-7	8591-8597	during	_	
39-8	8598-8601	the	_	
39-9	8602-8611	cognitive	_	
39-10	8612-8616	task	_	
39-11	8617-8620	was	_	
39-12	8621-8624	the	_	
39-13	8625-8632	primary	_	
39-14	8633-8640	outcome	_	
39-15	8641-8648	measure	_	
39-16	8648-8649	,	_	
39-17	8650-8653	and	_	
39-18	8654-8658	task	_	
39-19	8659-8670	performance	_	
39-20	8671-8674	was	_	
39-21	8675-8678	the	_	
39-22	8679-8688	secondary	_	
39-23	8689-8696	outcome	_	
39-24	8697-8704	measure	_	
39-25	8704-8705	.	_	

#Text=To address concurrent medication effects in relation to altered modafinil effects on BOLD signal change, we also derived measures of medication load at catecholamine autoreceptor subtypes, conferred by the schizophrenia patients’ treatment regimens, as determined by published standard indices of in vitro catecholamine receptor activity (see Supplement).
40-1	8706-8708	To	_	
40-2	8709-8716	address	_	
40-3	8717-8727	concurrent	_	
40-4	8728-8738	medication	_	
40-5	8739-8746	effects	_	
40-6	8747-8749	in	_	
40-7	8750-8758	relation	_	
40-8	8759-8761	to	_	
40-9	8762-8769	altered	_	
40-10	8770-8779	modafinil	_	
40-11	8780-8787	effects	_	
40-12	8788-8790	on	_	
40-13	8791-8795	BOLD	_	
40-14	8796-8802	signal	_	
40-15	8803-8809	change	_	
40-16	8809-8810	,	_	
40-17	8811-8813	we	_	
40-18	8814-8818	also	_	
40-19	8819-8826	derived	_	
40-20	8827-8835	measures	_	
40-21	8836-8838	of	_	
40-22	8839-8849	medication	_	
40-23	8850-8854	load	_	
40-24	8855-8857	at	_	
40-25	8858-8871	catecholamine	_	
40-26	8872-8884	autoreceptor	_	
40-27	8885-8893	subtypes	_	
40-28	8893-8894	,	_	
40-29	8895-8904	conferred	_	
40-30	8905-8907	by	_	
40-31	8908-8911	the	_	
40-32	8912-8925	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
40-33	8926-8934	patients	_	
40-34	8934-8935	’	_	
40-35	8936-8945	treatment	_	
40-36	8946-8954	regimens	_	
40-37	8954-8955	,	_	
40-38	8956-8958	as	_	
40-39	8959-8969	determined	_	
40-40	8970-8972	by	_	
40-41	8973-8982	published	_	
40-42	8983-8991	standard	_	
40-43	8992-8999	indices	_	
40-44	9000-9002	of	_	
40-45	9003-9005	in	_	
40-46	9006-9011	vitro	_	
40-47	9012-9025	catecholamine	_	
40-48	9026-9034	receptor	_	
40-49	9035-9043	activity	_	
40-50	9044-9045	(	_	
40-51	9045-9048	see	_	
40-52	9049-9059	Supplement	_	
40-53	9059-9060	)	_	
40-54	9060-9061	.	_	

#Text=We tested these hypothesized relationships by correlating concurrent medication loads with neural responses to modafinil, as an additional secondary outcome measure.
41-1	9062-9064	We	_	
41-2	9065-9071	tested	_	
41-3	9072-9077	these	_	
41-4	9078-9090	hypothesized	_	
41-5	9091-9104	relationships	_	
41-6	9105-9107	by	_	
41-7	9108-9119	correlating	_	
41-8	9120-9130	concurrent	_	
41-9	9131-9141	medication	_	
41-10	9142-9147	loads	_	
41-11	9148-9152	with	_	
41-12	9153-9159	neural	_	
41-13	9160-9169	responses	_	
41-14	9170-9172	to	_	
41-15	9173-9182	modafinil	_	
41-16	9182-9183	,	_	
41-17	9184-9186	as	_	
41-18	9187-9189	an	_	
41-19	9190-9200	additional	_	
41-20	9201-9210	secondary	_	
41-21	9211-9218	outcome	_	
41-22	9219-9226	measure	_	
41-23	9226-9227	.	_	

#Text=Tertiary outcome measures included subjective state measured with the POMS, and vital signs measured with a blood pressure cuff.
42-1	9228-9236	Tertiary	_	
42-2	9237-9244	outcome	_	
42-3	9245-9253	measures	_	
42-4	9254-9262	included	_	
42-5	9263-9273	subjective	_	
42-6	9274-9279	state	_	
42-7	9280-9288	measured	_	
42-8	9289-9293	with	_	
42-9	9294-9297	the	_	
42-10	9298-9302	POMS	_	
42-11	9302-9303	,	_	
42-12	9304-9307	and	_	
42-13	9308-9313	vital	_	
42-14	9314-9319	signs	_	
42-15	9320-9328	measured	_	
42-16	9329-9333	with	_	
42-17	9334-9335	a	_	
42-18	9336-9341	blood	_	
42-19	9342-9350	pressure	_	
42-20	9351-9355	cuff	_	
42-21	9355-9356	.	_	

#Text=While this was an unprecedented, preliminary study, sample size was approximated based on both preliminary results from the healthy comparison group and an earlier published study of modafinil effects on prefrontal cortical function.
43-1	9357-9362	While	_	
43-2	9363-9367	this	_	
43-3	9368-9371	was	_	
43-4	9372-9374	an	_	
43-5	9375-9388	unprecedented	_	
43-6	9388-9389	,	_	
43-7	9390-9401	preliminary	_	
43-8	9402-9407	study	_	
43-9	9407-9408	,	_	
43-10	9409-9415	sample	_	
43-11	9416-9420	size	_	
43-12	9421-9424	was	_	
43-13	9425-9437	approximated	_	
43-14	9438-9443	based	_	
43-15	9444-9446	on	_	
43-16	9447-9451	both	_	
43-17	9452-9463	preliminary	_	
43-18	9464-9471	results	_	
43-19	9472-9476	from	_	
43-20	9477-9480	the	_	
43-21	9481-9488	healthy	_	
43-22	9489-9499	comparison	_	
43-23	9500-9505	group	_	
43-24	9506-9509	and	_	
43-25	9510-9512	an	_	
43-26	9513-9520	earlier	_	
43-27	9521-9530	published	_	
43-28	9531-9536	study	_	
43-29	9537-9539	of	_	
43-30	9540-9549	modafinil	_	
43-31	9550-9557	effects	_	
43-32	9558-9560	on	_	
43-33	9561-9571	prefrontal	_	
43-34	9572-9580	cortical	_	
43-35	9581-9589	function	_	
43-36	9589-9590	.	_	

#Text=See Supplemental Methods for additional detail on the evaluation of subjects.
44-1	9591-9594	See	_	
44-2	9595-9607	Supplemental	_	
44-3	9608-9615	Methods	_	
44-4	9616-9619	for	_	
44-5	9620-9630	additional	_	
44-6	9631-9637	detail	_	
44-7	9638-9640	on	_	
44-8	9641-9644	the	_	
44-9	9645-9655	evaluation	_	
44-10	9656-9658	of	_	
44-11	9659-9667	subjects	_	
44-12	9667-9668	.	_	

#Text=Cognitive Paradigm
#Text=The Preparing to Overcome Prepotency (POP) Task (Supplemental Fig. 1) was presented using EPrime software.
45-1	9669-9678	Cognitive	_	
45-2	9679-9687	Paradigm	_	
45-3	9688-9691	The	_	
45-4	9692-9701	Preparing	_	
45-5	9702-9704	to	_	
45-6	9705-9713	Overcome	_	
45-7	9714-9724	Prepotency	_	
45-8	9725-9726	(	_	
45-9	9726-9729	POP	_	
45-10	9729-9730	)	_	
45-11	9731-9735	Task	_	
45-12	9736-9737	(	_	
45-13	9737-9749	Supplemental	_	
45-14	9750-9753	Fig	_	
45-15	9753-9754	.	_	
45-16	9755-9756	1	_	
45-17	9756-9757	)	_	
45-18	9758-9761	was	_	
45-19	9762-9771	presented	_	
45-20	9772-9777	using	_	
45-21	9778-9784	EPrime	_	
45-22	9785-9793	software	_	
45-23	9793-9794	.	_	

#Text=In this task, a visual cue (Red or Green color patches, 500 ms duration) in the center of the visual field instructs a stimulus-response (S–R) mapping to the probe, which occurs after a delay (7.5 s delay from cue offset to probe onset).
46-1	9795-9797	In	_	
46-2	9798-9802	this	_	
46-3	9803-9807	task	_	
46-4	9807-9808	,	_	
46-5	9809-9810	a	_	
46-6	9811-9817	visual	_	
46-7	9818-9821	cue	_	
46-8	9822-9823	(	_	
46-9	9823-9826	Red	_	
46-10	9827-9829	or	_	
46-11	9830-9835	Green	_	
46-12	9836-9841	color	_	
46-13	9842-9849	patches	_	
46-14	9849-9850	,	_	
46-15	9851-9854	500	_	
46-16	9855-9857	ms	_	
46-17	9858-9866	duration	_	
46-18	9866-9867	)	_	
46-19	9868-9870	in	_	
46-20	9871-9874	the	_	
46-21	9875-9881	center	_	
46-22	9882-9884	of	_	
46-23	9885-9888	the	_	
46-24	9889-9895	visual	_	
46-25	9896-9901	field	_	
46-26	9902-9911	instructs	_	
46-27	9912-9913	a	_	
46-28	9914-9931	stimulus-response	_	
46-29	9932-9933	(	_	
46-30	9933-9936	S–R	_	
46-31	9936-9937	)	_	
46-32	9938-9945	mapping	_	
46-33	9946-9948	to	_	
46-34	9949-9952	the	_	
46-35	9953-9958	probe	_	
46-36	9958-9959	,	_	
46-37	9960-9965	which	_	
46-38	9966-9972	occurs	_	
46-39	9973-9978	after	_	
46-40	9979-9980	a	_	
46-41	9981-9986	delay	_	
46-42	9987-9988	(	_	
46-43	9988-9991	7.5	_	
46-44	9992-9993	s	_	
46-45	9994-9999	delay	_	
46-46	10000-10004	from	_	
46-47	10005-10008	cue	_	
46-48	10009-10015	offset	_	
46-49	10016-10018	to	_	
46-50	10019-10024	probe	_	
46-51	10025-10030	onset	_	
46-52	10030-10031	)	_	
46-53	10031-10032	.	_	

#Text=The probe is an arrow that occurs with equal frequency pointing to the left or right, presented in the center of the visual field for 500 ms in duration.
47-1	10033-10036	The	_	
47-2	10037-10042	probe	_	
47-3	10043-10045	is	_	
47-4	10046-10048	an	_	
47-5	10049-10054	arrow	_	
47-6	10055-10059	that	_	
47-7	10060-10066	occurs	_	
47-8	10067-10071	with	_	
47-9	10072-10077	equal	_	
47-10	10078-10087	frequency	_	
47-11	10088-10096	pointing	_	
47-12	10097-10099	to	_	
47-13	10100-10103	the	_	
47-14	10104-10108	left	_	
47-15	10109-10111	or	_	
47-16	10112-10117	right	_	
47-17	10117-10118	,	_	
47-18	10119-10128	presented	_	
47-19	10129-10131	in	_	
47-20	10132-10135	the	_	
47-21	10136-10142	center	_	
47-22	10143-10145	of	_	
47-23	10146-10149	the	_	
47-24	10150-10156	visual	_	
47-25	10157-10162	field	_	
47-26	10163-10166	for	_	
47-27	10167-10170	500	_	
47-28	10171-10173	ms	_	
47-29	10174-10176	in	_	
47-30	10177-10185	duration	_	
47-31	10185-10186	.	_	

#Text=The direction of the arrow probe is randomized to preclude the preparation of specific motor responses in the cue-probe delay period.
48-1	10187-10190	The	_	
48-2	10191-10200	direction	_	
48-3	10201-10203	of	_	
48-4	10204-10207	the	_	
48-5	10208-10213	arrow	_	
48-6	10214-10219	probe	_	
48-7	10220-10222	is	_	
48-8	10223-10233	randomized	_	
48-9	10234-10236	to	_	
48-10	10237-10245	preclude	_	
48-11	10246-10249	the	_	
48-12	10250-10261	preparation	_	
48-13	10262-10264	of	_	
48-14	10265-10273	specific	_	
48-15	10274-10279	motor	_	
48-16	10280-10289	responses	_	
48-17	10290-10292	in	_	
48-18	10293-10296	the	_	
48-19	10297-10306	cue-probe	_	
48-20	10307-10312	delay	_	
48-21	10313-10319	period	_	
48-22	10319-10320	.	_	

#Text=The response demand is prepotent for Green-cued trials (i.e., the correct response is a left button-press for leftward arrows, and right for right), and is non-prepotent for Red-cued trials (i.e., left button-press for rightward arrows, and vice versa).
49-1	10321-10324	The	_	
49-2	10325-10333	response	_	
49-3	10334-10340	demand	_	
49-4	10341-10343	is	_	
49-5	10344-10353	prepotent	_	
49-6	10354-10357	for	_	
49-7	10358-10368	Green-cued	_	
49-8	10369-10375	trials	_	
49-9	10376-10377	(	_	
49-10	10377-10380	i.e	_	
49-11	10380-10381	.	_	
49-12	10381-10382	,	_	
49-13	10383-10386	the	_	
49-14	10387-10394	correct	_	
49-15	10395-10403	response	_	
49-16	10404-10406	is	_	
49-17	10407-10408	a	_	
49-18	10409-10413	left	_	
49-19	10414-10426	button-press	_	
49-20	10427-10430	for	_	
49-21	10431-10439	leftward	_	
49-22	10440-10446	arrows	_	
49-23	10446-10447	,	_	
49-24	10448-10451	and	_	
49-25	10452-10457	right	_	
49-26	10458-10461	for	_	
49-27	10462-10467	right	_	
49-28	10467-10468	)	_	
49-29	10468-10469	,	_	
49-30	10470-10473	and	_	
49-31	10474-10476	is	_	
49-32	10477-10490	non-prepotent	_	
49-33	10491-10494	for	_	
49-34	10495-10503	Red-cued	_	
49-35	10504-10510	trials	_	
49-36	10511-10512	(	_	
49-37	10512-10515	i.e	_	
49-38	10515-10516	.	_	
49-39	10516-10517	,	_	
49-40	10518-10522	left	_	
49-41	10523-10535	button-press	_	
49-42	10536-10539	for	_	
49-43	10540-10549	rightward	_	
49-44	10550-10556	arrows	_	
49-45	10556-10557	,	_	
49-46	10558-10561	and	_	
49-47	10562-10566	vice	_	
49-48	10567-10572	versa	_	
49-49	10572-10573	)	_	
49-50	10573-10574	.	_	

#Text=The period from probe onset to cue onset of the successive trial is 12 s.
50-1	10575-10578	The	_	
50-2	10579-10585	period	_	
50-3	10586-10590	from	_	
50-4	10591-10596	probe	_	
50-5	10597-10602	onset	_	
50-6	10603-10605	to	_	
50-7	10606-10609	cue	_	
50-8	10610-10615	onset	_	
50-9	10616-10618	of	_	
50-10	10619-10622	the	_	
50-11	10623-10633	successive	_	
50-12	10634-10639	trial	_	
50-13	10640-10642	is	_	
50-14	10643-10645	12	_	
50-15	10646-10647	s	_	
50-16	10647-10648	.	_	

#Text=During both cue-probe delay and probe-cue interval, subjects are instructed to fixate visually on a crosshair presented in the center of the visual field.
51-1	10649-10655	During	_	
51-2	10656-10660	both	_	
51-3	10661-10670	cue-probe	_	
51-4	10671-10676	delay	_	
51-5	10677-10680	and	_	
51-6	10681-10690	probe-cue	_	
51-7	10691-10699	interval	_	
51-8	10699-10700	,	_	
51-9	10701-10709	subjects	_	
51-10	10710-10713	are	_	
51-11	10714-10724	instructed	_	
51-12	10725-10727	to	_	
51-13	10728-10734	fixate	_	
51-14	10735-10743	visually	_	
51-15	10744-10746	on	_	
51-16	10747-10748	a	_	
51-17	10749-10758	crosshair	_	
51-18	10759-10768	presented	_	
51-19	10769-10771	in	_	
51-20	10772-10775	the	_	
51-21	10776-10782	center	_	
51-22	10783-10785	of	_	
51-23	10786-10789	the	_	
51-24	10790-10796	visual	_	
51-25	10797-10802	field	_	
51-26	10802-10803	.	_	

#Text=Four blocks with 20 trials each were performed, with randomized order of cues, 70% of which were comprised of prepotent (Green-cued) S–R mappings, and each block lasting 6 min 40 s.
52-1	10804-10808	Four	_	
52-2	10809-10815	blocks	_	
52-3	10816-10820	with	_	
52-4	10821-10823	20	_	
52-5	10824-10830	trials	_	
52-6	10831-10835	each	_	
52-7	10836-10840	were	_	
52-8	10841-10850	performed	_	
52-9	10850-10851	,	_	
52-10	10852-10856	with	_	
52-11	10857-10867	randomized	_	
52-12	10868-10873	order	_	
52-13	10874-10876	of	_	
52-14	10877-10881	cues	_	
52-15	10881-10882	,	_	
52-16	10883-10886	70%	_	
52-17	10887-10889	of	_	
52-18	10890-10895	which	_	
52-19	10896-10900	were	_	
52-20	10901-10910	comprised	_	
52-21	10911-10913	of	_	
52-22	10914-10923	prepotent	_	
52-23	10924-10925	(	_	
52-24	10925-10935	Green-cued	_	
52-25	10935-10936	)	_	
52-26	10937-10940	S–R	_	
52-27	10941-10949	mappings	_	
52-28	10949-10950	,	_	
52-29	10951-10954	and	_	
52-30	10955-10959	each	_	
52-31	10960-10965	block	_	
52-32	10966-10973	lasting	_	
52-33	10974-10975	6	_	
52-34	10976-10979	min	_	
52-35	10980-10982	40	_	
52-36	10983-10984	s	_	
52-37	10984-10985	.	_	

#Text=Subjects were instructed to ‘go as fast as you can without making mistakes.’
53-1	10986-10994	Subjects	_	
53-2	10995-10999	were	_	
53-3	11000-11010	instructed	_	
53-4	11011-11013	to	_	
53-5	11014-11015	‘	_	
53-6	11015-11017	go	_	
53-7	11018-11020	as	_	
53-8	11021-11025	fast	_	
53-9	11026-11028	as	_	
53-10	11029-11032	you	_	
53-11	11033-11036	can	_	
53-12	11037-11044	without	_	
53-13	11045-11051	making	_	
53-14	11052-11060	mistakes	_	
53-15	11060-11061	.	_	
53-16	11061-11062	’	_	

#Text=The POP task requires cognitive control to overcome a prepotent stimulus-response mapping.
54-1	11063-11066	The	_	
54-2	11067-11070	POP	_	
54-3	11071-11075	task	_	
54-4	11076-11084	requires	_	
54-5	11085-11094	cognitive	_	
54-6	11095-11102	control	_	
54-7	11103-11105	to	_	
54-8	11106-11114	overcome	_	
54-9	11115-11116	a	_	
54-10	11117-11126	prepotent	_	
54-11	11127-11144	stimulus-response	_	
54-12	11145-11152	mapping	_	
54-13	11152-11153	.	_	

#Text=High-control demands (Red-cued trials) are associated with decrements (costs) in response accuracy and speed, and robust activity of the lateral and medial PFC during the preparatory cue-probe delay period.
#Text=fMRI Acquisition and Pre-processing
#Text=Event-related fMRI was conducted on a 3 tesla Siemens Trio MRI system with a Siemens 8-channel phased array coil.
55-1	11154-11166	High-control	_	
55-2	11167-11174	demands	_	
55-3	11175-11176	(	_	
55-4	11176-11184	Red-cued	_	
55-5	11185-11191	trials	_	
55-6	11191-11192	)	_	
55-7	11193-11196	are	_	
55-8	11197-11207	associated	_	
55-9	11208-11212	with	_	
55-10	11213-11223	decrements	_	
55-11	11224-11225	(	_	
55-12	11225-11230	costs	_	
55-13	11230-11231	)	_	
55-14	11232-11234	in	_	
55-15	11235-11243	response	_	
55-16	11244-11252	accuracy	_	
55-17	11253-11256	and	_	
55-18	11257-11262	speed	_	
55-19	11262-11263	,	_	
55-20	11264-11267	and	_	
55-21	11268-11274	robust	_	
55-22	11275-11283	activity	_	
55-23	11284-11286	of	_	
55-24	11287-11290	the	_	
55-25	11291-11298	lateral	_	
55-26	11299-11302	and	_	
55-27	11303-11309	medial	_	
55-28	11310-11313	PFC	_	
55-29	11314-11320	during	_	
55-30	11321-11324	the	_	
55-31	11325-11336	preparatory	_	
55-32	11337-11346	cue-probe	_	
55-33	11347-11352	delay	_	
55-34	11353-11359	period	_	
55-35	11359-11360	.	_	
55-36	11361-11365	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
55-37	11366-11377	Acquisition	_	
55-38	11378-11381	and	_	
55-39	11382-11396	Pre-processing	_	
55-40	11397-11410	Event-related	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[6]	
55-41	11411-11415	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[6]	
55-42	11416-11419	was	_	
55-43	11420-11429	conducted	_	
55-44	11430-11432	on	_	
55-45	11433-11434	a	_	
55-46	11435-11436	3	_	
55-47	11437-11442	tesla	_	
55-48	11443-11450	Siemens	_	
55-49	11451-11455	Trio	_	
55-50	11456-11459	MRI	_	
55-51	11460-11466	system	_	
55-52	11467-11471	with	_	
55-53	11472-11473	a	_	
55-54	11474-11481	Siemens	_	
55-55	11482-11483	8	_	
55-56	11483-11484	-	_	
55-57	11484-11491	channel	_	
55-58	11492-11498	phased	_	
55-59	11499-11504	array	_	
55-60	11505-11509	coil	_	
55-61	11509-11510	.	_	

#Text=Measurement of Blood Oxygen Level-Dependent (BOLD) contrast was conducted during single-shot, echo-planar imaging (EPI), using a T2*-weighted sequence, and whole-brain coverage.
56-1	11511-11522	Measurement	_	
56-2	11523-11525	of	_	
56-3	11526-11531	Blood	_	
56-4	11532-11538	Oxygen	_	
56-5	11539-11554	Level-Dependent	_	
56-6	11555-11556	(	_	
56-7	11556-11560	BOLD	_	
56-8	11560-11561	)	_	
56-9	11562-11570	contrast	_	
56-10	11571-11574	was	_	
56-11	11575-11584	conducted	_	
56-12	11585-11591	during	_	
56-13	11592-11603	single-shot	_	
56-14	11603-11604	,	_	
56-15	11605-11616	echo-planar	_	
56-16	11617-11624	imaging	_	
56-17	11625-11626	(	_	
56-18	11626-11629	EPI	_	
56-19	11629-11630	)	_	
56-20	11630-11631	,	_	
56-21	11632-11637	using	_	
56-22	11638-11639	a	_	
56-23	11640-11642	T2	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[7]	
56-24	11642-11643	*	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[7]	
56-25	11643-11644	-	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[7]	
56-26	11644-11652	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[7]	
56-27	11653-11661	sequence	_	
56-28	11661-11662	,	_	
56-29	11663-11666	and	_	
56-30	11667-11678	whole-brain	_	
56-31	11679-11687	coverage	_	
56-32	11687-11688	.	_	

#Text=The parameters of the EPI sequence were TR 2000 ms, TE 30 ms, flip angle 90°, FOV 220 × 220 mm, with 36 contiguous slices in the axial oblique plane with voxel size 3.4 mm isotropic.
57-1	11689-11692	The	_	
57-2	11693-11703	parameters	_	
57-3	11704-11706	of	_	
57-4	11707-11710	the	_	
57-5	11711-11714	EPI	_	
57-6	11715-11723	sequence	_	
57-7	11724-11728	were	_	
57-8	11729-11731	TR	_	
57-9	11732-11736	2000	_	
57-10	11737-11739	ms	_	
57-11	11739-11740	,	_	
57-12	11741-11743	TE	_	
57-13	11744-11746	30	_	
57-14	11747-11749	ms	_	
57-15	11749-11750	,	_	
57-16	11751-11755	flip	_	
57-17	11756-11761	angle	_	
57-18	11762-11764	90	_	
57-19	11764-11765	°	_	
57-20	11765-11766	,	_	
57-21	11767-11770	FOV	_	
57-22	11771-11774	220	_	
57-23	11775-11776	×	_	
57-24	11777-11780	220	_	
57-25	11781-11783	mm	_	
57-26	11783-11784	,	_	
57-27	11785-11789	with	_	
57-28	11790-11792	36	_	
57-29	11793-11803	contiguous	_	
57-30	11804-11810	slices	_	
57-31	11811-11813	in	_	
57-32	11814-11817	the	_	
57-33	11818-11823	axial	_	
57-34	11824-11831	oblique	_	
57-35	11832-11837	plane	_	
57-36	11838-11842	with	_	
57-37	11843-11848	voxel	_	
57-38	11849-11853	size	_	
57-39	11854-11857	3.4	_	
57-40	11858-11860	mm	_	
57-41	11861-11870	isotropic	_	
57-42	11870-11871	.	_	

#Text=In addition, a structural MRI was acquired for normalization of EPI images to the template, using a Magnetization-Prepared Rapid Acquired Gradient Echo (MP-RAGE) sequence, with the following parameters: TR 2500 ms, TE 4.82 ms, acquisition time 9:20, flip angle 7°, FOV 256 × 256 mm, with 192 slices 1 mm thick.
58-1	11872-11874	In	_	
58-2	11875-11883	addition	_	
58-3	11883-11884	,	_	
58-4	11885-11886	a	_	
58-5	11887-11897	structural	_	
58-6	11898-11901	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging	
58-7	11902-11905	was	_	
58-8	11906-11914	acquired	_	
58-9	11915-11918	for	_	
58-10	11919-11932	normalization	_	
58-11	11933-11935	of	_	
58-12	11936-11939	EPI	_	
58-13	11940-11946	images	_	
58-14	11947-11949	to	_	
58-15	11950-11953	the	_	
58-16	11954-11962	template	_	
58-17	11962-11963	,	_	
58-18	11964-11969	using	_	
58-19	11970-11971	a	_	
58-20	11972-11994	Magnetization-Prepared	_	
58-21	11995-12000	Rapid	_	
58-22	12001-12009	Acquired	_	
58-23	12010-12018	Gradient	_	
58-24	12019-12023	Echo	_	
58-25	12024-12025	(	_	
58-26	12025-12032	MP-RAGE	_	
58-27	12032-12033	)	_	
58-28	12034-12042	sequence	_	
58-29	12042-12043	,	_	
58-30	12044-12048	with	_	
58-31	12049-12052	the	_	
58-32	12053-12062	following	_	
58-33	12063-12073	parameters	_	
58-34	12073-12074	:	_	
58-35	12075-12077	TR	_	
58-36	12078-12082	2500	_	
58-37	12083-12085	ms	_	
58-38	12085-12086	,	_	
58-39	12087-12089	TE	_	
58-40	12090-12094	4.82	_	
58-41	12095-12097	ms	_	
58-42	12097-12098	,	_	
58-43	12099-12110	acquisition	_	
58-44	12111-12115	time	_	
58-45	12116-12117	9	_	
58-46	12117-12118	:	_	
58-47	12118-12120	20	_	
58-48	12120-12121	,	_	
58-49	12122-12126	flip	_	
58-50	12127-12132	angle	_	
58-51	12133-12134	7	_	
58-52	12134-12135	°	_	
58-53	12135-12136	,	_	
58-54	12137-12140	FOV	_	
58-55	12141-12144	256	_	
58-56	12145-12146	×	_	
58-57	12147-12150	256	_	
58-58	12151-12153	mm	_	
58-59	12153-12154	,	_	
58-60	12155-12159	with	_	
58-61	12160-12163	192	_	
58-62	12164-12170	slices	_	
58-63	12171-12172	1	_	
58-64	12173-12175	mm	_	
58-65	12176-12181	thick	_	
58-66	12181-12182	.	_	

#Text=Pre-processing and analysis of EPI images were performed using SPM5.
59-1	12183-12197	Pre-processing	_	
59-2	12198-12201	and	_	
59-3	12202-12210	analysis	_	
59-4	12211-12213	of	_	
59-5	12214-12217	EPI	_	
59-6	12218-12224	images	_	
59-7	12225-12229	were	_	
59-8	12230-12239	performed	_	
59-9	12240-12245	using	_	
59-10	12246-12250	SPM5	_	
59-11	12250-12251	.	_	

#Text=The first four images (preceding onset of trial one of block one) were discarded to allow for stabilization of the scanner signal.
60-1	12252-12255	The	_	
60-2	12256-12261	first	_	
60-3	12262-12266	four	_	
60-4	12267-12273	images	_	
60-5	12274-12275	(	_	
60-6	12275-12284	preceding	_	
60-7	12285-12290	onset	_	
60-8	12291-12293	of	_	
60-9	12294-12299	trial	_	
60-10	12300-12303	one	_	
60-11	12304-12306	of	_	
60-12	12307-12312	block	_	
60-13	12313-12316	one	_	
60-14	12316-12317	)	_	
60-15	12318-12322	were	_	
60-16	12323-12332	discarded	_	
60-17	12333-12335	to	_	
60-18	12336-12341	allow	_	
60-19	12342-12345	for	_	
60-20	12346-12359	stabilization	_	
60-21	12360-12362	of	_	
60-22	12363-12366	the	_	
60-23	12367-12374	scanner	_	
60-24	12375-12381	signal	_	
60-25	12381-12382	.	_	

#Text=The remaining images were realigned (motion-corrected) to the first retained image in the first block, and adjusted for acquisition time (slice timing correction).
61-1	12383-12386	The	_	
61-2	12387-12396	remaining	_	
61-3	12397-12403	images	_	
61-4	12404-12408	were	_	
61-5	12409-12418	realigned	_	
61-6	12419-12420	(	_	
61-7	12420-12436	motion-corrected	_	
61-8	12436-12437	)	_	
61-9	12438-12440	to	_	
61-10	12441-12444	the	_	
61-11	12445-12450	first	_	
61-12	12451-12459	retained	_	
61-13	12460-12465	image	_	
61-14	12466-12468	in	_	
61-15	12469-12472	the	_	
61-16	12473-12478	first	_	
61-17	12479-12484	block	_	
61-18	12484-12485	,	_	
61-19	12486-12489	and	_	
61-20	12490-12498	adjusted	_	
61-21	12499-12502	for	_	
61-22	12503-12514	acquisition	_	
61-23	12515-12519	time	_	
61-24	12520-12521	(	_	
61-25	12521-12526	slice	_	
61-26	12527-12533	timing	_	
61-27	12534-12544	correction	_	
61-28	12544-12545	)	_	
61-29	12545-12546	.	_	

#Text=At this point, skull-stripping was performed on both MP-RAGE images and the single-subject T1 template from SPM.
62-1	12547-12549	At	_	
62-2	12550-12554	this	_	
62-3	12555-12560	point	_	
62-4	12560-12561	,	_	
62-5	12562-12577	skull-stripping	_	
62-6	12578-12581	was	_	
62-7	12582-12591	performed	_	
62-8	12592-12594	on	_	
62-9	12595-12599	both	_	
62-10	12600-12607	MP-RAGE	_	
62-11	12608-12614	images	_	
62-12	12615-12618	and	_	
62-13	12619-12622	the	_	
62-14	12623-12637	single-subject	_	
62-15	12638-12640	T1	_	
62-16	12641-12649	template	_	
62-17	12650-12654	from	_	
62-18	12655-12658	SPM	_	
62-19	12658-12659	.	_	

#Text=The MP-RAGE image from each subject was co-registered to the T1 template to determine normalization parameters, which were then applied to each EPI image for that subject via 6-parameter rigid-body affine transformation to standard MNI space.
63-1	12660-12663	The	_	
63-2	12664-12671	MP-RAGE	_	
63-3	12672-12677	image	_	
63-4	12678-12682	from	_	
63-5	12683-12687	each	_	
63-6	12688-12695	subject	_	
63-7	12696-12699	was	_	
63-8	12700-12713	co-registered	_	
63-9	12714-12716	to	_	
63-10	12717-12720	the	_	
63-11	12721-12723	T1	_	
63-12	12724-12732	template	_	
63-13	12733-12735	to	_	
63-14	12736-12745	determine	_	
63-15	12746-12759	normalization	_	
63-16	12760-12770	parameters	_	
63-17	12770-12771	,	_	
63-18	12772-12777	which	_	
63-19	12778-12782	were	_	
63-20	12783-12787	then	_	
63-21	12788-12795	applied	_	
63-22	12796-12798	to	_	
63-23	12799-12803	each	_	
63-24	12804-12807	EPI	_	
63-25	12808-12813	image	_	
63-26	12814-12817	for	_	
63-27	12818-12822	that	_	
63-28	12823-12830	subject	_	
63-29	12831-12834	via	_	
63-30	12835-12836	6	_	
63-31	12836-12837	-	_	
63-32	12837-12846	parameter	_	
63-33	12847-12857	rigid-body	_	
63-34	12858-12864	affine	_	
63-35	12865-12879	transformation	_	
63-36	12880-12882	to	_	
63-37	12883-12891	standard	_	
63-38	12892-12895	MNI	_	
63-39	12896-12901	space	_	
63-40	12901-12902	.	_	

#Text=Images were then resliced to 2 × 2 × 2 and spatially smoothed with an 8 mm, full-width-at-half-maximum Gaussian kernel.
64-1	12903-12909	Images	_	
64-2	12910-12914	were	_	
64-3	12915-12919	then	_	
64-4	12920-12928	resliced	_	
64-5	12929-12931	to	_	
64-6	12932-12933	2	_	
64-7	12934-12935	×	_	
64-8	12936-12937	2	_	
64-9	12938-12939	×	_	
64-10	12940-12941	2	_	
64-11	12942-12945	and	_	
64-12	12946-12955	spatially	_	
64-13	12956-12964	smoothed	_	
64-14	12965-12969	with	_	
64-15	12970-12972	an	_	
64-16	12973-12974	8	_	
64-17	12975-12977	mm	_	
64-18	12977-12978	,	_	
64-19	12979-13005	full-width-at-half-maximum	_	
64-20	13006-13014	Gaussian	_	
64-21	13015-13021	kernel	_	
64-22	13021-13022	.	_	

#Text=At this point, Drug and Placebo day scans were concatenated for modeling of the signal and inferential testing.
65-1	13023-13025	At	_	
65-2	13026-13030	this	_	
65-3	13031-13036	point	_	
65-4	13036-13037	,	_	
65-5	13038-13042	Drug	_	
65-6	13043-13046	and	_	
65-7	13047-13054	Placebo	_	
65-8	13055-13058	day	_	
65-9	13059-13064	scans	_	
65-10	13065-13069	were	_	
65-11	13070-13082	concatenated	_	
65-12	13083-13086	for	_	
65-13	13087-13095	modeling	_	
65-14	13096-13098	of	_	
65-15	13099-13102	the	_	
65-16	13103-13109	signal	_	
65-17	13110-13113	and	_	
65-18	13114-13125	inferential	_	
65-19	13126-13133	testing	_	
65-20	13133-13134	.	_	

#Text=Modeling and inferential testing of voxel-wise drug effects on neural activity
#Text=Derivation of the signal proceeded with the use of the General Linear Model.
66-1	13135-13143	Modeling	_	
66-2	13144-13147	and	_	
66-3	13148-13159	inferential	_	
66-4	13160-13167	testing	_	
66-5	13168-13170	of	_	
66-6	13171-13181	voxel-wise	_	
66-7	13182-13186	drug	_	
66-8	13187-13194	effects	_	
66-9	13195-13197	on	_	
66-10	13198-13204	neural	_	
66-11	13205-13213	activity	_	
66-12	13214-13224	Derivation	_	
66-13	13225-13227	of	_	
66-14	13228-13231	the	_	
66-15	13232-13238	signal	_	
66-16	13239-13248	proceeded	_	
66-17	13249-13253	with	_	
66-18	13254-13257	the	_	
66-19	13258-13261	use	_	
66-20	13262-13264	of	_	
66-21	13265-13268	the	_	
66-22	13269-13276	General	_	
66-23	13277-13283	Linear	_	
66-24	13284-13289	Model	_	
66-25	13289-13290	.	_	

#Text=Regressors were established for Drug_RedCues, Drug_GreenCues, Placebo_RedCues, and Placebo_GreenCues, and analogous regressors for Probes.
67-1	13291-13301	Regressors	_	
67-2	13302-13306	were	_	
67-3	13307-13318	established	_	
67-4	13319-13322	for	_	
67-5	13323-13335	Drug_RedCues	_	
67-6	13335-13336	,	_	
67-7	13337-13351	Drug_GreenCues	_	
67-8	13351-13352	,	_	
67-9	13353-13368	Placebo_RedCues	_	
67-10	13368-13369	,	_	
67-11	13370-13373	and	_	
67-12	13374-13391	Placebo_GreenCues	_	
67-13	13391-13392	,	_	
67-14	13393-13396	and	_	
67-15	13397-13406	analogous	_	
67-16	13407-13417	regressors	_	
67-17	13418-13421	for	_	
67-18	13422-13428	Probes	_	
67-19	13428-13429	.	_	

#Text=We also included a nuisance regressor for errors and trials lacking a motor response, to account for these event-related signal changes, but did not include these in the inferential testing, as they were too rare for reliable analysis (see task performance results).
68-1	13430-13432	We	_	
68-2	13433-13437	also	_	
68-3	13438-13446	included	_	
68-4	13447-13448	a	_	
68-5	13449-13457	nuisance	_	
68-6	13458-13467	regressor	_	
68-7	13468-13471	for	_	
68-8	13472-13478	errors	_	
68-9	13479-13482	and	_	
68-10	13483-13489	trials	_	
68-11	13490-13497	lacking	_	
68-12	13498-13499	a	_	
68-13	13500-13505	motor	_	
68-14	13506-13514	response	_	
68-15	13514-13515	,	_	
68-16	13516-13518	to	_	
68-17	13519-13526	account	_	
68-18	13527-13530	for	_	
68-19	13531-13536	these	_	
68-20	13537-13550	event-related	_	
68-21	13551-13557	signal	_	
68-22	13558-13565	changes	_	
68-23	13565-13566	,	_	
68-24	13567-13570	but	_	
68-25	13571-13574	did	_	
68-26	13575-13578	not	_	
68-27	13579-13586	include	_	
68-28	13587-13592	these	_	
68-29	13593-13595	in	_	
68-30	13596-13599	the	_	
68-31	13600-13611	inferential	_	
68-32	13612-13619	testing	_	
68-33	13619-13620	,	_	
68-34	13621-13623	as	_	
68-35	13624-13628	they	_	
68-36	13629-13633	were	_	
68-37	13634-13637	too	_	
68-38	13638-13642	rare	_	
68-39	13643-13646	for	_	
68-40	13647-13655	reliable	_	
68-41	13656-13664	analysis	_	
68-42	13665-13666	(	_	
68-43	13666-13669	see	_	
68-44	13670-13674	task	_	
68-45	13675-13686	performance	_	
68-46	13687-13694	results	_	
68-47	13694-13695	)	_	
68-48	13695-13696	.	_	

#Text=A canonical (double-Gaussian) hemodynamic response function was convolved with a series of delta functions to model the BOLD time series, with regressors placed at cue and probe onset.
69-1	13697-13698	A	_	
69-2	13699-13708	canonical	_	
69-3	13709-13710	(	_	
69-4	13710-13725	double-Gaussian	_	
69-5	13725-13726	)	_	
69-6	13727-13738	hemodynamic	_	
69-7	13739-13747	response	_	
69-8	13748-13756	function	_	
69-9	13757-13760	was	_	
69-10	13761-13770	convolved	_	
69-11	13771-13775	with	_	
69-12	13776-13777	a	_	
69-13	13778-13784	series	_	
69-14	13785-13787	of	_	
69-15	13788-13793	delta	_	
69-16	13794-13803	functions	_	
69-17	13804-13806	to	_	
69-18	13807-13812	model	_	
69-19	13813-13816	the	_	
69-20	13817-13821	BOLD	_	
69-21	13822-13826	time	_	
69-22	13827-13833	series	_	
69-23	13833-13834	,	_	
69-24	13835-13839	with	_	
69-25	13840-13850	regressors	_	
69-26	13851-13857	placed	_	
69-27	13858-13860	at	_	
69-28	13861-13864	cue	_	
69-29	13865-13868	and	_	
69-30	13869-13874	probe	_	
69-31	13875-13880	onset	_	
69-32	13880-13881	.	_	

#Text=We also established the temporal derivative of the HRF as a regressor, paired with each of the experimental condition regressors, to account for temporal variation in the latency of the event-related response.
70-1	13882-13884	We	_	
70-2	13885-13889	also	_	
70-3	13890-13901	established	_	
70-4	13902-13905	the	_	
70-5	13906-13914	temporal	_	
70-6	13915-13925	derivative	_	
70-7	13926-13928	of	_	
70-8	13929-13932	the	_	
70-9	13933-13936	HRF	_	
70-10	13937-13939	as	_	
70-11	13940-13941	a	_	
70-12	13942-13951	regressor	_	
70-13	13951-13952	,	_	
70-14	13953-13959	paired	_	
70-15	13960-13964	with	_	
70-16	13965-13969	each	_	
70-17	13970-13972	of	_	
70-18	13973-13976	the	_	
70-19	13977-13989	experimental	_	
70-20	13990-13999	condition	_	
70-21	14000-14010	regressors	_	
70-22	14010-14011	,	_	
70-23	14012-14014	to	_	
70-24	14015-14022	account	_	
70-25	14023-14026	for	_	
70-26	14027-14035	temporal	_	
70-27	14036-14045	variation	_	
70-28	14046-14048	in	_	
70-29	14049-14052	the	_	
70-30	14053-14060	latency	_	
70-31	14061-14063	of	_	
70-32	14064-14067	the	_	
70-33	14068-14081	event-related	_	
70-34	14082-14090	response	_	
70-35	14090-14091	.	_	

#Text=A 0.0125 Hz high-pass filter was used, a first-order autoregressive function to account for serial autocorrelations, and grand mean scaling to account for global differences in signal value across test days.
71-1	14092-14093	A	_	
71-2	14094-14100	0.0125	_	
71-3	14101-14103	Hz	_	
71-4	14104-14113	high-pass	_	
71-5	14114-14120	filter	_	
71-6	14121-14124	was	_	
71-7	14125-14129	used	_	
71-8	14129-14130	,	_	
71-9	14131-14132	a	_	
71-10	14133-14144	first-order	_	
71-11	14145-14159	autoregressive	_	
71-12	14160-14168	function	_	
71-13	14169-14171	to	_	
71-14	14172-14179	account	_	
71-15	14180-14183	for	_	
71-16	14184-14190	serial	_	
71-17	14191-14207	autocorrelations	_	
71-18	14207-14208	,	_	
71-19	14209-14212	and	_	
71-20	14213-14218	grand	_	
71-21	14219-14223	mean	_	
71-22	14224-14231	scaling	_	
71-23	14232-14234	to	_	
71-24	14235-14242	account	_	
71-25	14243-14246	for	_	
71-26	14247-14253	global	_	
71-27	14254-14265	differences	_	
71-28	14266-14268	in	_	
71-29	14269-14275	signal	_	
71-30	14276-14281	value	_	
71-31	14282-14288	across	_	
71-32	14289-14293	test	_	
71-33	14294-14298	days	_	
71-34	14298-14299	.	_	

#Text=After signal estimation, linear contrasts were defined at the single-subject level (see below), and then relevant contrast maps from individual subjects (containing voxel-wise parameter estimates for a given contrast) were entered into group-level analysis for inferential testing.
72-1	14300-14305	After	_	
72-2	14306-14312	signal	_	
72-3	14313-14323	estimation	_	
72-4	14323-14324	,	_	
72-5	14325-14331	linear	_	
72-6	14332-14341	contrasts	_	
72-7	14342-14346	were	_	
72-8	14347-14354	defined	_	
72-9	14355-14357	at	_	
72-10	14358-14361	the	_	
72-11	14362-14376	single-subject	_	
72-12	14377-14382	level	_	
72-13	14383-14384	(	_	
72-14	14384-14387	see	_	
72-15	14388-14393	below	_	
72-16	14393-14394	)	_	
72-17	14394-14395	,	_	
72-18	14396-14399	and	_	
72-19	14400-14404	then	_	
72-20	14405-14413	relevant	_	
72-21	14414-14422	contrast	_	
72-22	14423-14427	maps	_	
72-23	14428-14432	from	_	
72-24	14433-14443	individual	_	
72-25	14444-14452	subjects	_	
72-26	14453-14454	(	_	
72-27	14454-14464	containing	_	
72-28	14465-14475	voxel-wise	_	
72-29	14476-14485	parameter	_	
72-30	14486-14495	estimates	_	
72-31	14496-14499	for	_	
72-32	14500-14501	a	_	
72-33	14502-14507	given	_	
72-34	14508-14516	contrast	_	
72-35	14516-14517	)	_	
72-36	14518-14522	were	_	
72-37	14523-14530	entered	_	
72-38	14531-14535	into	_	
72-39	14536-14547	group-level	_	
72-40	14548-14556	analysis	_	
72-41	14557-14560	for	_	
72-42	14561-14572	inferential	_	
72-43	14573-14580	testing	_	
72-44	14580-14581	.	_	

#Text=The control-independent Treatment effect was tested with the contrast defined as (Drug_RedCue + Drug_GreenCue) > (Placebo_RedCue + Placebo_GreenCue).
73-1	14582-14585	The	_	
73-2	14586-14605	control-independent	_	
73-3	14606-14615	Treatment	_	
73-4	14616-14622	effect	_	
73-5	14623-14626	was	_	
73-6	14627-14633	tested	_	
73-7	14634-14638	with	_	
73-8	14639-14642	the	_	
73-9	14643-14651	contrast	_	
73-10	14652-14659	defined	_	
73-11	14660-14662	as	_	
73-12	14663-14664	(	_	
73-13	14664-14675	Drug_RedCue	_	
73-14	14676-14677	+	_	
73-15	14678-14691	Drug_GreenCue	_	
73-16	14691-14692	)	_	
73-17	14693-14694	>	_	
73-18	14695-14696	(	_	
73-19	14696-14710	Placebo_RedCue	_	
73-20	14711-14712	+	_	
73-21	14713-14729	Placebo_GreenCue	_	
73-22	14729-14730	)	_	
73-23	14730-14731	.	_	

#Text=This contrast uses all available data to estimate treatment effects that are independent of Task Condition, i.e., cognitive control demands.
74-1	14732-14736	This	_	
74-2	14737-14745	contrast	_	
74-3	14746-14750	uses	_	
74-4	14751-14754	all	_	
74-5	14755-14764	available	_	
74-6	14765-14769	data	_	
74-7	14770-14772	to	_	
74-8	14773-14781	estimate	_	
74-9	14782-14791	treatment	_	
74-10	14792-14799	effects	_	
74-11	14800-14804	that	_	
74-12	14805-14808	are	_	
74-13	14809-14820	independent	_	
74-14	14821-14823	of	_	
74-15	14824-14828	Task	_	
74-16	14829-14838	Condition	_	
74-17	14838-14839	,	_	
74-18	14840-14843	i.e	_	
74-19	14843-14844	.	_	
74-20	14844-14845	,	_	
74-21	14846-14855	cognitive	_	
74-22	14856-14863	control	_	
74-23	14864-14871	demands	_	
74-24	14871-14872	.	_	

#Text=We hypothesized that in this contrast, significant drug effects (relative to placebo) would be manifest as deactivations in both the LC and the VTA, attendant to the model of catecholamine neurotransmission at cell bodies, an effect well-established for catecholamine transporter inhibitors such as stimulants and antidepressants.
75-1	14873-14875	We	_	
75-2	14876-14888	hypothesized	_	
75-3	14889-14893	that	_	
75-4	14894-14896	in	_	
75-5	14897-14901	this	_	
75-6	14902-14910	contrast	_	
75-7	14910-14911	,	_	
75-8	14912-14923	significant	_	
75-9	14924-14928	drug	_	
75-10	14929-14936	effects	_	
75-11	14937-14938	(	_	
75-12	14938-14946	relative	_	
75-13	14947-14949	to	_	
75-14	14950-14957	placebo	_	
75-15	14957-14958	)	_	
75-16	14959-14964	would	_	
75-17	14965-14967	be	_	
75-18	14968-14976	manifest	_	
75-19	14977-14979	as	_	
75-20	14980-14993	deactivations	_	
75-21	14994-14996	in	_	
75-22	14997-15001	both	_	
75-23	15002-15005	the	_	
75-24	15006-15008	LC	_	
75-25	15009-15012	and	_	
75-26	15013-15016	the	_	
75-27	15017-15020	VTA	_	
75-28	15020-15021	,	_	
75-29	15022-15031	attendant	_	
75-30	15032-15034	to	_	
75-31	15035-15038	the	_	
75-32	15039-15044	model	_	
75-33	15045-15047	of	_	
75-34	15048-15061	catecholamine	_	
75-35	15062-15079	neurotransmission	_	
75-36	15080-15082	at	_	
75-37	15083-15087	cell	_	
75-38	15088-15094	bodies	_	
75-39	15094-15095	,	_	
75-40	15096-15098	an	_	
75-41	15099-15105	effect	_	
75-42	15106-15122	well-established	_	
75-43	15123-15126	for	_	
75-44	15127-15140	catecholamine	_	
75-45	15141-15152	transporter	_	
75-46	15153-15163	inhibitors	_	
75-47	15164-15168	such	_	
75-48	15169-15171	as	_	
75-49	15172-15182	stimulants	_	
75-50	15183-15186	and	_	
75-51	15187-15202	antidepressants	_	
75-52	15202-15203	.	_	

#Text=In contrast, for the control-related treatment effect on brain activity, the contrast was established as (Drug_RedCue minus Drug_GreenCue) > (Placebo_RedCue minus Placebo_GreenCue).
76-1	15204-15206	In	_	
76-2	15207-15215	contrast	_	
76-3	15215-15216	,	_	
76-4	15217-15220	for	_	
76-5	15221-15224	the	_	
76-6	15225-15240	control-related	_	
76-7	15241-15250	treatment	_	
76-8	15251-15257	effect	_	
76-9	15258-15260	on	_	
76-10	15261-15266	brain	_	
76-11	15267-15275	activity	_	
76-12	15275-15276	,	_	
76-13	15277-15280	the	_	
76-14	15281-15289	contrast	_	
76-15	15290-15293	was	_	
76-16	15294-15305	established	_	
76-17	15306-15308	as	_	
76-18	15309-15310	(	_	
76-19	15310-15321	Drug_RedCue	_	
76-20	15322-15327	minus	_	
76-21	15328-15341	Drug_GreenCue	_	
76-22	15341-15342	)	_	
76-23	15343-15344	>	_	
76-24	15345-15346	(	_	
76-25	15346-15360	Placebo_RedCue	_	
76-26	15361-15366	minus	_	
76-27	15367-15383	Placebo_GreenCue	_	
76-28	15383-15384	)	_	
76-29	15384-15385	.	_	

#Text=This is analogous to a directional test of the Treatment-by-Task Condition interaction in ANOVA terminology, and in this contrast, we hypothesized that the Drug would serve to positively enhance LC and VTA activity.
77-1	15386-15390	This	_	
77-2	15391-15393	is	_	
77-3	15394-15403	analogous	_	
77-4	15404-15406	to	_	
77-5	15407-15408	a	_	
77-6	15409-15420	directional	_	
77-7	15421-15425	test	_	
77-8	15426-15428	of	_	
77-9	15429-15432	the	_	
77-10	15433-15450	Treatment-by-Task	_	
77-11	15451-15460	Condition	_	
77-12	15461-15472	interaction	_	
77-13	15473-15475	in	_	
77-14	15476-15481	ANOVA	_	
77-15	15482-15493	terminology	_	
77-16	15493-15494	,	_	
77-17	15495-15498	and	_	
77-18	15499-15501	in	_	
77-19	15502-15506	this	_	
77-20	15507-15515	contrast	_	
77-21	15515-15516	,	_	
77-22	15517-15519	we	_	
77-23	15520-15532	hypothesized	_	
77-24	15533-15537	that	_	
77-25	15538-15541	the	_	
77-26	15542-15546	Drug	_	
77-27	15547-15552	would	_	
77-28	15553-15558	serve	_	
77-29	15559-15561	to	_	
77-30	15562-15572	positively	_	
77-31	15573-15580	enhance	_	
77-32	15581-15583	LC	_	
77-33	15584-15587	and	_	
77-34	15588-15591	VTA	_	
77-35	15592-15600	activity	_	
77-36	15600-15601	.	_	

#Text=This is because despite a control-independent effect of Drug manifest as deactivation, the drug should augment the positive difference in activity related to cognitive control demands (i.e., Red Cue over Green Cue-related activity), as the cellular model suggests that a modest decrease in tonic firing rates should be associated with an increased phasic (i.e., task-related) firing rate, as an expression of gain control in neural activity.
78-1	15602-15606	This	_	
78-2	15607-15609	is	_	
78-3	15610-15617	because	_	
78-4	15618-15625	despite	_	
78-5	15626-15627	a	_	
78-6	15628-15647	control-independent	_	
78-7	15648-15654	effect	_	
78-8	15655-15657	of	_	
78-9	15658-15662	Drug	_	
78-10	15663-15671	manifest	_	
78-11	15672-15674	as	_	
78-12	15675-15687	deactivation	_	
78-13	15687-15688	,	_	
78-14	15689-15692	the	_	
78-15	15693-15697	drug	_	
78-16	15698-15704	should	_	
78-17	15705-15712	augment	_	
78-18	15713-15716	the	_	
78-19	15717-15725	positive	_	
78-20	15726-15736	difference	_	
78-21	15737-15739	in	_	
78-22	15740-15748	activity	_	
78-23	15749-15756	related	_	
78-24	15757-15759	to	_	
78-25	15760-15769	cognitive	_	
78-26	15770-15777	control	_	
78-27	15778-15785	demands	_	
78-28	15786-15787	(	_	
78-29	15787-15790	i.e	_	
78-30	15790-15791	.	_	
78-31	15791-15792	,	_	
78-32	15793-15796	Red	_	
78-33	15797-15800	Cue	_	
78-34	15801-15805	over	_	
78-35	15806-15811	Green	_	
78-36	15812-15823	Cue-related	_	
78-37	15824-15832	activity	_	
78-38	15832-15833	)	_	
78-39	15833-15834	,	_	
78-40	15835-15837	as	_	
78-41	15838-15841	the	_	
78-42	15842-15850	cellular	_	
78-43	15851-15856	model	_	
78-44	15857-15865	suggests	_	
78-45	15866-15870	that	_	
78-46	15871-15872	a	_	
78-47	15873-15879	modest	_	
78-48	15880-15888	decrease	_	
78-49	15889-15891	in	_	
78-50	15892-15897	tonic	_	
78-51	15898-15904	firing	_	
78-52	15905-15910	rates	_	
78-53	15911-15917	should	_	
78-54	15918-15920	be	_	
78-55	15921-15931	associated	_	
78-56	15932-15936	with	_	
78-57	15937-15939	an	_	
78-58	15940-15949	increased	_	
78-59	15950-15956	phasic	_	
78-60	15957-15958	(	_	
78-61	15958-15961	i.e	_	
78-62	15961-15962	.	_	
78-63	15962-15963	,	_	
78-64	15964-15976	task-related	_	
78-65	15976-15977	)	_	
78-66	15978-15984	firing	_	
78-67	15985-15989	rate	_	
78-68	15989-15990	,	_	
78-69	15991-15993	as	_	
78-70	15994-15996	an	_	
78-71	15997-16007	expression	_	
78-72	16008-16010	of	_	
78-73	16011-16015	gain	_	
78-74	16016-16023	control	_	
78-75	16024-16026	in	_	
78-76	16027-16033	neural	_	
78-77	16034-16042	activity	_	
78-78	16042-16043	.	_	

#Text=This contrast also tested the hypothesis that elsewhere in the cognitive control network, the drug would be associated with a significantly greater enhancement of positive control-related BOLD signal change, again compared to placebo.
79-1	16044-16048	This	_	
79-2	16049-16057	contrast	_	
79-3	16058-16062	also	_	
79-4	16063-16069	tested	_	
79-5	16070-16073	the	_	
79-6	16074-16084	hypothesis	_	
79-7	16085-16089	that	_	
79-8	16090-16099	elsewhere	_	
79-9	16100-16102	in	_	
79-10	16103-16106	the	_	
79-11	16107-16116	cognitive	_	
79-12	16117-16124	control	_	
79-13	16125-16132	network	_	
79-14	16132-16133	,	_	
79-15	16134-16137	the	_	
79-16	16138-16142	drug	_	
79-17	16143-16148	would	_	
79-18	16149-16151	be	_	
79-19	16152-16162	associated	_	
79-20	16163-16167	with	_	
79-21	16168-16169	a	_	
79-22	16170-16183	significantly	_	
79-23	16184-16191	greater	_	
79-24	16192-16203	enhancement	_	
79-25	16204-16206	of	_	
79-26	16207-16215	positive	_	
79-27	16216-16231	control-related	_	
79-28	16232-16236	BOLD	_	
79-29	16237-16243	signal	_	
79-30	16244-16250	change	_	
79-31	16250-16251	,	_	
79-32	16252-16257	again	_	
79-33	16258-16266	compared	_	
79-34	16267-16269	to	_	
79-35	16270-16277	placebo	_	
79-36	16277-16278	.	_	

#Text=All contrast maps are depicted at a threshold of p < 0.05, with clusters corrected to p < 0.05 by small-volume (for LC and VTA) or the False Discovery Rate (for the cortical cognitive control network).
80-1	16279-16282	All	_	
80-2	16283-16291	contrast	_	
80-3	16292-16296	maps	_	
80-4	16297-16300	are	_	
80-5	16301-16309	depicted	_	
80-6	16310-16312	at	_	
80-7	16313-16314	a	_	
80-8	16315-16324	threshold	_	
80-9	16325-16327	of	_	
80-10	16328-16329	p	_	
80-11	16330-16331	<	_	
80-12	16332-16336	0.05	_	
80-13	16336-16337	,	_	
80-14	16338-16342	with	_	
80-15	16343-16351	clusters	_	
80-16	16352-16361	corrected	_	
80-17	16362-16364	to	_	
80-18	16365-16366	p	_	
80-19	16367-16368	<	_	
80-20	16369-16373	0.05	_	
80-21	16374-16376	by	_	
80-22	16377-16389	small-volume	_	
80-23	16390-16391	(	_	
80-24	16391-16394	for	_	
80-25	16395-16397	LC	_	
80-26	16398-16401	and	_	
80-27	16402-16405	VTA	_	
80-28	16405-16406	)	_	
80-29	16407-16409	or	_	
80-30	16410-16413	the	_	
80-31	16414-16419	False	_	
80-32	16420-16429	Discovery	_	
80-33	16430-16434	Rate	_	
80-34	16435-16436	(	_	
80-35	16436-16439	for	_	
80-36	16440-16443	the	_	
80-37	16444-16452	cortical	_	
80-38	16453-16462	cognitive	_	
80-39	16463-16470	control	_	
80-40	16471-16478	network	_	
80-41	16478-16479	)	_	
80-42	16479-16480	.	_	

#Text=Code availability
#Text=All neuroimaging data pre-processing and analyses were conducted using SPM5 software, which is readily available in the public domain.
81-1	16481-16485	Code	_	
81-2	16486-16498	availability	_	
81-3	16499-16502	All	_	
81-4	16503-16515	neuroimaging	_	
81-5	16516-16520	data	_	
81-6	16521-16535	pre-processing	_	
81-7	16536-16539	and	_	
81-8	16540-16548	analyses	_	
81-9	16549-16553	were	_	
81-10	16554-16563	conducted	_	
81-11	16564-16569	using	_	
81-12	16570-16574	SPM5	_	
81-13	16575-16583	software	_	
81-14	16583-16584	,	_	
81-15	16585-16590	which	_	
81-16	16591-16593	is	_	
81-17	16594-16601	readily	_	
81-18	16602-16611	available	_	
81-19	16612-16614	in	_	
81-20	16615-16618	the	_	
81-21	16619-16625	public	_	
81-22	16626-16632	domain	_	
81-23	16632-16633	.	_	

#Text=See the Supplemental Methods for details of localization of the LC, VTA and cognitive control network in EPI images, and correlation analysis of BOLD signal change with antipsychotic receptor-binding affinities.
82-1	16634-16637	See	_	
82-2	16638-16641	the	_	
82-3	16642-16654	Supplemental	_	
82-4	16655-16662	Methods	_	
82-5	16663-16666	for	_	
82-6	16667-16674	details	_	
82-7	16675-16677	of	_	
82-8	16678-16690	localization	_	
82-9	16691-16693	of	_	
82-10	16694-16697	the	_	
82-11	16698-16700	LC	_	
82-12	16700-16701	,	_	
82-13	16702-16705	VTA	_	
82-14	16706-16709	and	_	
82-15	16710-16719	cognitive	_	
82-16	16720-16727	control	_	
82-17	16728-16735	network	_	
82-18	16736-16738	in	_	
82-19	16739-16742	EPI	_	
82-20	16743-16749	images	_	
82-21	16749-16750	,	_	
82-22	16751-16754	and	_	
82-23	16755-16766	correlation	_	
82-24	16767-16775	analysis	_	
82-25	16776-16778	of	_	
82-26	16779-16783	BOLD	_	
82-27	16784-16790	signal	_	
82-28	16791-16797	change	_	
82-29	16798-16802	with	_	
82-30	16803-16816	antipsychotic	_	
82-31	16817-16833	receptor-binding	_	
82-32	16834-16844	affinities	_	
82-33	16844-16845	.	_	

#Text=Results
#Text=See Supplemental Results for task performance results
#Text=fMRI results within schizophrenia group
#Text=Modafinil effects on control-independent activity in locus coeruleus and ventral tegmental area in Schizophrenia Group.
83-1	16846-16853	Results	_	
83-2	16854-16857	See	_	
83-3	16858-16870	Supplemental	_	
83-4	16871-16878	Results	_	
83-5	16879-16882	for	_	
83-6	16883-16887	task	_	
83-7	16888-16899	performance	_	
83-8	16900-16907	results	_	
83-9	16908-16912	fMRI	_	
83-10	16913-16920	results	_	
83-11	16921-16927	within	_	
83-12	16928-16941	schizophrenia	_	
83-13	16942-16947	group	_	
83-14	16948-16957	Modafinil	_	
83-15	16958-16965	effects	_	
83-16	16966-16968	on	_	
83-17	16969-16988	control-independent	_	
83-18	16989-16997	activity	_	
83-19	16998-17000	in	_	
83-20	17001-17006	locus	_	
83-21	17007-17016	coeruleus	_	
83-22	17017-17020	and	_	
83-23	17021-17028	ventral	_	
83-24	17029-17038	tegmental	_	
83-25	17039-17043	area	_	
83-26	17044-17046	in	_	
83-27	17047-17060	Schizophrenia	_	
83-28	17061-17066	Group	_	
83-29	17066-17067	.	_	

#Text=Contrast maps of SZ group for Control-independent effect of Modafinil Treatment on decreased activity in locus coeruleus (a) and ventral tegmental area (b).
84-1	17068-17076	Contrast	_	
84-2	17077-17081	maps	_	
84-3	17082-17084	of	_	
84-4	17085-17087	SZ	_	
84-5	17088-17093	group	_	
84-6	17094-17097	for	_	
84-7	17098-17117	Control-independent	_	
84-8	17118-17124	effect	_	
84-9	17125-17127	of	_	
84-10	17128-17137	Modafinil	_	
84-11	17138-17147	Treatment	_	
84-12	17148-17150	on	_	
84-13	17151-17160	decreased	_	
84-14	17161-17169	activity	_	
84-15	17170-17172	in	_	
84-16	17173-17178	locus	_	
84-17	17179-17188	coeruleus	_	
84-18	17189-17190	(	_	
84-19	17190-17191	a	_	
84-20	17191-17192	)	_	
84-21	17193-17196	and	_	
84-22	17197-17204	ventral	_	
84-23	17205-17214	tegmental	_	
84-24	17215-17219	area	_	
84-25	17220-17221	(	_	
84-26	17221-17222	b	_	
84-27	17222-17223	)	_	
84-28	17223-17224	.	_	

#Text=Clusters depicted are small-volume-corrected to p < 0.05.
85-1	17225-17233	Clusters	_	
85-2	17234-17242	depicted	_	
85-3	17243-17246	are	_	
85-4	17247-17269	small-volume-corrected	_	
85-5	17270-17272	to	_	
85-6	17273-17274	p	_	
85-7	17275-17276	<	_	
85-8	17277-17281	0.05	_	
85-9	17281-17282	.	_	

#Text=Bar graph depicts mean betas (±s.d.) in statistically significant voxels for MOD (left) and PLC (right).
86-1	17283-17286	Bar	_	
86-2	17287-17292	graph	_	
86-3	17293-17300	depicts	_	
86-4	17301-17305	mean	_	
86-5	17306-17311	betas	_	
86-6	17312-17313	(	_	
86-7	17313-17314	±	_	
86-8	17314-17317	s.d	_	
86-9	17317-17318	.	_	
86-10	17318-17319	)	_	
86-11	17320-17322	in	_	
86-12	17323-17336	statistically	_	
86-13	17337-17348	significant	_	
86-14	17349-17355	voxels	_	
86-15	17356-17359	for	_	
86-16	17360-17363	MOD	_	
86-17	17364-17365	(	_	
86-18	17365-17369	left	_	
86-19	17369-17370	)	_	
86-20	17371-17374	and	_	
86-21	17375-17378	PLC	_	
86-22	17379-17380	(	_	
86-23	17380-17385	right	_	
86-24	17385-17386	)	_	
86-25	17386-17387	.	_	

#Text=See text for details of data acquisition and analysis.
87-1	17388-17391	See	_	
87-2	17392-17396	text	_	
87-3	17397-17400	for	_	
87-4	17401-17408	details	_	
87-5	17409-17411	of	_	
87-6	17412-17416	data	_	
87-7	17417-17428	acquisition	_	
87-8	17429-17432	and	_	
87-9	17433-17441	analysis	_	
87-10	17441-17442	.	_	

#Text=See Supplemental Table 5 for characteristics of clusters
#Text=The SZ group showed a significant control-independent effect of Treatment (i.e., across both cue types) in both the locus coeruleus (Fig. 2a; Supplemental Table 5) and ventral tegmental area (Fig. 2b; Supplemental Table 5).
88-1	17443-17446	See	_	
88-2	17447-17459	Supplemental	_	
88-3	17460-17465	Table	_	
88-4	17466-17467	5	_	
88-5	17468-17471	for	_	
88-6	17472-17487	characteristics	_	
88-7	17488-17490	of	_	
88-8	17491-17499	clusters	_	
88-9	17500-17503	The	_	
88-10	17504-17506	SZ	_	
88-11	17507-17512	group	_	
88-12	17513-17519	showed	_	
88-13	17520-17521	a	_	
88-14	17522-17533	significant	_	
88-15	17534-17553	control-independent	_	
88-16	17554-17560	effect	_	
88-17	17561-17563	of	_	
88-18	17564-17573	Treatment	_	
88-19	17574-17575	(	_	
88-20	17575-17578	i.e	_	
88-21	17578-17579	.	_	
88-22	17579-17580	,	_	
88-23	17581-17587	across	_	
88-24	17588-17592	both	_	
88-25	17593-17596	cue	_	
88-26	17597-17602	types	_	
88-27	17602-17603	)	_	
88-28	17604-17606	in	_	
88-29	17607-17611	both	_	
88-30	17612-17615	the	_	
88-31	17616-17621	locus	_	
88-32	17622-17631	coeruleus	_	
88-33	17632-17633	(	_	
88-34	17633-17636	Fig	_	
88-35	17636-17637	.	_	
88-36	17638-17640	2a	_	
88-37	17640-17641	;	_	
88-38	17642-17654	Supplemental	_	
88-39	17655-17660	Table	_	
88-40	17661-17662	5	_	
88-41	17662-17663	)	_	
88-42	17664-17667	and	_	
88-43	17668-17675	ventral	_	
88-44	17676-17685	tegmental	_	
88-45	17686-17690	area	_	
88-46	17691-17692	(	_	
88-47	17692-17695	Fig	_	
88-48	17695-17696	.	_	
88-49	17697-17699	2b	_	
88-50	17699-17700	;	_	
88-51	17701-17713	Supplemental	_	
88-52	17714-17719	Table	_	
88-53	17720-17721	5	_	
88-54	17721-17722	)	_	
88-55	17722-17723	.	_	

#Text=No control-independent Treatment effects meeting the FDR-corrected significance level were observed elsewhere in the brain (data not shown).
89-1	17724-17726	No	_	
89-2	17727-17746	control-independent	_	
89-3	17747-17756	Treatment	_	
89-4	17757-17764	effects	_	
89-5	17765-17772	meeting	_	
89-6	17773-17776	the	_	
89-7	17777-17790	FDR-corrected	_	
89-8	17791-17803	significance	_	
89-9	17804-17809	level	_	
89-10	17810-17814	were	_	
89-11	17815-17823	observed	_	
89-12	17824-17833	elsewhere	_	
89-13	17834-17836	in	_	
89-14	17837-17840	the	_	
89-15	17841-17846	brain	_	
89-16	17847-17848	(	_	
89-17	17848-17852	data	_	
89-18	17853-17856	not	_	
89-19	17857-17862	shown	_	
89-20	17862-17863	)	_	
89-21	17863-17864	.	_	

#Text=Control-related Treatment effects (i.e., on the Red Cue minus Green Cue difference) were also interrogated both within the LC and VTA, as well as throughout the rest of the brain.
90-1	17865-17880	Control-related	_	
90-2	17881-17890	Treatment	_	
90-3	17891-17898	effects	_	
90-4	17899-17900	(	_	
90-5	17900-17903	i.e	_	
90-6	17903-17904	.	_	
90-7	17904-17905	,	_	
90-8	17906-17908	on	_	
90-9	17909-17912	the	_	
90-10	17913-17916	Red	_	
90-11	17917-17920	Cue	_	
90-12	17921-17926	minus	_	
90-13	17927-17932	Green	_	
90-14	17933-17936	Cue	_	
90-15	17937-17947	difference	_	
90-16	17947-17948	)	_	
90-17	17949-17953	were	_	
90-18	17954-17958	also	_	
90-19	17959-17971	interrogated	_	
90-20	17972-17976	both	_	
90-21	17977-17983	within	_	
90-22	17984-17987	the	_	
90-23	17988-17990	LC	_	
90-24	17991-17994	and	_	
90-25	17995-17998	VTA	_	
90-26	17998-17999	,	_	
90-27	18000-18002	as	_	
90-28	18003-18007	well	_	
90-29	18008-18010	as	_	
90-30	18011-18021	throughout	_	
90-31	18022-18025	the	_	
90-32	18026-18030	rest	_	
90-33	18031-18033	of	_	
90-34	18034-18037	the	_	
90-35	18038-18043	brain	_	
90-36	18043-18044	.	_	

#Text=Here, no effects were observed that met the corrected significance level.
#Text=fMRI results comparing schizophrenia group to healthy control group
#Text=Modafinil effects on control-independent deactivation in schizophrenia group compared to healthy control group are shallower in locus coeruleus and deeper in ventral tegmental area.
91-1	18045-18049	Here	_	
91-2	18049-18050	,	_	
91-3	18051-18053	no	_	
91-4	18054-18061	effects	_	
91-5	18062-18066	were	_	
91-6	18067-18075	observed	_	
91-7	18076-18080	that	_	
91-8	18081-18084	met	_	
91-9	18085-18088	the	_	
91-10	18089-18098	corrected	_	
91-11	18099-18111	significance	_	
91-12	18112-18117	level	_	
91-13	18117-18118	.	_	
91-14	18119-18123	fMRI	_	
91-15	18124-18131	results	_	
91-16	18132-18141	comparing	_	
91-17	18142-18155	schizophrenia	_	
91-18	18156-18161	group	_	
91-19	18162-18164	to	_	
91-20	18165-18172	healthy	_	
91-21	18173-18180	control	_	
91-22	18181-18186	group	_	
91-23	18187-18196	Modafinil	_	
91-24	18197-18204	effects	_	
91-25	18205-18207	on	_	
91-26	18208-18227	control-independent	_	
91-27	18228-18240	deactivation	_	
91-28	18241-18243	in	_	
91-29	18244-18257	schizophrenia	_	
91-30	18258-18263	group	_	
91-31	18264-18272	compared	_	
91-32	18273-18275	to	_	
91-33	18276-18283	healthy	_	
91-34	18284-18291	control	_	
91-35	18292-18297	group	_	
91-36	18298-18301	are	_	
91-37	18302-18311	shallower	_	
91-38	18312-18314	in	_	
91-39	18315-18320	locus	_	
91-40	18321-18330	coeruleus	_	
91-41	18331-18334	and	_	
91-42	18335-18341	deeper	_	
91-43	18342-18344	in	_	
91-44	18345-18352	ventral	_	
91-45	18353-18362	tegmental	_	
91-46	18363-18367	area	_	
91-47	18367-18368	.	_	

#Text=Contrast maps of SZ group minus HC group, for Control-independent effect of Modafinil Treatment, on activity in locus coeruleus (a) and ventral tegmental area (b).
92-1	18369-18377	Contrast	_	
92-2	18378-18382	maps	_	
92-3	18383-18385	of	_	
92-4	18386-18388	SZ	_	
92-5	18389-18394	group	_	
92-6	18395-18400	minus	_	
92-7	18401-18403	HC	_	
92-8	18404-18409	group	_	
92-9	18409-18410	,	_	
92-10	18411-18414	for	_	
92-11	18415-18434	Control-independent	_	
92-12	18435-18441	effect	_	
92-13	18442-18444	of	_	
92-14	18445-18454	Modafinil	_	
92-15	18455-18464	Treatment	_	
92-16	18464-18465	,	_	
92-17	18466-18468	on	_	
92-18	18469-18477	activity	_	
92-19	18478-18480	in	_	
92-20	18481-18486	locus	_	
92-21	18487-18496	coeruleus	_	
92-22	18497-18498	(	_	
92-23	18498-18499	a	_	
92-24	18499-18500	)	_	
92-25	18501-18504	and	_	
92-26	18505-18512	ventral	_	
92-27	18513-18522	tegmental	_	
92-28	18523-18527	area	_	
92-29	18528-18529	(	_	
92-30	18529-18530	b	_	
92-31	18530-18531	)	_	
92-32	18531-18532	.	_	

#Text=Clusters depicted are small-volume-corrected to p < 0.05.
93-1	18533-18541	Clusters	_	
93-2	18542-18550	depicted	_	
93-3	18551-18554	are	_	
93-4	18555-18577	small-volume-corrected	_	
93-5	18578-18580	to	_	
93-6	18581-18582	p	_	
93-7	18583-18584	<	_	
93-8	18585-18589	0.05	_	
93-9	18589-18590	.	_	

#Text=Bar graph depicts mean betas (±s.d.) in statistically significant voxels for SZ (left) and HC (right) groups.
94-1	18591-18594	Bar	_	
94-2	18595-18600	graph	_	
94-3	18601-18608	depicts	_	
94-4	18609-18613	mean	_	
94-5	18614-18619	betas	_	
94-6	18620-18621	(	_	
94-7	18621-18622	±	_	
94-8	18622-18625	s.d	_	
94-9	18625-18626	.	_	
94-10	18626-18627	)	_	
94-11	18628-18630	in	_	
94-12	18631-18644	statistically	_	
94-13	18645-18656	significant	_	
94-14	18657-18663	voxels	_	
94-15	18664-18667	for	_	
94-16	18668-18670	SZ	_	
94-17	18671-18672	(	_	
94-18	18672-18676	left	_	
94-19	18676-18677	)	_	
94-20	18678-18681	and	_	
94-21	18682-18684	HC	_	
94-22	18685-18686	(	_	
94-23	18686-18691	right	_	
94-24	18691-18692	)	_	
94-25	18693-18699	groups	_	
94-26	18699-18700	.	_	

#Text=Note that the SZ group, compared to the HC group, shows relatively greater activity in LC, i.e., less deactivation, and relatively less activity in VTA, i.e., greater deactivation.
95-1	18701-18705	Note	_	
95-2	18706-18710	that	_	
95-3	18711-18714	the	_	
95-4	18715-18717	SZ	_	
95-5	18718-18723	group	_	
95-6	18723-18724	,	_	
95-7	18725-18733	compared	_	
95-8	18734-18736	to	_	
95-9	18737-18740	the	_	
95-10	18741-18743	HC	_	
95-11	18744-18749	group	_	
95-12	18749-18750	,	_	
95-13	18751-18756	shows	_	
95-14	18757-18767	relatively	_	
95-15	18768-18775	greater	_	
95-16	18776-18784	activity	_	
95-17	18785-18787	in	_	
95-18	18788-18790	LC	_	
95-19	18790-18791	,	_	
95-20	18792-18795	i.e	_	
95-21	18795-18796	.	_	
95-22	18796-18797	,	_	
95-23	18798-18802	less	_	
95-24	18803-18815	deactivation	_	
95-25	18815-18816	,	_	
95-26	18817-18820	and	_	
95-27	18821-18831	relatively	_	
95-28	18832-18836	less	_	
95-29	18837-18845	activity	_	
95-30	18846-18848	in	_	
95-31	18849-18852	VTA	_	
95-32	18852-18853	,	_	
95-33	18854-18857	i.e	_	
95-34	18857-18858	.	_	
95-35	18858-18859	,	_	
95-36	18860-18867	greater	_	
95-37	18868-18880	deactivation	_	
95-38	18880-18881	.	_	

#Text=See Supplemental Table 5 for characteristics of clusters
#Text=Modafinil effects on control-related positive activation in locus coeruleus, ventral tegmental area and neocortical cognitive control network are impaired in schizophrenia group compared to healthy control group.
96-1	18882-18885	See	_	
96-2	18886-18898	Supplemental	_	
96-3	18899-18904	Table	_	
96-4	18905-18906	5	_	
96-5	18907-18910	for	_	
96-6	18911-18926	characteristics	_	
96-7	18927-18929	of	_	
96-8	18930-18938	clusters	_	
96-9	18939-18948	Modafinil	_	
96-10	18949-18956	effects	_	
96-11	18957-18959	on	_	
96-12	18960-18975	control-related	_	
96-13	18976-18984	positive	_	
96-14	18985-18995	activation	_	
96-15	18996-18998	in	_	
96-16	18999-19004	locus	_	
96-17	19005-19014	coeruleus	_	
96-18	19014-19015	,	_	
96-19	19016-19023	ventral	_	
96-20	19024-19033	tegmental	_	
96-21	19034-19038	area	_	
96-22	19039-19042	and	_	
96-23	19043-19054	neocortical	_	
96-24	19055-19064	cognitive	_	
96-25	19065-19072	control	_	
96-26	19073-19080	network	_	
96-27	19081-19084	are	_	
96-28	19085-19093	impaired	_	
96-29	19094-19096	in	_	
96-30	19097-19110	schizophrenia	_	
96-31	19111-19116	group	_	
96-32	19117-19125	compared	_	
96-33	19126-19128	to	_	
96-34	19129-19136	healthy	_	
96-35	19137-19144	control	_	
96-36	19145-19150	group	_	
96-37	19150-19151	.	_	

#Text=Contrast maps of SZ group minus HC group, for Control-related effect of Modafinil Treatment on activity within locus coeruleus (a), ventral tegmental area (b), and brain as a whole (c).
97-1	19152-19160	Contrast	_	
97-2	19161-19165	maps	_	
97-3	19166-19168	of	_	
97-4	19169-19171	SZ	_	
97-5	19172-19177	group	_	
97-6	19178-19183	minus	_	
97-7	19184-19186	HC	_	
97-8	19187-19192	group	_	
97-9	19192-19193	,	_	
97-10	19194-19197	for	_	
97-11	19198-19213	Control-related	_	
97-12	19214-19220	effect	_	
97-13	19221-19223	of	_	
97-14	19224-19233	Modafinil	_	
97-15	19234-19243	Treatment	_	
97-16	19244-19246	on	_	
97-17	19247-19255	activity	_	
97-18	19256-19262	within	_	
97-19	19263-19268	locus	_	
97-20	19269-19278	coeruleus	_	
97-21	19279-19280	(	_	
97-22	19280-19281	a	_	
97-23	19281-19282	)	_	
97-24	19282-19283	,	_	
97-25	19284-19291	ventral	_	
97-26	19292-19301	tegmental	_	
97-27	19302-19306	area	_	
97-28	19307-19308	(	_	
97-29	19308-19309	b	_	
97-30	19309-19310	)	_	
97-31	19310-19311	,	_	
97-32	19312-19315	and	_	
97-33	19316-19321	brain	_	
97-34	19322-19324	as	_	
97-35	19325-19326	a	_	
97-36	19327-19332	whole	_	
97-37	19333-19334	(	_	
97-38	19334-19335	c	_	
97-39	19335-19336	)	_	
97-40	19336-19337	.	_	

#Text=Bar graph depicts mean betas (±s.d.) in statistically significant voxels for SZ (left) and HC (right) groups.
98-1	19338-19341	Bar	_	
98-2	19342-19347	graph	_	
98-3	19348-19355	depicts	_	
98-4	19356-19360	mean	_	
98-5	19361-19366	betas	_	
98-6	19367-19368	(	_	
98-7	19368-19369	±	_	
98-8	19369-19372	s.d	_	
98-9	19372-19373	.	_	
98-10	19373-19374	)	_	
98-11	19375-19377	in	_	
98-12	19378-19391	statistically	_	
98-13	19392-19403	significant	_	
98-14	19404-19410	voxels	_	
98-15	19411-19414	for	_	
98-16	19415-19417	SZ	_	
98-17	19418-19419	(	_	
98-18	19419-19423	left	_	
98-19	19423-19424	)	_	
98-20	19425-19428	and	_	
98-21	19429-19431	HC	_	
98-22	19432-19433	(	_	
98-23	19433-19438	right	_	
98-24	19438-19439	)	_	
98-25	19440-19446	groups	_	
98-26	19446-19447	.	_	

#Text=Note that the SZ group, compared to the HC group, shows relatively impaired Treatment effects on control-related activity in both subcortical catecholamine brain regions as well as in various regions of the fronto-subcortical cognitive control network.
99-1	19448-19452	Note	_	
99-2	19453-19457	that	_	
99-3	19458-19461	the	_	
99-4	19462-19464	SZ	_	
99-5	19465-19470	group	_	
99-6	19470-19471	,	_	
99-7	19472-19480	compared	_	
99-8	19481-19483	to	_	
99-9	19484-19487	the	_	
99-10	19488-19490	HC	_	
99-11	19491-19496	group	_	
99-12	19496-19497	,	_	
99-13	19498-19503	shows	_	
99-14	19504-19514	relatively	_	
99-15	19515-19523	impaired	_	
99-16	19524-19533	Treatment	_	
99-17	19534-19541	effects	_	
99-18	19542-19544	on	_	
99-19	19545-19560	control-related	_	
99-20	19561-19569	activity	_	
99-21	19570-19572	in	_	
99-22	19573-19577	both	_	
99-23	19578-19589	subcortical	_	
99-24	19590-19603	catecholamine	_	
99-25	19604-19609	brain	_	
99-26	19610-19617	regions	_	
99-27	19618-19620	as	_	
99-28	19621-19625	well	_	
99-29	19626-19628	as	_	
99-30	19629-19631	in	_	
99-31	19632-19639	various	_	
99-32	19640-19647	regions	_	
99-33	19648-19650	of	_	
99-34	19651-19654	the	_	
99-35	19655-19673	fronto-subcortical	_	
99-36	19674-19683	cognitive	_	
99-37	19684-19691	control	_	
99-38	19692-19699	network	_	
99-39	19699-19700	.	_	

#Text=See Supplemental Table 5 for characteristics of clusters meeting corrected threshold
#Text=Compared to the HC group, the SZ group showed altered control-independent Treatment effects, with relatively shallower (i.e., attenuated) deactivation in the LC (Fig. 3a; Supplemental Table 5), and deeper (i.e., stronger) deactivation in the VTA (Fig. 3b; Supplemental Table 5).
100-1	19701-19704	See	_	
100-2	19705-19717	Supplemental	_	
100-3	19718-19723	Table	_	
100-4	19724-19725	5	_	
100-5	19726-19729	for	_	
100-6	19730-19745	characteristics	_	
100-7	19746-19748	of	_	
100-8	19749-19757	clusters	_	
100-9	19758-19765	meeting	_	
100-10	19766-19775	corrected	_	
100-11	19776-19785	threshold	_	
100-12	19786-19794	Compared	_	
100-13	19795-19797	to	_	
100-14	19798-19801	the	_	
100-15	19802-19804	HC	_	
100-16	19805-19810	group	_	
100-17	19810-19811	,	_	
100-18	19812-19815	the	_	
100-19	19816-19818	SZ	_	
100-20	19819-19824	group	_	
100-21	19825-19831	showed	_	
100-22	19832-19839	altered	_	
100-23	19840-19859	control-independent	_	
100-24	19860-19869	Treatment	_	
100-25	19870-19877	effects	_	
100-26	19877-19878	,	_	
100-27	19879-19883	with	_	
100-28	19884-19894	relatively	_	
100-29	19895-19904	shallower	_	
100-30	19905-19906	(	_	
100-31	19906-19909	i.e	_	
100-32	19909-19910	.	_	
100-33	19910-19911	,	_	
100-34	19912-19922	attenuated	_	
100-35	19922-19923	)	_	
100-36	19924-19936	deactivation	_	
100-37	19937-19939	in	_	
100-38	19940-19943	the	_	
100-39	19944-19946	LC	_	
100-40	19947-19948	(	_	
100-41	19948-19951	Fig	_	
100-42	19951-19952	.	_	
100-43	19953-19955	3a	_	
100-44	19955-19956	;	_	
100-45	19957-19969	Supplemental	_	
100-46	19970-19975	Table	_	
100-47	19976-19977	5	_	
100-48	19977-19978	)	_	
100-49	19978-19979	,	_	
100-50	19980-19983	and	_	
100-51	19984-19990	deeper	_	
100-52	19991-19992	(	_	
100-53	19992-19995	i.e	_	
100-54	19995-19996	.	_	
100-55	19996-19997	,	_	
100-56	19998-20006	stronger	_	
100-57	20006-20007	)	_	
100-58	20008-20020	deactivation	_	
100-59	20021-20023	in	_	
100-60	20024-20027	the	_	
100-61	20028-20031	VTA	_	
100-62	20032-20033	(	_	
100-63	20033-20036	Fig	_	
100-64	20036-20037	.	_	
100-65	20038-20040	3b	_	
100-66	20040-20041	;	_	
100-67	20042-20054	Supplemental	_	
100-68	20055-20060	Table	_	
100-69	20061-20062	5	_	
100-70	20062-20063	)	_	
100-71	20063-20064	.	_	

#Text=For the control-related treatment effect, the SZ group was impaired relative to the HC group in both the LC and VTA (Fig. 4a,b; Supplemental Table 5).
101-1	20065-20068	For	_	
101-2	20069-20072	the	_	
101-3	20073-20088	control-related	_	
101-4	20089-20098	treatment	_	
101-5	20099-20105	effect	_	
101-6	20105-20106	,	_	
101-7	20107-20110	the	_	
101-8	20111-20113	SZ	_	
101-9	20114-20119	group	_	
101-10	20120-20123	was	_	
101-11	20124-20132	impaired	_	
101-12	20133-20141	relative	_	
101-13	20142-20144	to	_	
101-14	20145-20148	the	_	
101-15	20149-20151	HC	_	
101-16	20152-20157	group	_	
101-17	20158-20160	in	_	
101-18	20161-20165	both	_	
101-19	20166-20169	the	_	
101-20	20170-20172	LC	_	
101-21	20173-20176	and	_	
101-22	20177-20180	VTA	_	
101-23	20181-20182	(	_	
101-24	20182-20185	Fig	_	
101-25	20185-20186	.	_	
101-26	20187-20189	4a	_	
101-27	20189-20190	,	_	
101-28	20190-20191	b	_	
101-29	20191-20192	;	_	
101-30	20193-20205	Supplemental	_	
101-31	20206-20211	Table	_	
101-32	20212-20213	5	_	
101-33	20213-20214	)	_	
101-34	20214-20215	.	_	

#Text=In the cognitive control network, the control-related treatment effect of modafinil was impaired in the SZ group in several regions (Fig. 4c, Supplemental Table 5).
102-1	20216-20218	In	_	
102-2	20219-20222	the	_	
102-3	20223-20232	cognitive	_	
102-4	20233-20240	control	_	
102-5	20241-20248	network	_	
102-6	20248-20249	,	_	
102-7	20250-20253	the	_	
102-8	20254-20269	control-related	_	
102-9	20270-20279	treatment	_	
102-10	20280-20286	effect	_	
102-11	20287-20289	of	_	
102-12	20290-20299	modafinil	_	
102-13	20300-20303	was	_	
102-14	20304-20312	impaired	_	
102-15	20313-20315	in	_	
102-16	20316-20319	the	_	
102-17	20320-20322	SZ	_	
102-18	20323-20328	group	_	
102-19	20329-20331	in	_	
102-20	20332-20339	several	_	
102-21	20340-20347	regions	_	
102-22	20348-20349	(	_	
102-23	20349-20352	Fig	_	
102-24	20352-20353	.	_	
102-25	20354-20356	4c	_	
102-26	20356-20357	,	_	
102-27	20358-20370	Supplemental	_	
102-28	20371-20376	Table	_	
102-29	20377-20378	5	_	
102-30	20378-20379	)	_	
102-31	20379-20380	.	_	

#Text=These included PFC regions in the bilateral superior/medial frontal gyrus (primarily in supplementary motor area and pre-SMA), right inferior frontal gyrus (in ventrolateral PFC), and bilateral middle frontal gyrus (in premotor cortex); and bilateral middle and posterior cingulate gyrus.
103-1	20381-20386	These	_	
103-2	20387-20395	included	_	
103-3	20396-20399	PFC	_	
103-4	20400-20407	regions	_	
103-5	20408-20410	in	_	
103-6	20411-20414	the	_	
103-7	20415-20424	bilateral	_	
103-8	20425-20433	superior	_	
103-9	20433-20434	/	_	
103-10	20434-20440	medial	_	
103-11	20441-20448	frontal	_	
103-12	20449-20454	gyrus	_	
103-13	20455-20456	(	_	
103-14	20456-20465	primarily	_	
103-15	20466-20468	in	_	
103-16	20469-20482	supplementary	_	
103-17	20483-20488	motor	_	
103-18	20489-20493	area	_	
103-19	20494-20497	and	_	
103-20	20498-20505	pre-SMA	_	
103-21	20505-20506	)	_	
103-22	20506-20507	,	_	
103-23	20508-20513	right	_	
103-24	20514-20522	inferior	_	
103-25	20523-20530	frontal	_	
103-26	20531-20536	gyrus	_	
103-27	20537-20538	(	_	
103-28	20538-20540	in	_	
103-29	20541-20554	ventrolateral	_	
103-30	20555-20558	PFC	_	
103-31	20558-20559	)	_	
103-32	20559-20560	,	_	
103-33	20561-20564	and	_	
103-34	20565-20574	bilateral	_	
103-35	20575-20581	middle	_	
103-36	20582-20589	frontal	_	
103-37	20590-20595	gyrus	_	
103-38	20596-20597	(	_	
103-39	20597-20599	in	_	
103-40	20600-20608	premotor	_	
103-41	20609-20615	cortex	_	
103-42	20615-20616	)	_	
103-43	20616-20617	;	_	
103-44	20618-20621	and	_	
103-45	20622-20631	bilateral	_	
103-46	20632-20638	middle	_	
103-47	20639-20642	and	_	
103-48	20643-20652	posterior	_	
103-49	20653-20662	cingulate	_	
103-50	20663-20668	gyrus	_	
103-51	20668-20669	.	_	

#Text=More posterior regions included temporoparietal areas such as the right middle temporal gyrus, and bilateral inferior parietal lobule.
104-1	20670-20674	More	_	
104-2	20675-20684	posterior	_	
104-3	20685-20692	regions	_	
104-4	20693-20701	included	_	
104-5	20702-20717	temporoparietal	_	
104-6	20718-20723	areas	_	
104-7	20724-20728	such	_	
104-8	20729-20731	as	_	
104-9	20732-20735	the	_	
104-10	20736-20741	right	_	
104-11	20742-20748	middle	_	
104-12	20749-20757	temporal	_	
104-13	20758-20763	gyrus	_	
104-14	20763-20764	,	_	
104-15	20765-20768	and	_	
104-16	20769-20778	bilateral	_	
104-17	20779-20787	inferior	_	
104-18	20788-20796	parietal	_	
104-19	20797-20803	lobule	_	
104-20	20803-20804	.	_	

#Text=Subcortical areas included the cerebellar vermis, left hippocampus, and bilateral putamen extending into thalamus.
105-1	20805-20816	Subcortical	_	
105-2	20817-20822	areas	_	
105-3	20823-20831	included	_	
105-4	20832-20835	the	_	
105-5	20836-20846	cerebellar	_	
105-6	20847-20853	vermis	_	
105-7	20853-20854	,	_	
105-8	20855-20859	left	_	
105-9	20860-20871	hippocampus	_	
105-10	20871-20872	,	_	
105-11	20873-20876	and	_	
105-12	20877-20886	bilateral	_	
105-13	20887-20894	putamen	_	
105-14	20895-20904	extending	_	
105-15	20905-20909	into	_	
105-16	20910-20918	thalamus	_	
105-17	20918-20919	.	_	

#Text=No regions were observed that exhibited a stronger control-related Treatment effect in the SZ group compared to the HC group.
106-1	20920-20922	No	_	
106-2	20923-20930	regions	_	
106-3	20931-20935	were	_	
106-4	20936-20944	observed	_	
106-5	20945-20949	that	_	
106-6	20950-20959	exhibited	_	
106-7	20960-20961	a	_	
106-8	20962-20970	stronger	_	
106-9	20971-20986	control-related	_	
106-10	20987-20996	Treatment	_	
106-11	20997-21003	effect	_	
106-12	21004-21006	in	_	
106-13	21007-21010	the	_	
106-14	21011-21013	SZ	_	
106-15	21014-21019	group	_	
106-16	21020-21028	compared	_	
106-17	21029-21031	to	_	
106-18	21032-21035	the	_	
106-19	21036-21038	HC	_	
106-20	21039-21044	group	_	
106-21	21044-21045	.	_	

#Text=Association of catecholamine receptor actions of concurrent medications with modafinil effects in LC and VTA
#Text=We evaluated how the patients’ concurrent antipsychotic medications may relate to altered brainstem responses to modafinil, as a function of antagonism of catecholamine receptors that serve as autoreceptors (Supplemental Methods).
107-1	21046-21057	Association	_	
107-2	21058-21060	of	_	
107-3	21061-21074	catecholamine	_	
107-4	21075-21083	receptor	_	
107-5	21084-21091	actions	_	
107-6	21092-21094	of	_	
107-7	21095-21105	concurrent	_	
107-8	21106-21117	medications	_	
107-9	21118-21122	with	_	
107-10	21123-21132	modafinil	_	
107-11	21133-21140	effects	_	
107-12	21141-21143	in	_	
107-13	21144-21146	LC	_	
107-14	21147-21150	and	_	
107-15	21151-21154	VTA	_	
107-16	21155-21157	We	_	
107-17	21158-21167	evaluated	_	
107-18	21168-21171	how	_	
107-19	21172-21175	the	_	
107-20	21176-21184	patients	_	
107-21	21184-21185	’	_	
107-22	21186-21196	concurrent	_	
107-23	21197-21210	antipsychotic	_	
107-24	21211-21222	medications	_	
107-25	21223-21226	may	_	
107-26	21227-21233	relate	_	
107-27	21234-21236	to	_	
107-28	21237-21244	altered	_	
107-29	21245-21254	brainstem	_	
107-30	21255-21264	responses	_	
107-31	21265-21267	to	_	
107-32	21268-21277	modafinil	_	
107-33	21277-21278	,	_	
107-34	21279-21281	as	_	
107-35	21282-21283	a	_	
107-36	21284-21292	function	_	
107-37	21293-21295	of	_	
107-38	21296-21306	antagonism	_	
107-39	21307-21309	of	_	
107-40	21310-21323	catecholamine	_	
107-41	21324-21333	receptors	_	
107-42	21334-21338	that	_	
107-43	21339-21344	serve	_	
107-44	21345-21347	as	_	
107-45	21348-21361	autoreceptors	_	
107-46	21362-21363	(	_	
107-47	21363-21375	Supplemental	_	
107-48	21376-21383	Methods	_	
107-49	21383-21384	)	_	
107-50	21384-21385	.	_	

#Text=LC effects
#Text=Relationship of modafinil effects in LC and VTA to catecholamine receptor antagonism by concurrent antipsychotic medications.
#Text=a Control-related effect of modafinil in LC is attenuated by α2 antagonism of concurrent antipsychotic medications.
108-1	21386-21388	LC	_	
108-2	21389-21396	effects	_	
108-3	21397-21409	Relationship	_	
108-4	21410-21412	of	_	
108-5	21413-21422	modafinil	_	
108-6	21423-21430	effects	_	
108-7	21431-21433	in	_	
108-8	21434-21436	LC	_	
108-9	21437-21440	and	_	
108-10	21441-21444	VTA	_	
108-11	21445-21447	to	_	
108-12	21448-21461	catecholamine	_	
108-13	21462-21470	receptor	_	
108-14	21471-21481	antagonism	_	
108-15	21482-21484	by	_	
108-16	21485-21495	concurrent	_	
108-17	21496-21509	antipsychotic	_	
108-18	21510-21521	medications	_	
108-19	21521-21522	.	_	
108-20	21523-21524	a	_	
108-21	21525-21540	Control-related	_	
108-22	21541-21547	effect	_	
108-23	21548-21550	of	_	
108-24	21551-21560	modafinil	_	
108-25	21561-21563	in	_	
108-26	21564-21566	LC	_	
108-27	21567-21569	is	_	
108-28	21570-21580	attenuated	_	
108-29	21581-21583	by	_	
108-30	21584-21586	α2	_	
108-31	21587-21597	antagonism	_	
108-32	21598-21600	of	_	
108-33	21601-21611	concurrent	_	
108-34	21612-21625	antipsychotic	_	
108-35	21626-21637	medications	_	
108-36	21637-21638	.	_	

#Text=Scatterplot of mean betas in control-related modafinil effect in LC, as a function of α2 receptor loads (in haloperidol equivalents) conferred by patients’ antipsychotic medications.
109-1	21639-21650	Scatterplot	_	
109-2	21651-21653	of	_	
109-3	21654-21658	mean	_	
109-4	21659-21664	betas	_	
109-5	21665-21667	in	_	
109-6	21668-21683	control-related	_	
109-7	21684-21693	modafinil	_	
109-8	21694-21700	effect	_	
109-9	21701-21703	in	_	
109-10	21704-21706	LC	_	
109-11	21706-21707	,	_	
109-12	21708-21710	as	_	
109-13	21711-21712	a	_	
109-14	21713-21721	function	_	
109-15	21722-21724	of	_	
109-16	21725-21727	α2	_	
109-17	21728-21736	receptor	_	
109-18	21737-21742	loads	_	
109-19	21743-21744	(	_	
109-20	21744-21746	in	_	
109-21	21747-21758	haloperidol	_	
109-22	21759-21770	equivalents	_	
109-23	21770-21771	)	_	
109-24	21772-21781	conferred	_	
109-25	21782-21784	by	_	
109-26	21785-21793	patients	_	
109-27	21793-21794	’	_	
109-28	21795-21808	antipsychotic	_	
109-29	21809-21820	medications	_	
109-30	21820-21821	.	_	

#Text=Subgroup (n = 21) on monotherapy with atypical antipsychotics. r = −0.60, p = 0.005. b Control-Independent effect of modafinil on deactivation in VTA is positively related to D2 antagonism by concurrent antipsychotic medications.
110-1	21822-21830	Subgroup	_	
110-2	21831-21832	(	_	
110-3	21832-21833	n	_	
110-4	21834-21835	=	_	
110-5	21836-21838	21	_	
110-6	21838-21839	)	_	
110-7	21840-21842	on	_	
110-8	21843-21854	monotherapy	_	
110-9	21855-21859	with	_	
110-10	21860-21868	atypical	_	
110-11	21869-21883	antipsychotics	_	
110-12	21883-21884	.	_	
110-13	21885-21886	r	_	
110-14	21887-21888	=	_	
110-15	21889-21890	−	_	
110-16	21890-21894	0.60	_	
110-17	21894-21895	,	_	
110-18	21896-21897	p	_	
110-19	21898-21899	=	_	
110-20	21900-21905	0.005	_	
110-21	21905-21906	.	_	
110-22	21907-21908	b	_	
110-23	21909-21928	Control-Independent	_	
110-24	21929-21935	effect	_	
110-25	21936-21938	of	_	
110-26	21939-21948	modafinil	_	
110-27	21949-21951	on	_	
110-28	21952-21964	deactivation	_	
110-29	21965-21967	in	_	
110-30	21968-21971	VTA	_	
110-31	21972-21974	is	_	
110-32	21975-21985	positively	_	
110-33	21986-21993	related	_	
110-34	21994-21996	to	_	
110-35	21997-21999	D2	_	
110-36	22000-22010	antagonism	_	
110-37	22011-22013	by	_	
110-38	22014-22024	concurrent	_	
110-39	22025-22038	antipsychotic	_	
110-40	22039-22050	medications	_	
110-41	22050-22051	.	_	

#Text=Scatterplot of mean betas in VTA in response to control-independent modafinil effect (Drug minus Placebo), as a function of D2 receptor loads conferred by patients’ antipsychotic medications (n = 27). r = −0.42, p = 0.031
#Text=The α2 receptor load of the patients’ concurrent atypical antipsychotic medications was reasonably normally distributed across the sample (skew = 1.24, kurtosis = 0.62), as was the control-related modafinil effect on LC activity (skew = −0.92, kurtosis = 0.65).
111-1	22052-22063	Scatterplot	_	
111-2	22064-22066	of	_	
111-3	22067-22071	mean	_	
111-4	22072-22077	betas	_	
111-5	22078-22080	in	_	
111-6	22081-22084	VTA	_	
111-7	22085-22087	in	_	
111-8	22088-22096	response	_	
111-9	22097-22099	to	_	
111-10	22100-22119	control-independent	_	
111-11	22120-22129	modafinil	_	
111-12	22130-22136	effect	_	
111-13	22137-22138	(	_	
111-14	22138-22142	Drug	_	
111-15	22143-22148	minus	_	
111-16	22149-22156	Placebo	_	
111-17	22156-22157	)	_	
111-18	22157-22158	,	_	
111-19	22159-22161	as	_	
111-20	22162-22163	a	_	
111-21	22164-22172	function	_	
111-22	22173-22175	of	_	
111-23	22176-22178	D2	_	
111-24	22179-22187	receptor	_	
111-25	22188-22193	loads	_	
111-26	22194-22203	conferred	_	
111-27	22204-22206	by	_	
111-28	22207-22215	patients	_	
111-29	22215-22216	’	_	
111-30	22217-22230	antipsychotic	_	
111-31	22231-22242	medications	_	
111-32	22243-22244	(	_	
111-33	22244-22245	n	_	
111-34	22246-22247	=	_	
111-35	22248-22250	27	_	
111-36	22250-22251	)	_	
111-37	22251-22252	.	_	
111-38	22253-22254	r	_	
111-39	22255-22256	=	_	
111-40	22257-22258	−	_	
111-41	22258-22262	0.42	_	
111-42	22262-22263	,	_	
111-43	22264-22265	p	_	
111-44	22266-22267	=	_	
111-45	22268-22273	0.031	_	
111-46	22274-22277	The	_	
111-47	22278-22280	α2	_	
111-48	22281-22289	receptor	_	
111-49	22290-22294	load	_	
111-50	22295-22297	of	_	
111-51	22298-22301	the	_	
111-52	22302-22310	patients	_	
111-53	22310-22311	’	_	
111-54	22312-22322	concurrent	_	
111-55	22323-22331	atypical	_	
111-56	22332-22345	antipsychotic	_	
111-57	22346-22357	medications	_	
111-58	22358-22361	was	_	
111-59	22362-22372	reasonably	_	
111-60	22373-22381	normally	_	
111-61	22382-22393	distributed	_	
111-62	22394-22400	across	_	
111-63	22401-22404	the	_	
111-64	22405-22411	sample	_	
111-65	22412-22413	(	_	
111-66	22413-22417	skew	_	
111-67	22418-22419	=	_	
111-68	22420-22424	1.24	_	
111-69	22424-22425	,	_	
111-70	22426-22434	kurtosis	_	
111-71	22435-22436	=	_	
111-72	22437-22441	0.62	_	
111-73	22441-22442	)	_	
111-74	22442-22443	,	_	
111-75	22444-22446	as	_	
111-76	22447-22450	was	_	
111-77	22451-22454	the	_	
111-78	22455-22470	control-related	_	
111-79	22471-22480	modafinil	_	
111-80	22481-22487	effect	_	
111-81	22488-22490	on	_	
111-82	22491-22493	LC	_	
111-83	22494-22502	activity	_	
111-84	22503-22504	(	_	
111-85	22504-22508	skew	_	
111-86	22509-22510	=	_	
111-87	22511-22512	−	_	
111-88	22512-22516	0.92	_	
111-89	22516-22517	,	_	
111-90	22518-22526	kurtosis	_	
111-91	22527-22528	=	_	
111-92	22529-22533	0.65	_	
111-93	22533-22534	)	_	
111-94	22534-22535	.	_	

#Text=This α2 receptor load was strongly inversely related to control-related modafinil effects on LC activity (r = −.60, p = 0.005; Fig. 5a).
112-1	22536-22540	This	_	
112-2	22541-22543	α2	_	
112-3	22544-22552	receptor	_	
112-4	22553-22557	load	_	
112-5	22558-22561	was	_	
112-6	22562-22570	strongly	_	
112-7	22571-22580	inversely	_	
112-8	22581-22588	related	_	
112-9	22589-22591	to	_	
112-10	22592-22607	control-related	_	
112-11	22608-22617	modafinil	_	
112-12	22618-22625	effects	_	
112-13	22626-22628	on	_	
112-14	22629-22631	LC	_	
112-15	22632-22640	activity	_	
112-16	22641-22642	(	_	
112-17	22642-22643	r	_	
112-18	22644-22645	=	_	
112-19	22646-22647	−	_	
112-20	22647-22650	.60	_	
112-21	22650-22651	,	_	
112-22	22652-22653	p	_	
112-23	22654-22655	=	_	
112-24	22656-22661	0.005	_	
112-25	22661-22662	;	_	
112-26	22663-22666	Fig	_	
112-27	22666-22667	.	_	
112-28	22668-22670	5a	_	
112-29	22670-22671	)	_	
112-30	22671-22672	.	_	

#Text=These correlations persisted upon controlling for D2 load (rpartial = −.57, p = 0.009) and muscarinic load (rpartial = −.58, p = 0.007), suggesting a specific relationship between α2 receptor load and LC effects that was not accounted for by other neurochemical actions nor the total dose of the antipsychotic medications.
113-1	22673-22678	These	_	
113-2	22679-22691	correlations	_	
113-3	22692-22701	persisted	_	
113-4	22702-22706	upon	_	
113-5	22707-22718	controlling	_	
113-6	22719-22722	for	_	
113-7	22723-22725	D2	_	
113-8	22726-22730	load	_	
113-9	22731-22732	(	_	
113-10	22732-22740	rpartial	_	
113-11	22741-22742	=	_	
113-12	22743-22744	−	_	
113-13	22744-22747	.57	_	
113-14	22747-22748	,	_	
113-15	22749-22750	p	_	
113-16	22751-22752	=	_	
113-17	22753-22758	0.009	_	
113-18	22758-22759	)	_	
113-19	22760-22763	and	_	
113-20	22764-22774	muscarinic	_	
113-21	22775-22779	load	_	
113-22	22780-22781	(	_	
113-23	22781-22789	rpartial	_	
113-24	22790-22791	=	_	
113-25	22792-22793	−	_	
113-26	22793-22796	.58	_	
113-27	22796-22797	,	_	
113-28	22798-22799	p	_	
113-29	22800-22801	=	_	
113-30	22802-22807	0.007	_	
113-31	22807-22808	)	_	
113-32	22808-22809	,	_	
113-33	22810-22820	suggesting	_	
113-34	22821-22822	a	_	
113-35	22823-22831	specific	_	
113-36	22832-22844	relationship	_	
113-37	22845-22852	between	_	
113-38	22853-22855	α2	_	
113-39	22856-22864	receptor	_	
113-40	22865-22869	load	_	
113-41	22870-22873	and	_	
113-42	22874-22876	LC	_	
113-43	22877-22884	effects	_	
113-44	22885-22889	that	_	
113-45	22890-22893	was	_	
113-46	22894-22897	not	_	
113-47	22898-22907	accounted	_	
113-48	22908-22911	for	_	
113-49	22912-22914	by	_	
113-50	22915-22920	other	_	
113-51	22921-22934	neurochemical	_	
113-52	22935-22942	actions	_	
113-53	22943-22946	nor	_	
113-54	22947-22950	the	_	
113-55	22951-22956	total	_	
113-56	22957-22961	dose	_	
113-57	22962-22964	of	_	
113-58	22965-22968	the	_	
113-59	22969-22982	antipsychotic	_	
113-60	22983-22994	medications	_	
113-61	22994-22995	.	_	

#Text=Furthermore, muscarinic load was not associated with control-related modafinil effects on LC activity (r = .16; p = .50).
114-1	22996-23007	Furthermore	_	
114-2	23007-23008	,	_	
114-3	23009-23019	muscarinic	_	
114-4	23020-23024	load	_	
114-5	23025-23028	was	_	
114-6	23029-23032	not	_	
114-7	23033-23043	associated	_	
114-8	23044-23048	with	_	
114-9	23049-23064	control-related	_	
114-10	23065-23074	modafinil	_	
114-11	23075-23082	effects	_	
114-12	23083-23085	on	_	
114-13	23086-23088	LC	_	
114-14	23089-23097	activity	_	
114-15	23098-23099	(	_	
114-16	23099-23100	r	_	
114-17	23101-23102	=	_	
114-18	23103-23106	.16	_	
114-19	23106-23107	;	_	
114-20	23108-23109	p	_	
114-21	23110-23111	=	_	
114-22	23112-23115	.50	_	
114-23	23115-23116	)	_	
114-24	23116-23117	.	_	

#Text=These results indicate that α2 receptor antagonism of the patients’ concurrent antipsychotic medications was strongly and specifically related to impaired modafinil effects on control-related LC activity.
115-1	23118-23123	These	_	
115-2	23124-23131	results	_	
115-3	23132-23140	indicate	_	
115-4	23141-23145	that	_	
115-5	23146-23148	α2	_	
115-6	23149-23157	receptor	_	
115-7	23158-23168	antagonism	_	
115-8	23169-23171	of	_	
115-9	23172-23175	the	_	
115-10	23176-23184	patients	_	
115-11	23184-23185	’	_	
115-12	23186-23196	concurrent	_	
115-13	23197-23210	antipsychotic	_	
115-14	23211-23222	medications	_	
115-15	23223-23226	was	_	
115-16	23227-23235	strongly	_	
115-17	23236-23239	and	_	
115-18	23240-23252	specifically	_	
115-19	23253-23260	related	_	
115-20	23261-23263	to	_	
115-21	23264-23272	impaired	_	
115-22	23273-23282	modafinil	_	
115-23	23283-23290	effects	_	
115-24	23291-23293	on	_	
115-25	23294-23309	control-related	_	
115-26	23310-23312	LC	_	
115-27	23313-23321	activity	_	
115-28	23321-23322	.	_	

#Text=VTA effects
#Text=The D2 receptor load of the patients’ antipsychotic medications was normally distributed across the sample (skew = 0.76, kurtosis = 0.13), as was the VTA response to modafinil (skew = 0.18, kurtosis = −0.83).
116-1	23323-23326	VTA	_	
116-2	23327-23334	effects	_	
116-3	23335-23338	The	_	
116-4	23339-23341	D2	_	
116-5	23342-23350	receptor	_	
116-6	23351-23355	load	_	
116-7	23356-23358	of	_	
116-8	23359-23362	the	_	
116-9	23363-23371	patients	_	
116-10	23371-23372	’	_	
116-11	23373-23386	antipsychotic	_	
116-12	23387-23398	medications	_	
116-13	23399-23402	was	_	
116-14	23403-23411	normally	_	
116-15	23412-23423	distributed	_	
116-16	23424-23430	across	_	
116-17	23431-23434	the	_	
116-18	23435-23441	sample	_	
116-19	23442-23443	(	_	
116-20	23443-23447	skew	_	
116-21	23448-23449	=	_	
116-22	23450-23454	0.76	_	
116-23	23454-23455	,	_	
116-24	23456-23464	kurtosis	_	
116-25	23465-23466	=	_	
116-26	23467-23471	0.13	_	
116-27	23471-23472	)	_	
116-28	23472-23473	,	_	
116-29	23474-23476	as	_	
116-30	23477-23480	was	_	
116-31	23481-23484	the	_	
116-32	23485-23488	VTA	_	
116-33	23489-23497	response	_	
116-34	23498-23500	to	_	
116-35	23501-23510	modafinil	_	
116-36	23511-23512	(	_	
116-37	23512-23516	skew	_	
116-38	23517-23518	=	_	
116-39	23519-23523	0.18	_	
116-40	23523-23524	,	_	
116-41	23525-23533	kurtosis	_	
116-42	23534-23535	=	_	
116-43	23536-23537	−	_	
116-44	23537-23541	0.83	_	
116-45	23541-23542	)	_	
116-46	23542-23543	.	_	

#Text=This D2 load was significantly related to modafinil effects on VTA deactivation (r = .42, p = 0.031; Fig. 5b).
117-1	23544-23548	This	_	
117-2	23549-23551	D2	_	
117-3	23552-23556	load	_	
117-4	23557-23560	was	_	
117-5	23561-23574	significantly	_	
117-6	23575-23582	related	_	
117-7	23583-23585	to	_	
117-8	23586-23595	modafinil	_	
117-9	23596-23603	effects	_	
117-10	23604-23606	on	_	
117-11	23607-23610	VTA	_	
117-12	23611-23623	deactivation	_	
117-13	23624-23625	(	_	
117-14	23625-23626	r	_	
117-15	23627-23628	=	_	
117-16	23629-23632	.42	_	
117-17	23632-23633	,	_	
117-18	23634-23635	p	_	
117-19	23636-23637	=	_	
117-20	23638-23643	0.031	_	
117-21	23643-23644	;	_	
117-22	23645-23648	Fig	_	
117-23	23648-23649	.	_	
117-24	23650-23652	5b	_	
117-25	23652-23653	)	_	
117-26	23653-23654	.	_	

#Text=There was a modest decrement in this association when controlling for global SAPS scores (rpartial = .33, p = 0.10).
118-1	23655-23660	There	_	
118-2	23661-23664	was	_	
118-3	23665-23666	a	_	
118-4	23667-23673	modest	_	
118-5	23674-23683	decrement	_	
118-6	23684-23686	in	_	
118-7	23687-23691	this	_	
118-8	23692-23703	association	_	
118-9	23704-23708	when	_	
118-10	23709-23720	controlling	_	
118-11	23721-23724	for	_	
118-12	23725-23731	global	_	
118-13	23732-23736	SAPS	_	
118-14	23737-23743	scores	_	
118-15	23744-23745	(	_	
118-16	23745-23753	rpartial	_	
118-17	23754-23755	=	_	
118-18	23756-23759	.33	_	
118-19	23759-23760	,	_	
118-20	23761-23762	p	_	
118-21	23763-23764	=	_	
118-22	23765-23769	0.10	_	
118-23	23769-23770	)	_	
118-24	23770-23771	.	_	

#Text=Muscarinic load was not associated with modafinil effects on VTA deactivation (r = −.13; p = 0.52).
119-1	23772-23782	Muscarinic	_	
119-2	23783-23787	load	_	
119-3	23788-23791	was	_	
119-4	23792-23795	not	_	
119-5	23796-23806	associated	_	
119-6	23807-23811	with	_	
119-7	23812-23821	modafinil	_	
119-8	23822-23829	effects	_	
119-9	23830-23832	on	_	
119-10	23833-23836	VTA	_	
119-11	23837-23849	deactivation	_	
119-12	23850-23851	(	_	
119-13	23851-23852	r	_	
119-14	23853-23854	=	_	
119-15	23855-23856	−	_	
119-16	23856-23859	.13	_	
119-17	23859-23860	;	_	
119-18	23861-23862	p	_	
119-19	23863-23864	=	_	
119-20	23865-23869	0.52	_	
119-21	23869-23870	)	_	
119-22	23870-23871	.	_	

#Text=These results indicate that D2 receptor antagonism of the patients’ concurrent medications was moderately and specifically related to stronger deactivating effects of modafinil in the VTA.
120-1	23872-23877	These	_	
120-2	23878-23885	results	_	
120-3	23886-23894	indicate	_	
120-4	23895-23899	that	_	
120-5	23900-23902	D2	_	
120-6	23903-23911	receptor	_	
120-7	23912-23922	antagonism	_	
120-8	23923-23925	of	_	
120-9	23926-23929	the	_	
120-10	23930-23938	patients	_	
120-11	23938-23939	’	_	
120-12	23940-23950	concurrent	_	
120-13	23951-23962	medications	_	
120-14	23963-23966	was	_	
120-15	23967-23977	moderately	_	
120-16	23978-23981	and	_	
120-17	23982-23994	specifically	_	
120-18	23995-24002	related	_	
120-19	24003-24005	to	_	
120-20	24006-24014	stronger	_	
120-21	24015-24027	deactivating	_	
120-22	24028-24035	effects	_	
120-23	24036-24038	of	_	
120-24	24039-24048	modafinil	_	
120-25	24049-24051	in	_	
120-26	24052-24055	the	_	
120-27	24056-24059	VTA	_	
120-28	24059-24060	.	_	

#Text=Discussion
#Text=In this study, we provide the first available evidence that fMRI can be used to demonstrate the modulatory effects of a drug with pro-cognitive potential on activity in the locus coeruleus and the ventral tegmental area, in a cognitively-impaired clinical population during cognitive performance.
121-1	24061-24071	Discussion	_	
121-2	24072-24074	In	_	
121-3	24075-24079	this	_	
121-4	24080-24085	study	_	
121-5	24085-24086	,	_	
121-6	24087-24089	we	_	
121-7	24090-24097	provide	_	
121-8	24098-24101	the	_	
121-9	24102-24107	first	_	
121-10	24108-24117	available	_	
121-11	24118-24126	evidence	_	
121-12	24127-24131	that	_	
121-13	24132-24136	fMRI	_	
121-14	24137-24140	can	_	
121-15	24141-24143	be	_	
121-16	24144-24148	used	_	
121-17	24149-24151	to	_	
121-18	24152-24163	demonstrate	_	
121-19	24164-24167	the	_	
121-20	24168-24178	modulatory	_	
121-21	24179-24186	effects	_	
121-22	24187-24189	of	_	
121-23	24190-24191	a	_	
121-24	24192-24196	drug	_	
121-25	24197-24201	with	_	
121-26	24202-24215	pro-cognitive	_	
121-27	24216-24225	potential	_	
121-28	24226-24228	on	_	
121-29	24229-24237	activity	_	
121-30	24238-24240	in	_	
121-31	24241-24244	the	_	
121-32	24245-24250	locus	_	
121-33	24251-24260	coeruleus	_	
121-34	24261-24264	and	_	
121-35	24265-24268	the	_	
121-36	24269-24276	ventral	_	
121-37	24277-24286	tegmental	_	
121-38	24287-24291	area	_	
121-39	24291-24292	,	_	
121-40	24293-24295	in	_	
121-41	24296-24297	a	_	
121-42	24298-24318	cognitively-impaired	_	
121-43	24319-24327	clinical	_	
121-44	24328-24338	population	_	
121-45	24339-24345	during	_	
121-46	24346-24355	cognitive	_	
121-47	24356-24367	performance	_	
121-48	24367-24368	.	_	

#Text=We found that modafinil administration leads to relative deactivation in LC and VTA in schizophrenia patients, consistent with predictions of control-independent effects arising from NET and DAT inhibition at cell bodies in these subcortical regions (Fig. 1a).
122-1	24369-24371	We	_	
122-2	24372-24377	found	_	
122-3	24378-24382	that	_	
122-4	24383-24392	modafinil	_	
122-5	24393-24407	administration	_	
122-6	24408-24413	leads	_	
122-7	24414-24416	to	_	
122-8	24417-24425	relative	_	
122-9	24426-24438	deactivation	_	
122-10	24439-24441	in	_	
122-11	24442-24444	LC	_	
122-12	24445-24448	and	_	
122-13	24449-24452	VTA	_	
122-14	24453-24455	in	_	
122-15	24456-24469	schizophrenia	_	
122-16	24470-24478	patients	_	
122-17	24478-24479	,	_	
122-18	24480-24490	consistent	_	
122-19	24491-24495	with	_	
122-20	24496-24507	predictions	_	
122-21	24508-24510	of	_	
122-22	24511-24530	control-independent	_	
122-23	24531-24538	effects	_	
122-24	24539-24546	arising	_	
122-25	24547-24551	from	_	
122-26	24552-24555	NET	_	
122-27	24556-24559	and	_	
122-28	24560-24563	DAT	_	
122-29	24564-24574	inhibition	_	
122-30	24575-24577	at	_	
122-31	24578-24582	cell	_	
122-32	24583-24589	bodies	_	
122-33	24590-24592	in	_	
122-34	24593-24598	these	_	
122-35	24599-24610	subcortical	_	
122-36	24611-24618	regions	_	
122-37	24619-24620	(	_	
122-38	24620-24623	Fig	_	
122-39	24623-24624	.	_	
122-40	24625-24627	1a	_	
122-41	24627-24628	)	_	
122-42	24628-24629	.	_	

#Text=Importantly, these effects were altered compared to a healthy control group, with two lines of evidence suggesting an interaction with the concurrent antipsychotic medications prescribed to these patients was responsible for these altered responses.
123-1	24630-24641	Importantly	_	
123-2	24641-24642	,	_	
123-3	24643-24648	these	_	
123-4	24649-24656	effects	_	
123-5	24657-24661	were	_	
123-6	24662-24669	altered	_	
123-7	24670-24678	compared	_	
123-8	24679-24681	to	_	
123-9	24682-24683	a	_	
123-10	24684-24691	healthy	_	
123-11	24692-24699	control	_	
123-12	24700-24705	group	_	
123-13	24705-24706	,	_	
123-14	24707-24711	with	_	
123-15	24712-24715	two	_	
123-16	24716-24721	lines	_	
123-17	24722-24724	of	_	
123-18	24725-24733	evidence	_	
123-19	24734-24744	suggesting	_	
123-20	24745-24747	an	_	
123-21	24748-24759	interaction	_	
123-22	24760-24764	with	_	
123-23	24765-24768	the	_	
123-24	24769-24779	concurrent	_	
123-25	24780-24793	antipsychotic	_	
123-26	24794-24805	medications	_	
123-27	24806-24816	prescribed	_	
123-28	24817-24819	to	_	
123-29	24820-24825	these	_	
123-30	24826-24834	patients	_	
123-31	24835-24838	was	_	
123-32	24839-24850	responsible	_	
123-33	24851-24854	for	_	
123-34	24855-24860	these	_	
123-35	24861-24868	altered	_	
123-36	24869-24878	responses	_	
123-37	24878-24879	.	_	

#Text=First, relative to the healthy control group, the patients responded to modafinil with shallower deactivation in LC and deeper deactivation in VTA.
124-1	24880-24885	First	_	
124-2	24885-24886	,	_	
124-3	24887-24895	relative	_	
124-4	24896-24898	to	_	
124-5	24899-24902	the	_	
124-6	24903-24910	healthy	_	
124-7	24911-24918	control	_	
124-8	24919-24924	group	_	
124-9	24924-24925	,	_	
124-10	24926-24929	the	_	
124-11	24930-24938	patients	_	
124-12	24939-24948	responded	_	
124-13	24949-24951	to	_	
124-14	24952-24961	modafinil	_	
124-15	24962-24966	with	_	
124-16	24967-24976	shallower	_	
124-17	24977-24989	deactivation	_	
124-18	24990-24992	in	_	
124-19	24993-24995	LC	_	
124-20	24996-24999	and	_	
124-21	25000-25006	deeper	_	
124-22	25007-25019	deactivation	_	
124-23	25020-25022	in	_	
124-24	25023-25026	VTA	_	
124-25	25026-25027	.	_	

#Text=This pattern is consistent with the underlying effects of chronic antipsychotic medication treatment, which lead to sustained decreases in tonic firing in the VTA, and increases in tonic firing in the LC.
125-1	25028-25032	This	_	
125-2	25033-25040	pattern	_	
125-3	25041-25043	is	_	
125-4	25044-25054	consistent	_	
125-5	25055-25059	with	_	
125-6	25060-25063	the	_	
125-7	25064-25074	underlying	_	
125-8	25075-25082	effects	_	
125-9	25083-25085	of	_	
125-10	25086-25093	chronic	_	
125-11	25094-25107	antipsychotic	_	
125-12	25108-25118	medication	_	
125-13	25119-25128	treatment	_	
125-14	25128-25129	,	_	
125-15	25130-25135	which	_	
125-16	25136-25140	lead	_	
125-17	25141-25143	to	_	
125-18	25144-25153	sustained	_	
125-19	25154-25163	decreases	_	
125-20	25164-25166	in	_	
125-21	25167-25172	tonic	_	
125-22	25173-25179	firing	_	
125-23	25180-25182	in	_	
125-24	25183-25186	the	_	
125-25	25187-25190	VTA	_	
125-26	25190-25191	,	_	
125-27	25192-25195	and	_	
125-28	25196-25205	increases	_	
125-29	25206-25208	in	_	
125-30	25209-25214	tonic	_	
125-31	25215-25221	firing	_	
125-32	25222-25224	in	_	
125-33	25225-25228	the	_	
125-34	25229-25231	LC	_	
125-35	25231-25232	.	_	

#Text=Second, these altered modafinil effects in the LC and VTA were significantly correlated respectively with antagonism at α2 and D2 receptors (despite the relatively simple measure of receptor load used here), These receptor subtypes serve an important regulatory autoreceptor-mediated inhibition of NE and DA neurons, respectively.
126-1	25233-25239	Second	_	
126-2	25239-25240	,	_	
126-3	25241-25246	these	_	
126-4	25247-25254	altered	_	
126-5	25255-25264	modafinil	_	
126-6	25265-25272	effects	_	
126-7	25273-25275	in	_	
126-8	25276-25279	the	_	
126-9	25280-25282	LC	_	
126-10	25283-25286	and	_	
126-11	25287-25290	VTA	_	
126-12	25291-25295	were	_	
126-13	25296-25309	significantly	_	
126-14	25310-25320	correlated	_	
126-15	25321-25333	respectively	_	
126-16	25334-25338	with	_	
126-17	25339-25349	antagonism	_	
126-18	25350-25352	at	_	
126-19	25353-25355	α2	_	
126-20	25356-25359	and	_	
126-21	25360-25362	D2	_	
126-22	25363-25372	receptors	_	
126-23	25373-25374	(	_	
126-24	25374-25381	despite	_	
126-25	25382-25385	the	_	
126-26	25386-25396	relatively	_	
126-27	25397-25403	simple	_	
126-28	25404-25411	measure	_	
126-29	25412-25414	of	_	
126-30	25415-25423	receptor	_	
126-31	25424-25428	load	_	
126-32	25429-25433	used	_	
126-33	25434-25438	here	_	
126-34	25438-25439	)	_	
126-35	25439-25440	,	_	
126-36	25441-25446	These	_	
126-37	25447-25455	receptor	_	
126-38	25456-25464	subtypes	_	
126-39	25465-25470	serve	_	
126-40	25471-25473	an	_	
126-41	25474-25483	important	_	
126-42	25484-25494	regulatory	_	
126-43	25495-25516	autoreceptor-mediated	_	
126-44	25517-25527	inhibition	_	
126-45	25528-25530	of	_	
126-46	25531-25533	NE	_	
126-47	25534-25537	and	_	
126-48	25538-25540	DA	_	
126-49	25541-25548	neurons	_	
126-50	25548-25549	,	_	
126-51	25550-25562	respectively	_	
126-52	25562-25563	.	_	

#Text=In the patients overall, the consequences of altered responses to modafinil was that the drug was less able to positively modulate control-related increases in activity, in both these subcortical regions and in neocortical and subcortical terminal fields that support cognitive control (see Fig. 1b for hypothetical model of altered modafinil effects on catecholamine neuron activity in SZ).
127-1	25564-25566	In	_	
127-2	25567-25570	the	_	
127-3	25571-25579	patients	_	
127-4	25580-25587	overall	_	
127-5	25587-25588	,	_	
127-6	25589-25592	the	_	
127-7	25593-25605	consequences	_	
127-8	25606-25608	of	_	
127-9	25609-25616	altered	_	
127-10	25617-25626	responses	_	
127-11	25627-25629	to	_	
127-12	25630-25639	modafinil	_	
127-13	25640-25643	was	_	
127-14	25644-25648	that	_	
127-15	25649-25652	the	_	
127-16	25653-25657	drug	_	
127-17	25658-25661	was	_	
127-18	25662-25666	less	_	
127-19	25667-25671	able	_	
127-20	25672-25674	to	_	
127-21	25675-25685	positively	_	
127-22	25686-25694	modulate	_	
127-23	25695-25710	control-related	_	
127-24	25711-25720	increases	_	
127-25	25721-25723	in	_	
127-26	25724-25732	activity	_	
127-27	25732-25733	,	_	
127-28	25734-25736	in	_	
127-29	25737-25741	both	_	
127-30	25742-25747	these	_	
127-31	25748-25759	subcortical	_	
127-32	25760-25767	regions	_	
127-33	25768-25771	and	_	
127-34	25772-25774	in	_	
127-35	25775-25786	neocortical	_	
127-36	25787-25790	and	_	
127-37	25791-25802	subcortical	_	
127-38	25803-25811	terminal	_	
127-39	25812-25818	fields	_	
127-40	25819-25823	that	_	
127-41	25824-25831	support	_	
127-42	25832-25841	cognitive	_	
127-43	25842-25849	control	_	
127-44	25850-25851	(	_	
127-45	25851-25854	see	_	
127-46	25855-25858	Fig	_	
127-47	25858-25859	.	_	
127-48	25860-25862	1b	_	
127-49	25863-25866	for	_	
127-50	25867-25879	hypothetical	_	
127-51	25880-25885	model	_	
127-52	25886-25888	of	_	
127-53	25889-25896	altered	_	
127-54	25897-25906	modafinil	_	
127-55	25907-25914	effects	_	
127-56	25915-25917	on	_	
127-57	25918-25931	catecholamine	_	
127-58	25932-25938	neuron	_	
127-59	25939-25947	activity	_	
127-60	25948-25950	in	_	
127-61	25951-25953	SZ	_	
127-62	25953-25954	)	_	
127-63	25954-25955	.	_	

#Text=These findings have significant potential implications for the prospects of candidate drugs to normalize cortical dysfunction in schizophrenia, to remediate impaired cognition.
128-1	25956-25961	These	_	
128-2	25962-25970	findings	_	
128-3	25971-25975	have	_	
128-4	25976-25987	significant	_	
128-5	25988-25997	potential	_	
128-6	25998-26010	implications	_	
128-7	26011-26014	for	_	
128-8	26015-26018	the	_	
128-9	26019-26028	prospects	_	
128-10	26029-26031	of	_	
128-11	26032-26041	candidate	_	
128-12	26042-26047	drugs	_	
128-13	26048-26050	to	_	
128-14	26051-26060	normalize	_	
128-15	26061-26069	cortical	_	
128-16	26070-26081	dysfunction	_	
128-17	26082-26084	in	_	
128-18	26085-26098	schizophrenia	_	
128-19	26098-26099	,	_	
128-20	26100-26102	to	_	
128-21	26103-26112	remediate	_	
128-22	26113-26121	impaired	_	
128-23	26122-26131	cognition	_	
128-24	26131-26132	.	_	

#Text=Chronic treatment with either typical or atypical antipsychotics leads to sustained increases in firing of LC neurons.
129-1	26133-26140	Chronic	_	
129-2	26141-26150	treatment	_	
129-3	26151-26155	with	_	
129-4	26156-26162	either	_	
129-5	26163-26170	typical	_	
129-6	26171-26173	or	_	
129-7	26174-26182	atypical	_	
129-8	26183-26197	antipsychotics	_	
129-9	26198-26203	leads	_	
129-10	26204-26206	to	_	
129-11	26207-26216	sustained	_	
129-12	26217-26226	increases	_	
129-13	26227-26229	in	_	
129-14	26230-26236	firing	_	
129-15	26237-26239	of	_	
129-16	26240-26242	LC	_	
129-17	26243-26250	neurons	_	
129-18	26250-26251	.	_	

#Text=The tonic disinhibition of LC-NE neurons may then mitigate or override the feedback inhibition of LC-NE activity via cell-body autoreceptors, which would be manifest as the shallower control-independent deactivation in patients that we observed by fMRI.
130-1	26252-26255	The	_	
130-2	26256-26261	tonic	_	
130-3	26262-26275	disinhibition	_	
130-4	26276-26278	of	_	
130-5	26279-26284	LC-NE	_	
130-6	26285-26292	neurons	_	
130-7	26293-26296	may	_	
130-8	26297-26301	then	_	
130-9	26302-26310	mitigate	_	
130-10	26311-26313	or	_	
130-11	26314-26322	override	_	
130-12	26323-26326	the	_	
130-13	26327-26335	feedback	_	
130-14	26336-26346	inhibition	_	
130-15	26347-26349	of	_	
130-16	26350-26355	LC-NE	_	
130-17	26356-26364	activity	_	
130-18	26365-26368	via	_	
130-19	26369-26378	cell-body	_	
130-20	26379-26392	autoreceptors	_	
130-21	26392-26393	,	_	
130-22	26394-26399	which	_	
130-23	26400-26405	would	_	
130-24	26406-26408	be	_	
130-25	26409-26417	manifest	_	
130-26	26418-26420	as	_	
130-27	26421-26424	the	_	
130-28	26425-26434	shallower	_	
130-29	26435-26454	control-independent	_	
130-30	26455-26467	deactivation	_	
130-31	26468-26470	in	_	
130-32	26471-26479	patients	_	
130-33	26480-26484	that	_	
130-34	26485-26487	we	_	
130-35	26488-26496	observed	_	
130-36	26497-26499	by	_	
130-37	26500-26504	fMRI	_	
130-38	26504-26505	.	_	

#Text=Given the relationship of tonic to phasic LC activity, proxied here respectively as control-independent and control-related BOLD signal change, this increased tonic LC activity (unnormalized by modafinil) would impede relative control-related increases in LC-NE activity.
131-1	26506-26511	Given	_	
131-2	26512-26515	the	_	
131-3	26516-26528	relationship	_	
131-4	26529-26531	of	_	
131-5	26532-26537	tonic	_	
131-6	26538-26540	to	_	
131-7	26541-26547	phasic	_	
131-8	26548-26550	LC	_	
131-9	26551-26559	activity	_	
131-10	26559-26560	,	_	
131-11	26561-26568	proxied	_	
131-12	26569-26573	here	_	
131-13	26574-26586	respectively	_	
131-14	26587-26589	as	_	
131-15	26590-26609	control-independent	_	
131-16	26610-26613	and	_	
131-17	26614-26629	control-related	_	
131-18	26630-26634	BOLD	_	
131-19	26635-26641	signal	_	
131-20	26642-26648	change	_	
131-21	26648-26649	,	_	
131-22	26650-26654	this	_	
131-23	26655-26664	increased	_	
131-24	26665-26670	tonic	_	
131-25	26671-26673	LC	_	
131-26	26674-26682	activity	_	
131-27	26683-26684	(	_	
131-28	26684-26696	unnormalized	_	
131-29	26697-26699	by	_	
131-30	26700-26709	modafinil	_	
131-31	26709-26710	)	_	
131-32	26711-26716	would	_	
131-33	26717-26723	impede	_	
131-34	26724-26732	relative	_	
131-35	26733-26748	control-related	_	
131-36	26749-26758	increases	_	
131-37	26759-26761	in	_	
131-38	26762-26767	LC-NE	_	
131-39	26768-26776	activity	_	
131-40	26776-26777	.	_	

#Text=We have observed just this combination of control-independent and control-related drug effects in our patient sample.
132-1	26778-26780	We	_	
132-2	26781-26785	have	_	
132-3	26786-26794	observed	_	
132-4	26795-26799	just	_	
132-5	26800-26804	this	_	
132-6	26805-26816	combination	_	
132-7	26817-26819	of	_	
132-8	26820-26839	control-independent	_	
132-9	26840-26843	and	_	
132-10	26844-26859	control-related	_	
132-11	26860-26864	drug	_	
132-12	26865-26872	effects	_	
132-13	26873-26875	in	_	
132-14	26876-26879	our	_	
132-15	26880-26887	patient	_	
132-16	26888-26894	sample	_	
132-17	26894-26895	.	_	

#Text=It remains unclear which monoamine receptor(s) mediates the antipsychotic effect on LC activity.
133-1	26896-26898	It	_	
133-2	26899-26906	remains	_	
133-3	26907-26914	unclear	_	
133-4	26915-26920	which	_	
133-5	26921-26930	monoamine	_	
133-6	26931-26939	receptor	_	
133-7	26939-26940	(	_	
133-8	26940-26941	s	_	
133-9	26941-26942	)	_	
133-10	26943-26951	mediates	_	
133-11	26952-26955	the	_	
133-12	26956-26969	antipsychotic	_	
133-13	26970-26976	effect	_	
133-14	26977-26979	on	_	
133-15	26980-26982	LC	_	
133-16	26983-26991	activity	_	
133-17	26991-26992	.	_	

#Text=However, we found that the α2 antagonist load of the concurrent antipsychotics was strongly and specifically related to impaired modafinil effects on control-related LC activity.
134-1	26993-27000	However	_	
134-2	27000-27001	,	_	
134-3	27002-27004	we	_	
134-4	27005-27010	found	_	
134-5	27011-27015	that	_	
134-6	27016-27019	the	_	
134-7	27020-27022	α2	_	
134-8	27023-27033	antagonist	_	
134-9	27034-27038	load	_	
134-10	27039-27041	of	_	
134-11	27042-27045	the	_	
134-12	27046-27056	concurrent	_	
134-13	27057-27071	antipsychotics	_	
134-14	27072-27075	was	_	
134-15	27076-27084	strongly	_	
134-16	27085-27088	and	_	
134-17	27089-27101	specifically	_	
134-18	27102-27109	related	_	
134-19	27110-27112	to	_	
134-20	27113-27121	impaired	_	
134-21	27122-27131	modafinil	_	
134-22	27132-27139	effects	_	
134-23	27140-27142	on	_	
134-24	27143-27158	control-related	_	
134-25	27159-27161	LC	_	
134-26	27162-27170	activity	_	
134-27	27170-27171	.	_	

#Text=This convergent evidence suggests that antagonism of the cell-body α2 autoreceptor leads to impaired optimization of control-related phasic LC activity.
135-1	27172-27176	This	_	
135-2	27177-27187	convergent	_	
135-3	27188-27196	evidence	_	
135-4	27197-27205	suggests	_	
135-5	27206-27210	that	_	
135-6	27211-27221	antagonism	_	
135-7	27222-27224	of	_	
135-8	27225-27228	the	_	
135-9	27229-27238	cell-body	_	
135-10	27239-27241	α2	_	
135-11	27242-27254	autoreceptor	_	
135-12	27255-27260	leads	_	
135-13	27261-27263	to	_	
135-14	27264-27272	impaired	_	
135-15	27273-27285	optimization	_	
135-16	27286-27288	of	_	
135-17	27289-27304	control-related	_	
135-18	27305-27311	phasic	_	
135-19	27312-27314	LC	_	
135-20	27315-27323	activity	_	
135-21	27323-27324	.	_	

#Text=This evidence supports the model we outlined previously, where modafinil action to inhibit NET at LC cell bodies leads to autoreceptor-mediated slowing of control-independent LC activity, allowing optimized control-related phasic LC activity to effectively modulate the cognitive control network (Fig. 1b).
136-1	27325-27329	This	_	
136-2	27330-27338	evidence	_	
136-3	27339-27347	supports	_	
136-4	27348-27351	the	_	
136-5	27352-27357	model	_	
136-6	27358-27360	we	_	
136-7	27361-27369	outlined	_	
136-8	27370-27380	previously	_	
136-9	27380-27381	,	_	
136-10	27382-27387	where	_	
136-11	27388-27397	modafinil	_	
136-12	27398-27404	action	_	
136-13	27405-27407	to	_	
136-14	27408-27415	inhibit	_	
136-15	27416-27419	NET	_	
136-16	27420-27422	at	_	
136-17	27423-27425	LC	_	
136-18	27426-27430	cell	_	
136-19	27431-27437	bodies	_	
136-20	27438-27443	leads	_	
136-21	27444-27446	to	_	
136-22	27447-27468	autoreceptor-mediated	_	
136-23	27469-27476	slowing	_	
136-24	27477-27479	of	_	
136-25	27480-27499	control-independent	_	
136-26	27500-27502	LC	_	
136-27	27503-27511	activity	_	
136-28	27511-27512	,	_	
136-29	27513-27521	allowing	_	
136-30	27522-27531	optimized	_	
136-31	27532-27547	control-related	_	
136-32	27548-27554	phasic	_	
136-33	27555-27557	LC	_	
136-34	27558-27566	activity	_	
136-35	27567-27569	to	_	
136-36	27570-27581	effectively	_	
136-37	27582-27590	modulate	_	
136-38	27591-27594	the	_	
136-39	27595-27604	cognitive	_	
136-40	27605-27612	control	_	
136-41	27613-27620	network	_	
136-42	27621-27622	(	_	
136-43	27622-27625	Fig	_	
136-44	27625-27626	.	_	
136-45	27627-27629	1b	_	
136-46	27629-27630	)	_	
136-47	27630-27631	.	_	

#Text=In contrast to the activating effects on the LC, chronic antipsychotic treatment induces depolarization inactivation in VTA-DA neurons, rendering the cell-body less able to generate action potentials (reviewed in).
137-1	27632-27634	In	_	
137-2	27635-27643	contrast	_	
137-3	27644-27646	to	_	
137-4	27647-27650	the	_	
137-5	27651-27661	activating	_	
137-6	27662-27669	effects	_	
137-7	27670-27672	on	_	
137-8	27673-27676	the	_	
137-9	27677-27679	LC	_	
137-10	27679-27680	,	_	
137-11	27681-27688	chronic	_	
137-12	27689-27702	antipsychotic	_	
137-13	27703-27712	treatment	_	
137-14	27713-27720	induces	_	
137-15	27721-27735	depolarization	_	
137-16	27736-27748	inactivation	_	
137-17	27749-27751	in	_	
137-18	27752-27758	VTA-DA	_	
137-19	27759-27766	neurons	_	
137-20	27766-27767	,	_	
137-21	27768-27777	rendering	_	
137-22	27778-27781	the	_	
137-23	27782-27791	cell-body	_	
137-24	27792-27796	less	_	
137-25	27797-27801	able	_	
137-26	27802-27804	to	_	
137-27	27805-27813	generate	_	
137-28	27814-27820	action	_	
137-29	27821-27831	potentials	_	
137-30	27832-27833	(	_	
137-31	27833-27841	reviewed	_	
137-32	27842-27844	in	_	
137-33	27844-27845	)	_	
137-34	27845-27846	.	_	

#Text=The relatively depolarized (but not discharging) state of antipsychotic-exposed VTA-DA neurons may then render these neurons relatively more sensitive to DAT inhibitor effects that increase DA at cell bodies.
138-1	27847-27850	The	_	
138-2	27851-27861	relatively	_	
138-3	27862-27873	depolarized	_	
138-4	27874-27875	(	_	
138-5	27875-27878	but	_	
138-6	27879-27882	not	_	
138-7	27883-27894	discharging	_	
138-8	27894-27895	)	_	
138-9	27896-27901	state	_	
138-10	27902-27904	of	_	
138-11	27905-27926	antipsychotic-exposed	_	
138-12	27927-27933	VTA-DA	_	
138-13	27934-27941	neurons	_	
138-14	27942-27945	may	_	
138-15	27946-27950	then	_	
138-16	27951-27957	render	_	
138-17	27958-27963	these	_	
138-18	27964-27971	neurons	_	
138-19	27972-27982	relatively	_	
138-20	27983-27987	more	_	
138-21	27988-27997	sensitive	_	
138-22	27998-28000	to	_	
138-23	28001-28004	DAT	_	
138-24	28005-28014	inhibitor	_	
138-25	28015-28022	effects	_	
138-26	28023-28027	that	_	
138-27	28028-28036	increase	_	
138-28	28037-28039	DA	_	
138-29	28040-28042	at	_	
138-30	28043-28047	cell	_	
138-31	28048-28054	bodies	_	
138-32	28054-28055	.	_	

#Text=This increased sensitivity could also result from relatively more D2 receptors in a high-affinity state, which is induced with chronic antipsychotic treatment and associated with the D2 affinity of these medications.
139-1	28056-28060	This	_	
139-2	28061-28070	increased	_	
139-3	28071-28082	sensitivity	_	
139-4	28083-28088	could	_	
139-5	28089-28093	also	_	
139-6	28094-28100	result	_	
139-7	28101-28105	from	_	
139-8	28106-28116	relatively	_	
139-9	28117-28121	more	_	
139-10	28122-28124	D2	_	
139-11	28125-28134	receptors	_	
139-12	28135-28137	in	_	
139-13	28138-28139	a	_	
139-14	28140-28153	high-affinity	_	
139-15	28154-28159	state	_	
139-16	28159-28160	,	_	
139-17	28161-28166	which	_	
139-18	28167-28169	is	_	
139-19	28170-28177	induced	_	
139-20	28178-28182	with	_	
139-21	28183-28190	chronic	_	
139-22	28191-28204	antipsychotic	_	
139-23	28205-28214	treatment	_	
139-24	28215-28218	and	_	
139-25	28219-28229	associated	_	
139-26	28230-28234	with	_	
139-27	28235-28238	the	_	
139-28	28239-28241	D2	_	
139-29	28242-28250	affinity	_	
139-30	28251-28253	of	_	
139-31	28254-28259	these	_	
139-32	28260-28271	medications	_	
139-33	28271-28272	.	_	

#Text=One of the present findings, that the deactivating effect of modafinil on the VTA was significantly related to the D2 load conferred by the patients’ concurrent antipsychotic medications, suggests that D2-receptor effects interact with modafinil responses in the VTA.
140-1	28273-28276	One	_	
140-2	28277-28279	of	_	
140-3	28280-28283	the	_	
140-4	28284-28291	present	_	
140-5	28292-28300	findings	_	
140-6	28300-28301	,	_	
140-7	28302-28306	that	_	
140-8	28307-28310	the	_	
140-9	28311-28323	deactivating	_	
140-10	28324-28330	effect	_	
140-11	28331-28333	of	_	
140-12	28334-28343	modafinil	_	
140-13	28344-28346	on	_	
140-14	28347-28350	the	_	
140-15	28351-28354	VTA	_	
140-16	28355-28358	was	_	
140-17	28359-28372	significantly	_	
140-18	28373-28380	related	_	
140-19	28381-28383	to	_	
140-20	28384-28387	the	_	
140-21	28388-28390	D2	_	
140-22	28391-28395	load	_	
140-23	28396-28405	conferred	_	
140-24	28406-28408	by	_	
140-25	28409-28412	the	_	
140-26	28413-28421	patients	_	
140-27	28421-28422	’	_	
140-28	28423-28433	concurrent	_	
140-29	28434-28447	antipsychotic	_	
140-30	28448-28459	medications	_	
140-31	28459-28460	,	_	
140-32	28461-28469	suggests	_	
140-33	28470-28474	that	_	
140-34	28475-28477	D2	_	
140-35	28477-28478	-	_	
140-36	28478-28486	receptor	_	
140-37	28487-28494	effects	_	
140-38	28495-28503	interact	_	
140-39	28504-28508	with	_	
140-40	28509-28518	modafinil	_	
140-41	28519-28528	responses	_	
140-42	28529-28531	in	_	
140-43	28532-28535	the	_	
140-44	28536-28539	VTA	_	
140-45	28539-28540	.	_	

#Text=Exaggerated deactivation of the VTA to modafinil could render these neurons suboptimally-responsive to control-related excitatory inputs, leading to the dissociation of cell-body vs. terminal effects of DAT inhibition (see penultimate paragraph below).
141-1	28541-28552	Exaggerated	_	
141-2	28553-28565	deactivation	_	
141-3	28566-28568	of	_	
141-4	28569-28572	the	_	
141-5	28573-28576	VTA	_	
141-6	28577-28579	to	_	
141-7	28580-28589	modafinil	_	
141-8	28590-28595	could	_	
141-9	28596-28602	render	_	
141-10	28603-28608	these	_	
141-11	28609-28616	neurons	_	
141-12	28617-28640	suboptimally-responsive	_	
141-13	28641-28643	to	_	
141-14	28644-28659	control-related	_	
141-15	28660-28670	excitatory	_	
141-16	28671-28677	inputs	_	
141-17	28677-28678	,	_	
141-18	28679-28686	leading	_	
141-19	28687-28689	to	_	
141-20	28690-28693	the	_	
141-21	28694-28706	dissociation	_	
141-22	28707-28709	of	_	
141-23	28710-28719	cell-body	_	
141-24	28720-28722	vs	_	
141-25	28722-28723	.	_	
141-26	28724-28732	terminal	_	
141-27	28733-28740	effects	_	
141-28	28741-28743	of	_	
141-29	28744-28747	DAT	_	
141-30	28748-28758	inhibition	_	
141-31	28759-28760	(	_	
141-32	28760-28763	see	_	
141-33	28764-28775	penultimate	_	
141-34	28776-28785	paragraph	_	
141-35	28786-28791	below	_	
141-36	28791-28792	)	_	
141-37	28792-28793	.	_	

#Text=This effect may also interact with underlying pathophysiology in this system, manifest in either neurochemical disturbances and/or altered responses to cognitive demands.
142-1	28794-28798	This	_	
142-2	28799-28805	effect	_	
142-3	28806-28809	may	_	
142-4	28810-28814	also	_	
142-5	28815-28823	interact	_	
142-6	28824-28828	with	_	
142-7	28829-28839	underlying	_	
142-8	28840-28855	pathophysiology	_	
142-9	28856-28858	in	_	
142-10	28859-28863	this	_	
142-11	28864-28870	system	_	
142-12	28870-28871	,	_	
142-13	28872-28880	manifest	_	
142-14	28881-28883	in	_	
142-15	28884-28890	either	_	
142-16	28891-28904	neurochemical	_	
142-17	28905-28917	disturbances	_	
142-18	28918-28921	and	_	
142-19	28921-28922	/	_	
142-20	28922-28924	or	_	
142-21	28925-28932	altered	_	
142-22	28933-28942	responses	_	
142-23	28943-28945	to	_	
142-24	28946-28955	cognitive	_	
142-25	28956-28963	demands	_	
142-26	28963-28964	.	_	

#Text=These considerations highlight the utility of an experimental medicine approach using in vivo methods such as fMRI, to afford direct tests in patient populations of model-driven predictions about the pharmacological modulation of these systems during cognitive processes.
143-1	28965-28970	These	_	
143-2	28971-28985	considerations	_	
143-3	28986-28995	highlight	_	
143-4	28996-28999	the	_	
143-5	29000-29007	utility	_	
143-6	29008-29010	of	_	
143-7	29011-29013	an	_	
143-8	29014-29026	experimental	_	
143-9	29027-29035	medicine	_	
143-10	29036-29044	approach	_	
143-11	29045-29050	using	_	
143-12	29051-29053	in	_	
143-13	29054-29058	vivo	_	
143-14	29059-29066	methods	_	
143-15	29067-29071	such	_	
143-16	29072-29074	as	_	
143-17	29075-29079	fMRI	_	
143-18	29079-29080	,	_	
143-19	29081-29083	to	_	
143-20	29084-29090	afford	_	
143-21	29091-29097	direct	_	
143-22	29098-29103	tests	_	
143-23	29104-29106	in	_	
143-24	29107-29114	patient	_	
143-25	29115-29126	populations	_	
143-26	29127-29129	of	_	
143-27	29130-29142	model-driven	_	
143-28	29143-29154	predictions	_	
143-29	29155-29160	about	_	
143-30	29161-29164	the	_	
143-31	29165-29180	pharmacological	_	
143-32	29181-29191	modulation	_	
143-33	29192-29194	of	_	
143-34	29195-29200	these	_	
143-35	29201-29208	systems	_	
143-36	29209-29215	during	_	
143-37	29216-29225	cognitive	_	
143-38	29226-29235	processes	_	
143-39	29235-29236	.	_	

#Text=The emphasis here on cell-body effects of modafinil, and modulation of neuronal activity in the LC and VTA, is entirely compatible with models of catecholamine function that emphasize post-synaptic actions in the PFC.
144-1	29237-29240	The	_	
144-2	29241-29249	emphasis	_	
144-3	29250-29254	here	_	
144-4	29255-29257	on	_	
144-5	29258-29267	cell-body	_	
144-6	29268-29275	effects	_	
144-7	29276-29278	of	_	
144-8	29279-29288	modafinil	_	
144-9	29288-29289	,	_	
144-10	29290-29293	and	_	
144-11	29294-29304	modulation	_	
144-12	29305-29307	of	_	
144-13	29308-29316	neuronal	_	
144-14	29317-29325	activity	_	
144-15	29326-29328	in	_	
144-16	29329-29332	the	_	
144-17	29333-29335	LC	_	
144-18	29336-29339	and	_	
144-19	29340-29343	VTA	_	
144-20	29343-29344	,	_	
144-21	29345-29347	is	_	
144-22	29348-29356	entirely	_	
144-23	29357-29367	compatible	_	
144-24	29368-29372	with	_	
144-25	29373-29379	models	_	
144-26	29380-29382	of	_	
144-27	29383-29396	catecholamine	_	
144-28	29397-29405	function	_	
144-29	29406-29410	that	_	
144-30	29411-29420	emphasize	_	
144-31	29421-29434	post-synaptic	_	
144-32	29435-29442	actions	_	
144-33	29443-29445	in	_	
144-34	29446-29449	the	_	
144-35	29450-29453	PFC	_	
144-36	29453-29454	.	_	

#Text=Phasic activity in both VTA and LC neurons leads to greater neurotransmitter release compared to tonic activity, and optimizes throughput in active cortical ensembles, which may be mediated by D1 or α2 receptors.
145-1	29455-29461	Phasic	_	
145-2	29462-29470	activity	_	
145-3	29471-29473	in	_	
145-4	29474-29478	both	_	
145-5	29479-29482	VTA	_	
145-6	29483-29486	and	_	
145-7	29487-29489	LC	_	
145-8	29490-29497	neurons	_	
145-9	29498-29503	leads	_	
145-10	29504-29506	to	_	
145-11	29507-29514	greater	_	
145-12	29515-29531	neurotransmitter	_	
145-13	29532-29539	release	_	
145-14	29540-29548	compared	_	
145-15	29549-29551	to	_	
145-16	29552-29557	tonic	_	
145-17	29558-29566	activity	_	
145-18	29566-29567	,	_	
145-19	29568-29571	and	_	
145-20	29572-29581	optimizes	_	
145-21	29582-29592	throughput	_	
145-22	29593-29595	in	_	
145-23	29596-29602	active	_	
145-24	29603-29611	cortical	_	
145-25	29612-29621	ensembles	_	
145-26	29621-29622	,	_	
145-27	29623-29628	which	_	
145-28	29629-29632	may	_	
145-29	29633-29635	be	_	
145-30	29636-29644	mediated	_	
145-31	29645-29647	by	_	
145-32	29648-29650	D1	_	
145-33	29651-29653	or	_	
145-34	29654-29656	α2	_	
145-35	29657-29666	receptors	_	
145-36	29666-29667	.	_	

#Text=It remains likely that modafinil exerts important actions at NET in terminals in the PFC, probably to amplify the beneficial effects of cell-body modulation.
146-1	29668-29670	It	_	
146-2	29671-29678	remains	_	
146-3	29679-29685	likely	_	
146-4	29686-29690	that	_	
146-5	29691-29700	modafinil	_	
146-6	29701-29707	exerts	_	
146-7	29708-29717	important	_	
146-8	29718-29725	actions	_	
146-9	29726-29728	at	_	
146-10	29729-29732	NET	_	
146-11	29733-29735	in	_	
146-12	29736-29745	terminals	_	
146-13	29746-29748	in	_	
146-14	29749-29752	the	_	
146-15	29753-29756	PFC	_	
146-16	29756-29757	,	_	
146-17	29758-29766	probably	_	
146-18	29767-29769	to	_	
146-19	29770-29777	amplify	_	
146-20	29778-29781	the	_	
146-21	29782-29792	beneficial	_	
146-22	29793-29800	effects	_	
146-23	29801-29803	of	_	
146-24	29804-29813	cell-body	_	
146-25	29814-29824	modulation	_	
146-26	29824-29825	.	_	

#Text=The D2-mediated antipsychotic effects observed here could also relate to actions at DA terminals in the PFC, and α2 antagonist effects also manifest directly at post-synaptic receptors in PFC, both leading to altered descending cortical input to the LC and VTA.
147-1	29826-29829	The	_	
147-2	29830-29832	D2	_	
147-3	29832-29833	-	_	
147-4	29833-29841	mediated	_	
147-5	29842-29855	antipsychotic	_	
147-6	29856-29863	effects	_	
147-7	29864-29872	observed	_	
147-8	29873-29877	here	_	
147-9	29878-29883	could	_	
147-10	29884-29888	also	_	
147-11	29889-29895	relate	_	
147-12	29896-29898	to	_	
147-13	29899-29906	actions	_	
147-14	29907-29909	at	_	
147-15	29910-29912	DA	_	
147-16	29913-29922	terminals	_	
147-17	29923-29925	in	_	
147-18	29926-29929	the	_	
147-19	29930-29933	PFC	_	
147-20	29933-29934	,	_	
147-21	29935-29938	and	_	
147-22	29939-29941	α2	_	
147-23	29942-29952	antagonist	_	
147-24	29953-29960	effects	_	
147-25	29961-29965	also	_	
147-26	29966-29974	manifest	_	
147-27	29975-29983	directly	_	
147-28	29984-29986	at	_	
147-29	29987-30000	post-synaptic	_	
147-30	30001-30010	receptors	_	
147-31	30011-30013	in	_	
147-32	30014-30017	PFC	_	
147-33	30017-30018	,	_	
147-34	30019-30023	both	_	
147-35	30024-30031	leading	_	
147-36	30032-30034	to	_	
147-37	30035-30042	altered	_	
147-38	30043-30053	descending	_	
147-39	30054-30062	cortical	_	
147-40	30063-30068	input	_	
147-41	30069-30071	to	_	
147-42	30072-30075	the	_	
147-43	30076-30078	LC	_	
147-44	30079-30082	and	_	
147-45	30083-30086	VTA	_	
147-46	30086-30087	.	_	

#Text=Antipsychotic treatment may in fact induce a state where cell-body, terminal and post-synaptic actions are uncoupled in response to catecholamine transport inhibition.
148-1	30088-30101	Antipsychotic	_	
148-2	30102-30111	treatment	_	
148-3	30112-30115	may	_	
148-4	30116-30118	in	_	
148-5	30119-30123	fact	_	
148-6	30124-30130	induce	_	
148-7	30131-30132	a	_	
148-8	30133-30138	state	_	
148-9	30139-30144	where	_	
148-10	30145-30154	cell-body	_	
148-11	30154-30155	,	_	
148-12	30156-30164	terminal	_	
148-13	30165-30168	and	_	
148-14	30169-30182	post-synaptic	_	
148-15	30183-30190	actions	_	
148-16	30191-30194	are	_	
148-17	30195-30204	uncoupled	_	
148-18	30205-30207	in	_	
148-19	30208-30216	response	_	
148-20	30217-30219	to	_	
148-21	30220-30233	catecholamine	_	
148-22	30234-30243	transport	_	
148-23	30244-30254	inhibition	_	
148-24	30254-30255	.	_	

#Text=In this scenario, antipsychotic treatment leads to: (1) altered effects of pro-cognitive NET/DAT inhibition on cell-body activity (observed here), combined with (2) increased release of residual NE and DA, resulting from both terminal autoreceptor antagonism (by antipsychotics) plus NET and DAT inhibition (by modafinil), but in a manner uncoupled to cell-body activity (and the influence of control-related excitatory input to catecholamine neurons from the PFC and elsewhere), and (3) direct antagonism by antipsychotics of post-synaptic D2 and α2 receptors in the cortex.
149-1	30256-30258	In	_	
149-2	30259-30263	this	_	
149-3	30264-30272	scenario	_	
149-4	30272-30273	,	_	
149-5	30274-30287	antipsychotic	_	
149-6	30288-30297	treatment	_	
149-7	30298-30303	leads	_	
149-8	30304-30306	to	_	
149-9	30306-30307	:	_	
149-10	30308-30309	(	_	
149-11	30309-30310	1	_	
149-12	30310-30311	)	_	
149-13	30312-30319	altered	_	
149-14	30320-30327	effects	_	
149-15	30328-30330	of	_	
149-16	30331-30344	pro-cognitive	_	
149-17	30345-30348	NET	_	
149-18	30348-30349	/	_	
149-19	30349-30352	DAT	_	
149-20	30353-30363	inhibition	_	
149-21	30364-30366	on	_	
149-22	30367-30376	cell-body	_	
149-23	30377-30385	activity	_	
149-24	30386-30387	(	_	
149-25	30387-30395	observed	_	
149-26	30396-30400	here	_	
149-27	30400-30401	)	_	
149-28	30401-30402	,	_	
149-29	30403-30411	combined	_	
149-30	30412-30416	with	_	
149-31	30417-30418	(	_	
149-32	30418-30419	2	_	
149-33	30419-30420	)	_	
149-34	30421-30430	increased	_	
149-35	30431-30438	release	_	
149-36	30439-30441	of	_	
149-37	30442-30450	residual	_	
149-38	30451-30453	NE	_	
149-39	30454-30457	and	_	
149-40	30458-30460	DA	_	
149-41	30460-30461	,	_	
149-42	30462-30471	resulting	_	
149-43	30472-30476	from	_	
149-44	30477-30481	both	_	
149-45	30482-30490	terminal	_	
149-46	30491-30503	autoreceptor	_	
149-47	30504-30514	antagonism	_	
149-48	30515-30516	(	_	
149-49	30516-30518	by	_	
149-50	30519-30533	antipsychotics	_	
149-51	30533-30534	)	_	
149-52	30535-30539	plus	_	
149-53	30540-30543	NET	_	
149-54	30544-30547	and	_	
149-55	30548-30551	DAT	_	
149-56	30552-30562	inhibition	_	
149-57	30563-30564	(	_	
149-58	30564-30566	by	_	
149-59	30567-30576	modafinil	_	
149-60	30576-30577	)	_	
149-61	30577-30578	,	_	
149-62	30579-30582	but	_	
149-63	30583-30585	in	_	
149-64	30586-30587	a	_	
149-65	30588-30594	manner	_	
149-66	30595-30604	uncoupled	_	
149-67	30605-30607	to	_	
149-68	30608-30617	cell-body	_	
149-69	30618-30626	activity	_	
149-70	30627-30628	(	_	
149-71	30628-30631	and	_	
149-72	30632-30635	the	_	
149-73	30636-30645	influence	_	
149-74	30646-30648	of	_	
149-75	30649-30664	control-related	_	
149-76	30665-30675	excitatory	_	
149-77	30676-30681	input	_	
149-78	30682-30684	to	_	
149-79	30685-30698	catecholamine	_	
149-80	30699-30706	neurons	_	
149-81	30707-30711	from	_	
149-82	30712-30715	the	_	
149-83	30716-30719	PFC	_	
149-84	30720-30723	and	_	
149-85	30724-30733	elsewhere	_	
149-86	30733-30734	)	_	
149-87	30734-30735	,	_	
149-88	30736-30739	and	_	
149-89	30740-30741	(	_	
149-90	30741-30742	3	_	
149-91	30742-30743	)	_	
149-92	30744-30750	direct	_	
149-93	30751-30761	antagonism	_	
149-94	30762-30764	by	_	
149-95	30765-30779	antipsychotics	_	
149-96	30780-30782	of	_	
149-97	30783-30796	post-synaptic	_	
149-98	30797-30799	D2	_	
149-99	30800-30803	and	_	
149-100	30804-30806	α2	_	
149-101	30807-30816	receptors	_	
149-102	30817-30819	in	_	
149-103	30820-30823	the	_	
149-104	30824-30830	cortex	_	
149-105	30830-30831	.	_	

#Text=Thus, the circuit that maintains bidirectional influence of these subcortical neurochemical systems with cortical networks would be disrupted, unable to respond to a modulatory drug with pro-cognitive potential such as modafinil.
150-1	30832-30836	Thus	_	
150-2	30836-30837	,	_	
150-3	30838-30841	the	_	
150-4	30842-30849	circuit	_	
150-5	30850-30854	that	_	
150-6	30855-30864	maintains	_	
150-7	30865-30878	bidirectional	_	
150-8	30879-30888	influence	_	
150-9	30889-30891	of	_	
150-10	30892-30897	these	_	
150-11	30898-30909	subcortical	_	
150-12	30910-30923	neurochemical	_	
150-13	30924-30931	systems	_	
150-14	30932-30936	with	_	
150-15	30937-30945	cortical	_	
150-16	30946-30954	networks	_	
150-17	30955-30960	would	_	
150-18	30961-30963	be	_	
150-19	30964-30973	disrupted	_	
150-20	30973-30974	,	_	
150-21	30975-30981	unable	_	
150-22	30982-30984	to	_	
150-23	30985-30992	respond	_	
150-24	30993-30995	to	_	
150-25	30996-30997	a	_	
150-26	30998-31008	modulatory	_	
150-27	31009-31013	drug	_	
150-28	31014-31018	with	_	
150-29	31019-31032	pro-cognitive	_	
150-30	31033-31042	potential	_	
150-31	31043-31047	such	_	
150-32	31048-31050	as	_	
150-33	31051-31060	modafinil	_	
150-34	31060-31061	.	_	

#Text=This study is limited by a rather modest sample size, and that the antipsychotic medication treatment was naturalistic and not randomized nor blinded, unlike the single dose of modafinil.
151-1	31062-31066	This	_	
151-2	31067-31072	study	_	
151-3	31073-31075	is	_	
151-4	31076-31083	limited	_	
151-5	31084-31086	by	_	
151-6	31087-31088	a	_	
151-7	31089-31095	rather	_	
151-8	31096-31102	modest	_	
151-9	31103-31109	sample	_	
151-10	31110-31114	size	_	
151-11	31114-31115	,	_	
151-12	31116-31119	and	_	
151-13	31120-31124	that	_	
151-14	31125-31128	the	_	
151-15	31129-31142	antipsychotic	_	
151-16	31143-31153	medication	_	
151-17	31154-31163	treatment	_	
151-18	31164-31167	was	_	
151-19	31168-31180	naturalistic	_	
151-20	31181-31184	and	_	
151-21	31185-31188	not	_	
151-22	31189-31199	randomized	_	
151-23	31200-31203	nor	_	
151-24	31204-31211	blinded	_	
151-25	31211-31212	,	_	
151-26	31213-31219	unlike	_	
151-27	31220-31223	the	_	
151-28	31224-31230	single	_	
151-29	31231-31235	dose	_	
151-30	31236-31238	of	_	
151-31	31239-31248	modafinil	_	
151-32	31248-31249	.	_	

#Text=Nevertheless, the correlations of BOLD signal change in response to modafinil exhibited specificity in their relationships with monoamine receptor-mediated effects of antipsychotics, which were predicted based on the known neurochemical effects of both modafinil and antipsychotics, and were generally not attributable to overall illness severity as measured by psychotic symptoms nor proxied by other neurochemical effects of the antipsychotics.
152-1	31250-31262	Nevertheless	_	
152-2	31262-31263	,	_	
152-3	31264-31267	the	_	
152-4	31268-31280	correlations	_	
152-5	31281-31283	of	_	
152-6	31284-31288	BOLD	_	
152-7	31289-31295	signal	_	
152-8	31296-31302	change	_	
152-9	31303-31305	in	_	
152-10	31306-31314	response	_	
152-11	31315-31317	to	_	
152-12	31318-31327	modafinil	_	
152-13	31328-31337	exhibited	_	
152-14	31338-31349	specificity	_	
152-15	31350-31352	in	_	
152-16	31353-31358	their	_	
152-17	31359-31372	relationships	_	
152-18	31373-31377	with	_	
152-19	31378-31387	monoamine	_	
152-20	31388-31405	receptor-mediated	_	
152-21	31406-31413	effects	_	
152-22	31414-31416	of	_	
152-23	31417-31431	antipsychotics	_	
152-24	31431-31432	,	_	
152-25	31433-31438	which	_	
152-26	31439-31443	were	_	
152-27	31444-31453	predicted	_	
152-28	31454-31459	based	_	
152-29	31460-31462	on	_	
152-30	31463-31466	the	_	
152-31	31467-31472	known	_	
152-32	31473-31486	neurochemical	_	
152-33	31487-31494	effects	_	
152-34	31495-31497	of	_	
152-35	31498-31502	both	_	
152-36	31503-31512	modafinil	_	
152-37	31513-31516	and	_	
152-38	31517-31531	antipsychotics	_	
152-39	31531-31532	,	_	
152-40	31533-31536	and	_	
152-41	31537-31541	were	_	
152-42	31542-31551	generally	_	
152-43	31552-31555	not	_	
152-44	31556-31568	attributable	_	
152-45	31569-31571	to	_	
152-46	31572-31579	overall	_	
152-47	31580-31587	illness	_	
152-48	31588-31596	severity	_	
152-49	31597-31599	as	_	
152-50	31600-31608	measured	_	
152-51	31609-31611	by	_	
152-52	31612-31621	psychotic	_	
152-53	31622-31630	symptoms	_	
152-54	31631-31634	nor	_	
152-55	31635-31642	proxied	_	
152-56	31643-31645	by	_	
152-57	31646-31651	other	_	
152-58	31652-31665	neurochemical	_	
152-59	31666-31673	effects	_	
152-60	31674-31676	of	_	
152-61	31677-31680	the	_	
152-62	31681-31695	antipsychotics	_	
152-63	31695-31696	.	_	

#Text=In addition, many of these subjects were concurrently prescribed other psychotropic agents (and in a few cases, non-psychiatric medications, for other medical conditions).
153-1	31697-31699	In	_	
153-2	31700-31708	addition	_	
153-3	31708-31709	,	_	
153-4	31710-31714	many	_	
153-5	31715-31717	of	_	
153-6	31718-31723	these	_	
153-7	31724-31732	subjects	_	
153-8	31733-31737	were	_	
153-9	31738-31750	concurrently	_	
153-10	31751-31761	prescribed	_	
153-11	31762-31767	other	_	
153-12	31768-31780	psychotropic	_	
153-13	31781-31787	agents	_	
153-14	31788-31789	(	_	
153-15	31789-31792	and	_	
153-16	31793-31795	in	_	
153-17	31796-31797	a	_	
153-18	31798-31801	few	_	
153-19	31802-31807	cases	_	
153-20	31807-31808	,	_	
153-21	31809-31824	non-psychiatric	_	
153-22	31825-31836	medications	_	
153-23	31836-31837	,	_	
153-24	31838-31841	for	_	
153-25	31842-31847	other	_	
153-26	31848-31855	medical	_	
153-27	31856-31866	conditions	_	
153-28	31866-31867	)	_	
153-29	31867-31868	.	_	

#Text=It remains unclear if these other medications may have contributed to the altered neural responses to modafinil observed here.
154-1	31869-31871	It	_	
154-2	31872-31879	remains	_	
154-3	31880-31887	unclear	_	
154-4	31888-31890	if	_	
154-5	31891-31896	these	_	
154-6	31897-31902	other	_	
154-7	31903-31914	medications	_	
154-8	31915-31918	may	_	
154-9	31919-31923	have	_	
154-10	31924-31935	contributed	_	
154-11	31936-31938	to	_	
154-12	31939-31942	the	_	
154-13	31943-31950	altered	_	
154-14	31951-31957	neural	_	
154-15	31958-31967	responses	_	
154-16	31968-31970	to	_	
154-17	31971-31980	modafinil	_	
154-18	31981-31989	observed	_	
154-19	31990-31994	here	_	
154-20	31994-31995	.	_	

#Text=Nonetheless, the pattern of observed effects fit very well the predicted pattern based on the actions of antipsychotic drugs on these systems, and how they would be expected to interact with modafinil.
155-1	31996-32007	Nonetheless	_	
155-2	32007-32008	,	_	
155-3	32009-32012	the	_	
155-4	32013-32020	pattern	_	
155-5	32021-32023	of	_	
155-6	32024-32032	observed	_	
155-7	32033-32040	effects	_	
155-8	32041-32044	fit	_	
155-9	32045-32049	very	_	
155-10	32050-32054	well	_	
155-11	32055-32058	the	_	
155-12	32059-32068	predicted	_	
155-13	32069-32076	pattern	_	
155-14	32077-32082	based	_	
155-15	32083-32085	on	_	
155-16	32086-32089	the	_	
155-17	32090-32097	actions	_	
155-18	32098-32100	of	_	
155-19	32101-32114	antipsychotic	_	
155-20	32115-32120	drugs	_	
155-21	32121-32123	on	_	
155-22	32124-32129	these	_	
155-23	32130-32137	systems	_	
155-24	32137-32138	,	_	
155-25	32139-32142	and	_	
155-26	32143-32146	how	_	
155-27	32147-32151	they	_	
155-28	32152-32157	would	_	
155-29	32158-32160	be	_	
155-30	32161-32169	expected	_	
155-31	32170-32172	to	_	
155-32	32173-32181	interact	_	
155-33	32182-32186	with	_	
155-34	32187-32196	modafinil	_	
155-35	32196-32197	.	_	

#Text=In addition, the supplemental medications are reasonably-representative of the adjunctive treatments that are routinely used with schizophrenia outpatients, suggesting that the observed altered brain responses are likely representative of those that may be found among schizophrenia patients more generally.
156-1	32198-32200	In	_	
156-2	32201-32209	addition	_	
156-3	32209-32210	,	_	
156-4	32211-32214	the	_	
156-5	32215-32227	supplemental	_	
156-6	32228-32239	medications	_	
156-7	32240-32243	are	_	
156-8	32244-32269	reasonably-representative	_	
156-9	32270-32272	of	_	
156-10	32273-32276	the	_	
156-11	32277-32287	adjunctive	_	
156-12	32288-32298	treatments	_	
156-13	32299-32303	that	_	
156-14	32304-32307	are	_	
156-15	32308-32317	routinely	_	
156-16	32318-32322	used	_	
156-17	32323-32327	with	_	
156-18	32328-32341	schizophrenia	_	
156-19	32342-32353	outpatients	_	
156-20	32353-32354	,	_	
156-21	32355-32365	suggesting	_	
156-22	32366-32370	that	_	
156-23	32371-32374	the	_	
156-24	32375-32383	observed	_	
156-25	32384-32391	altered	_	
156-26	32392-32397	brain	_	
156-27	32398-32407	responses	_	
156-28	32408-32411	are	_	
156-29	32412-32418	likely	_	
156-30	32419-32433	representative	_	
156-31	32434-32436	of	_	
156-32	32437-32442	those	_	
156-33	32443-32447	that	_	
156-34	32448-32451	may	_	
156-35	32452-32454	be	_	
156-36	32455-32460	found	_	
156-37	32461-32466	among	_	
156-38	32467-32480	schizophrenia	_	
156-39	32481-32489	patients	_	
156-40	32490-32494	more	_	
156-41	32495-32504	generally	_	
156-42	32504-32505	.	_	

#Text=In addition, the patient sample was quite characteristic of outpatient, community-dwelling populations with schizophrenia, in terms of demographics, symptomatology and functional status.
157-1	32506-32508	In	_	
157-2	32509-32517	addition	_	
157-3	32517-32518	,	_	
157-4	32519-32522	the	_	
157-5	32523-32530	patient	_	
157-6	32531-32537	sample	_	
157-7	32538-32541	was	_	
157-8	32542-32547	quite	_	
157-9	32548-32562	characteristic	_	
157-10	32563-32565	of	_	
157-11	32566-32576	outpatient	_	
157-12	32576-32577	,	_	
157-13	32578-32596	community-dwelling	_	
157-14	32597-32608	populations	_	
157-15	32609-32613	with	_	
157-16	32614-32627	schizophrenia	_	
157-17	32627-32628	,	_	
157-18	32629-32631	in	_	
157-19	32632-32637	terms	_	
157-20	32638-32640	of	_	
157-21	32641-32653	demographics	_	
157-22	32653-32654	,	_	
157-23	32655-32669	symptomatology	_	
157-24	32670-32673	and	_	
157-25	32674-32684	functional	_	
157-26	32685-32691	status	_	
157-27	32691-32692	.	_	

#Text=These observations suggest that the present findings may have general relevance for the future clinical management of outpatients with schizophrenia, and the potential challenge of resolving treatment for psychotic symptoms that are the clinical hallmark of the disorder, with the cognitive impairment, which is not a defining feature of schizophrenia yet remains a major determinant of functional outcome.
158-1	32693-32698	These	_	
158-2	32699-32711	observations	_	
158-3	32712-32719	suggest	_	
158-4	32720-32724	that	_	
158-5	32725-32728	the	_	
158-6	32729-32736	present	_	
158-7	32737-32745	findings	_	
158-8	32746-32749	may	_	
158-9	32750-32754	have	_	
158-10	32755-32762	general	_	
158-11	32763-32772	relevance	_	
158-12	32773-32776	for	_	
158-13	32777-32780	the	_	
158-14	32781-32787	future	_	
158-15	32788-32796	clinical	_	
158-16	32797-32807	management	_	
158-17	32808-32810	of	_	
158-18	32811-32822	outpatients	_	
158-19	32823-32827	with	_	
158-20	32828-32841	schizophrenia	_	
158-21	32841-32842	,	_	
158-22	32843-32846	and	_	
158-23	32847-32850	the	_	
158-24	32851-32860	potential	_	
158-25	32861-32870	challenge	_	
158-26	32871-32873	of	_	
158-27	32874-32883	resolving	_	
158-28	32884-32893	treatment	_	
158-29	32894-32897	for	_	
158-30	32898-32907	psychotic	_	
158-31	32908-32916	symptoms	_	
158-32	32917-32921	that	_	
158-33	32922-32925	are	_	
158-34	32926-32929	the	_	
158-35	32930-32938	clinical	_	
158-36	32939-32947	hallmark	_	
158-37	32948-32950	of	_	
158-38	32951-32954	the	_	
158-39	32955-32963	disorder	_	
158-40	32963-32964	,	_	
158-41	32965-32969	with	_	
158-42	32970-32973	the	_	
158-43	32974-32983	cognitive	_	
158-44	32984-32994	impairment	_	
158-45	32994-32995	,	_	
158-46	32996-33001	which	_	
158-47	33002-33004	is	_	
158-48	33005-33008	not	_	
158-49	33009-33010	a	_	
158-50	33011-33019	defining	_	
158-51	33020-33027	feature	_	
158-52	33028-33030	of	_	
158-53	33031-33044	schizophrenia	_	
158-54	33045-33048	yet	_	
158-55	33049-33056	remains	_	
158-56	33057-33058	a	_	
158-57	33059-33064	major	_	
158-58	33065-33076	determinant	_	
158-59	33077-33079	of	_	
158-60	33080-33090	functional	_	
158-61	33091-33098	outcome	_	
158-62	33098-33099	.	_	

#Text=It is very important to emphasize that in no way do these considerations suggest that modern antipsychotic medications be abandoned or that their use be curtailed.
159-1	33100-33102	It	_	
159-2	33103-33105	is	_	
159-3	33106-33110	very	_	
159-4	33111-33120	important	_	
159-5	33121-33123	to	_	
159-6	33124-33133	emphasize	_	
159-7	33134-33138	that	_	
159-8	33139-33141	in	_	
159-9	33142-33144	no	_	
159-10	33145-33148	way	_	
159-11	33149-33151	do	_	
159-12	33152-33157	these	_	
159-13	33158-33172	considerations	_	
159-14	33173-33180	suggest	_	
159-15	33181-33185	that	_	
159-16	33186-33192	modern	_	
159-17	33193-33206	antipsychotic	_	
159-18	33207-33218	medications	_	
159-19	33219-33221	be	_	
159-20	33222-33231	abandoned	_	
159-21	33232-33234	or	_	
159-22	33235-33239	that	_	
159-23	33240-33245	their	_	
159-24	33246-33249	use	_	
159-25	33250-33252	be	_	
159-26	33253-33262	curtailed	_	
159-27	33262-33263	.	_	

#Text=These medications are the mainstay of treatment of all psychotic disorders, and remain the most important advance in the history of schizophrenia treatment.
160-1	33264-33269	These	_	
160-2	33270-33281	medications	_	
160-3	33282-33285	are	_	
160-4	33286-33289	the	_	
160-5	33290-33298	mainstay	_	
160-6	33299-33301	of	_	
160-7	33302-33311	treatment	_	
160-8	33312-33314	of	_	
160-9	33315-33318	all	_	
160-10	33319-33328	psychotic	_	
160-11	33329-33338	disorders	_	
160-12	33338-33339	,	_	
160-13	33340-33343	and	_	
160-14	33344-33350	remain	_	
160-15	33351-33354	the	_	
160-16	33355-33359	most	_	
160-17	33360-33369	important	_	
160-18	33370-33377	advance	_	
160-19	33378-33380	in	_	
160-20	33381-33384	the	_	
160-21	33385-33392	history	_	
160-22	33393-33395	of	_	
160-23	33396-33409	schizophrenia	_	
160-24	33410-33419	treatment	_	
160-25	33419-33420	.	_	

#Text=It is nonetheless interesting to consider how an antipsychotic agent with relatively less catecholamine antagonist activity may mitigate these problems and serve as a better alternative, in combination with novel pro-cognitive agents, to facilitate the development of new treatments for cognition in this illness.
161-1	33421-33423	It	_	
161-2	33424-33426	is	_	
161-3	33427-33438	nonetheless	_	
161-4	33439-33450	interesting	_	
161-5	33451-33453	to	_	
161-6	33454-33462	consider	_	
161-7	33463-33466	how	_	
161-8	33467-33469	an	_	
161-9	33470-33483	antipsychotic	_	
161-10	33484-33489	agent	_	
161-11	33490-33494	with	_	
161-12	33495-33505	relatively	_	
161-13	33506-33510	less	_	
161-14	33511-33524	catecholamine	_	
161-15	33525-33535	antagonist	_	
161-16	33536-33544	activity	_	
161-17	33545-33548	may	_	
161-18	33549-33557	mitigate	_	
161-19	33558-33563	these	_	
161-20	33564-33572	problems	_	
161-21	33573-33576	and	_	
161-22	33577-33582	serve	_	
161-23	33583-33585	as	_	
161-24	33586-33587	a	_	
161-25	33588-33594	better	_	
161-26	33595-33606	alternative	_	
161-27	33606-33607	,	_	
161-28	33608-33610	in	_	
161-29	33611-33622	combination	_	
161-30	33623-33627	with	_	
161-31	33628-33633	novel	_	
161-32	33634-33647	pro-cognitive	_	
161-33	33648-33654	agents	_	
161-34	33654-33655	,	_	
161-35	33656-33658	to	_	
161-36	33659-33669	facilitate	_	
161-37	33670-33673	the	_	
161-38	33674-33685	development	_	
161-39	33686-33688	of	_	
161-40	33689-33692	new	_	
161-41	33693-33703	treatments	_	
161-42	33704-33707	for	_	
161-43	33708-33717	cognition	_	
161-44	33718-33720	in	_	
161-45	33721-33725	this	_	
161-46	33726-33733	illness	_	
161-47	33733-33734	.	_	

#Text=Electronic supplementary material
#Text=Electronic supplementary material
#Text=Supplementary Information accompanies this paper at 10.1038/s41398-018-0104-z.
162-1	33735-33745	Electronic	_	
162-2	33746-33759	supplementary	_	
162-3	33760-33768	material	_	
162-4	33769-33779	Electronic	_	
162-5	33780-33793	supplementary	_	
162-6	33794-33802	material	_	
162-7	33803-33816	Supplementary	_	
162-8	33817-33828	Information	_	
162-9	33829-33840	accompanies	_	
162-10	33841-33845	this	_	
162-11	33846-33851	paper	_	
162-12	33852-33854	at	_	
162-13	33855-33862	10.1038	_	
162-14	33862-33863	/	_	
162-15	33863-33869	s41398	_	
162-16	33869-33870	-	_	
162-17	33870-33873	018	_	
162-18	33873-33874	-	_	
162-19	33874-33878	0104	_	
162-20	33878-33879	-	_	
162-21	33879-33880	z	_	
162-22	33880-33881	.	_	

#Text=Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
163-1	33882-33893	Publisher's	_	
163-2	33894-33898	note	_	
163-3	33898-33899	:	_	
163-4	33900-33908	Springer	_	
163-5	33909-33915	Nature	_	
163-6	33916-33923	remains	_	
163-7	33924-33931	neutral	_	
163-8	33932-33936	with	_	
163-9	33937-33943	regard	_	
163-10	33944-33946	to	_	
163-11	33947-33961	jurisdictional	_	
163-12	33962-33968	claims	_	
163-13	33969-33971	in	_	
163-14	33972-33981	published	_	
163-15	33982-33986	maps	_	
163-16	33987-33990	and	_	
163-17	33991-34004	institutional	_	
163-18	34005-34017	affiliations	_	
163-19	34017-34018	.	_	

#Text=Conflict of interest
#Text=The authors declare that they have no conflict of interest.
164-1	34019-34027	Conflict	_	
164-2	34028-34030	of	_	
164-3	34031-34039	interest	_	
164-4	34040-34043	The	_	
164-5	34044-34051	authors	_	
164-6	34052-34059	declare	_	
164-7	34060-34064	that	_	
164-8	34065-34069	they	_	
164-9	34070-34074	have	_	
164-10	34075-34077	no	_	
164-11	34078-34086	conflict	_	
164-12	34087-34089	of	_	
164-13	34090-34098	interest	_	
164-14	34098-34099	.	_	

#Text=References
#Text=Cognition in schizophrenia: impairments, determinants, and functional importance
#Text=What are the functional consequences of neurocognitive deficits in schizophrenia?
165-1	34100-34110	References	_	
165-2	34111-34120	Cognition	_	
165-3	34121-34123	in	_	
165-4	34124-34137	schizophrenia	_	
165-5	34137-34138	:	_	
165-6	34139-34150	impairments	_	
165-7	34150-34151	,	_	
165-8	34152-34164	determinants	_	
165-9	34164-34165	,	_	
165-10	34166-34169	and	_	
165-11	34170-34180	functional	_	
165-12	34181-34191	importance	_	
165-13	34192-34196	What	_	
165-14	34197-34200	are	_	
165-15	34201-34204	the	_	
165-16	34205-34215	functional	_	
165-17	34216-34228	consequences	_	
165-18	34229-34231	of	_	
165-19	34232-34246	neurocognitive	_	
165-20	34247-34255	deficits	_	
165-21	34256-34258	in	_	
165-22	34259-34272	schizophrenia	_	
165-23	34272-34273	?	_	

#Text=Cognitive control deficits in schizophrenia: mechanisms and meaning
#Text=Genes, dopamine and cortical signal-to-noise ratio in schizophrenia
#Text=An integrative theory of locus coeruleus-norepinephrine function: adaptive gain and optimal performance
#Text=The dual-state theory of prefrontal cortex dopamine function with relevance to catechol-o-methyltransferase genotypes and schizophrenia
#Text=D(1) receptors in prefrontal cells and circuits
#Text=The regulation of forebrain dopamine transmission: relevance to the pathophysiology and psychopathology of schizophrenia
#Text=The neuropsychopharmacology of fronto-executive function: monoaminergic modulation
#Text=The ability of the mesocortical dopamine system to operate in distinct temporal modes
#Text=The influence of spike rate and stimulus duration on noradrenergic neurons
#Text=Molecular control of locus coeruleus neurotransmission
#Text=Modulation of cellular activity and synaptic transmission in the ventral tegmental area
#Text=Modafinil occupies dopamine and norepinephrine transporters in vivo and modulates the transporters and trace amine activity in vitro
#Text=Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications
#Text=Modafinil: a review of neurochemical actions and effects on cognition
#Text=Modafinil shifts human locus coeruleus to low-tonic, high-phasic activity during functional MRI
#Text=Modafinil improves cognition and attentional set shifting in patients with chronic schizophrenia
#Text=The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later?
166-1	34274-34283	Cognitive	_	
166-2	34284-34291	control	_	
166-3	34292-34300	deficits	_	
166-4	34301-34303	in	_	
166-5	34304-34317	schizophrenia	_	
166-6	34317-34318	:	_	
166-7	34319-34329	mechanisms	_	
166-8	34330-34333	and	_	
166-9	34334-34341	meaning	_	
166-10	34342-34347	Genes	_	
166-11	34347-34348	,	_	
166-12	34349-34357	dopamine	_	
166-13	34358-34361	and	_	
166-14	34362-34370	cortical	_	
166-15	34371-34386	signal-to-noise	_	
166-16	34387-34392	ratio	_	
166-17	34393-34395	in	_	
166-18	34396-34409	schizophrenia	_	
166-19	34410-34412	An	_	
166-20	34413-34424	integrative	_	
166-21	34425-34431	theory	_	
166-22	34432-34434	of	_	
166-23	34435-34440	locus	_	
166-24	34441-34465	coeruleus-norepinephrine	_	
166-25	34466-34474	function	_	
166-26	34474-34475	:	_	
166-27	34476-34484	adaptive	_	
166-28	34485-34489	gain	_	
166-29	34490-34493	and	_	
166-30	34494-34501	optimal	_	
166-31	34502-34513	performance	_	
166-32	34514-34517	The	_	
166-33	34518-34528	dual-state	_	
166-34	34529-34535	theory	_	
166-35	34536-34538	of	_	
166-36	34539-34549	prefrontal	_	
166-37	34550-34556	cortex	_	
166-38	34557-34565	dopamine	_	
166-39	34566-34574	function	_	
166-40	34575-34579	with	_	
166-41	34580-34589	relevance	_	
166-42	34590-34592	to	_	
166-43	34593-34621	catechol-o-methyltransferase	_	
166-44	34622-34631	genotypes	_	
166-45	34632-34635	and	_	
166-46	34636-34649	schizophrenia	_	
166-47	34650-34651	D	_	
166-48	34651-34652	(	_	
166-49	34652-34653	1	_	
166-50	34653-34654	)	_	
166-51	34655-34664	receptors	_	
166-52	34665-34667	in	_	
166-53	34668-34678	prefrontal	_	
166-54	34679-34684	cells	_	
166-55	34685-34688	and	_	
166-56	34689-34697	circuits	_	
166-57	34698-34701	The	_	
166-58	34702-34712	regulation	_	
166-59	34713-34715	of	_	
166-60	34716-34725	forebrain	_	
166-61	34726-34734	dopamine	_	
166-62	34735-34747	transmission	_	
166-63	34747-34748	:	_	
166-64	34749-34758	relevance	_	
166-65	34759-34761	to	_	
166-66	34762-34765	the	_	
166-67	34766-34781	pathophysiology	_	
166-68	34782-34785	and	_	
166-69	34786-34801	psychopathology	_	
166-70	34802-34804	of	_	
166-71	34805-34818	schizophrenia	_	
166-72	34819-34822	The	_	
166-73	34823-34846	neuropsychopharmacology	_	
166-74	34847-34849	of	_	
166-75	34850-34866	fronto-executive	_	
166-76	34867-34875	function	_	
166-77	34875-34876	:	_	
166-78	34877-34890	monoaminergic	_	
166-79	34891-34901	modulation	_	
166-80	34902-34905	The	_	
166-81	34906-34913	ability	_	
166-82	34914-34916	of	_	
166-83	34917-34920	the	_	
166-84	34921-34933	mesocortical	_	
166-85	34934-34942	dopamine	_	
166-86	34943-34949	system	_	
166-87	34950-34952	to	_	
166-88	34953-34960	operate	_	
166-89	34961-34963	in	_	
166-90	34964-34972	distinct	_	
166-91	34973-34981	temporal	_	
166-92	34982-34987	modes	_	
166-93	34988-34991	The	_	
166-94	34992-35001	influence	_	
166-95	35002-35004	of	_	
166-96	35005-35010	spike	_	
166-97	35011-35015	rate	_	
166-98	35016-35019	and	_	
166-99	35020-35028	stimulus	_	
166-100	35029-35037	duration	_	
166-101	35038-35040	on	_	
166-102	35041-35054	noradrenergic	_	
166-103	35055-35062	neurons	_	
166-104	35063-35072	Molecular	_	
166-105	35073-35080	control	_	
166-106	35081-35083	of	_	
166-107	35084-35089	locus	_	
166-108	35090-35099	coeruleus	_	
166-109	35100-35117	neurotransmission	_	
166-110	35118-35128	Modulation	_	
166-111	35129-35131	of	_	
166-112	35132-35140	cellular	_	
166-113	35141-35149	activity	_	
166-114	35150-35153	and	_	
166-115	35154-35162	synaptic	_	
166-116	35163-35175	transmission	_	
166-117	35176-35178	in	_	
166-118	35179-35182	the	_	
166-119	35183-35190	ventral	_	
166-120	35191-35200	tegmental	_	
166-121	35201-35205	area	_	
166-122	35206-35215	Modafinil	_	
166-123	35216-35224	occupies	_	
166-124	35225-35233	dopamine	_	
166-125	35234-35237	and	_	
166-126	35238-35252	norepinephrine	_	
166-127	35253-35265	transporters	_	
166-128	35266-35268	in	_	
166-129	35269-35273	vivo	_	
166-130	35274-35277	and	_	
166-131	35278-35287	modulates	_	
166-132	35288-35291	the	_	
166-133	35292-35304	transporters	_	
166-134	35305-35308	and	_	
166-135	35309-35314	trace	_	
166-136	35315-35320	amine	_	
166-137	35321-35329	activity	_	
166-138	35330-35332	in	_	
166-139	35333-35338	vitro	_	
166-140	35339-35346	Effects	_	
166-141	35347-35349	of	_	
166-142	35350-35359	modafinil	_	
166-143	35360-35362	on	_	
166-144	35363-35371	dopamine	_	
166-145	35372-35375	and	_	
166-146	35376-35384	dopamine	_	
166-147	35385-35397	transporters	_	
166-148	35398-35400	in	_	
166-149	35401-35404	the	_	
166-150	35405-35409	male	_	
166-151	35410-35415	human	_	
166-152	35416-35421	brain	_	
166-153	35421-35422	:	_	
166-154	35423-35431	clinical	_	
166-155	35432-35444	implications	_	
166-156	35445-35454	Modafinil	_	
166-157	35454-35455	:	_	
166-158	35456-35457	a	_	
166-159	35458-35464	review	_	
166-160	35465-35467	of	_	
166-161	35468-35481	neurochemical	_	
166-162	35482-35489	actions	_	
166-163	35490-35493	and	_	
166-164	35494-35501	effects	_	
166-165	35502-35504	on	_	
166-166	35505-35514	cognition	_	
166-167	35515-35524	Modafinil	_	
166-168	35525-35531	shifts	_	
166-169	35532-35537	human	_	
166-170	35538-35543	locus	_	
166-171	35544-35553	coeruleus	_	
166-172	35554-35556	to	_	
166-173	35557-35566	low-tonic	_	
166-174	35566-35567	,	_	
166-175	35568-35579	high-phasic	_	
166-176	35580-35588	activity	_	
166-177	35589-35595	during	_	
166-178	35596-35606	functional	_	
166-179	35607-35610	MRI	_	
166-180	35611-35620	Modafinil	_	
166-181	35621-35629	improves	_	
166-182	35630-35639	cognition	_	
166-183	35640-35643	and	_	
166-184	35644-35655	attentional	_	
166-185	35656-35659	set	_	
166-186	35660-35668	shifting	_	
166-187	35669-35671	in	_	
166-188	35672-35680	patients	_	
166-189	35681-35685	with	_	
166-190	35686-35693	chronic	_	
166-191	35694-35707	schizophrenia	_	
166-192	35708-35711	The	_	
166-193	35712-35728	FDA-NIMH-MATRICS	_	
166-194	35729-35739	guidelines	_	
166-195	35740-35743	for	_	
166-196	35744-35752	clinical	_	
166-197	35753-35758	trial	_	
166-198	35759-35765	design	_	
166-199	35766-35768	of	_	
166-200	35769-35788	cognitive-enhancing	_	
166-201	35789-35794	drugs	_	
166-202	35794-35795	:	_	
166-203	35796-35800	what	_	
166-204	35801-35803	do	_	
166-205	35804-35806	we	_	
166-206	35807-35811	know	_	
166-207	35812-35813	5	_	
166-208	35814-35819	years	_	
166-209	35820-35825	later	_	
166-210	35825-35826	?	_	

#Text=A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia
#Text=The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments
#Text=Another view of therapy for cognition in schizophrenia
#Text=Initial phase 2 trial of a nicotinic agonist in schizophrenia
#Text=Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial
#Text=Dopamine-cell depolarization block as a model for the therapeutic actions of antipsychotic drugs
#Text=Olanzapine activates the rat locus coeruleus: in vivo electrophysiology and c-Fos immunoreactivity
#Text=Effects of chronic risperidone on central noradrenergic transmission
#Text=Locus coeruleus norepinephrine-containing neurons: effects produced by acute and subchronic treatment with antipsychotic drugs and amphetamine
#Text=Chronic coadministration of olanzapine and fluoxetine activates locus coeruleus neurons in rats: implications for bipolar disorder
#Text=Effects of short-term and chronic olanzapine treatment on immediate early gene protein and tyrosine hydroxylase immunoreactivity in the rat locus coeruleus and medial prefrontal cortex
#Text=Anatomical substrates for glutamate-dopamine interactions: evidence for specificity of connections and extrasynaptic actions
#Text=Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence
#Text=Modafinil modulates anterior cingulate function in chronic schizophrenia
#Text=Characterization of the electrophysiological properties of triple reuptake inhibitors on monoaminergic neurons
#Text=Psychosis pathways converge via D2high dopamine receptors
#Text=Neurobiology of dopamine in schizophrenia
#Text=Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia
#Text=Substantia nigra/ventral tegmental reward prediction error disruption in psychosis
#Text=Midbrain activation during Pavlovian conditioning and delusional symptoms in schizophrenia
#Text=The ultimate model organism: progress in experimental medicine
#Text=Relationship between locus coeruleus discharge rates and rates of norepinephrine release within neocortex as assessed by in vivo microdialysis
#Text=Enhanced norepinephrine release in prefrontal cortex with burst stimulation of the locus coeruleus
#Text=Catching up on schizophrenia: natural history and neurobiology
167-1	35827-35828	A	_	
167-2	35829-35839	randomized	_	
167-3	35840-35848	clinical	_	
167-4	35849-35854	trial	_	
167-5	35855-35857	of	_	
167-6	35858-35860	MK	_	
167-7	35860-35861	-	_	
167-8	35861-35865	0777	_	
167-9	35866-35869	for	_	
167-10	35870-35873	the	_	
167-11	35874-35883	treatment	_	
167-12	35884-35886	of	_	
167-13	35887-35896	cognitive	_	
167-14	35897-35908	impairments	_	
167-15	35909-35911	in	_	
167-16	35912-35918	people	_	
167-17	35919-35923	with	_	
167-18	35924-35937	schizophrenia	_	
167-19	35938-35941	The	_	
167-20	35942-35951	Cognitive	_	
167-21	35952-35955	and	_	
167-22	35956-35964	Negative	_	
167-23	35965-35973	Symptoms	_	
167-24	35974-35976	in	_	
167-25	35977-35990	Schizophrenia	_	
167-26	35991-35996	Trial	_	
167-27	35997-35998	(	_	
167-28	35998-36005	CONSIST	_	
167-29	36005-36006	)	_	
167-30	36006-36007	:	_	
167-31	36008-36011	the	_	
167-32	36012-36020	efficacy	_	
167-33	36021-36023	of	_	
167-34	36024-36037	glutamatergic	_	
167-35	36038-36044	agents	_	
167-36	36045-36048	for	_	
167-37	36049-36057	negative	_	
167-38	36058-36066	symptoms	_	
167-39	36067-36070	and	_	
167-40	36071-36080	cognitive	_	
167-41	36081-36092	impairments	_	
167-42	36093-36100	Another	_	
167-43	36101-36105	view	_	
167-44	36106-36108	of	_	
167-45	36109-36116	therapy	_	
167-46	36117-36120	for	_	
167-47	36121-36130	cognition	_	
167-48	36131-36133	in	_	
167-49	36134-36147	schizophrenia	_	
167-50	36148-36155	Initial	_	
167-51	36156-36161	phase	_	
167-52	36162-36163	2	_	
167-53	36164-36169	trial	_	
167-54	36170-36172	of	_	
167-55	36173-36174	a	_	
167-56	36175-36184	nicotinic	_	
167-57	36185-36192	agonist	_	
167-58	36193-36195	in	_	
167-59	36196-36209	schizophrenia	_	
167-60	36210-36224	Neurocognitive	_	
167-61	36225-36232	effects	_	
167-62	36233-36235	of	_	
167-63	36236-36249	antipsychotic	_	
167-64	36250-36261	medications	_	
167-65	36262-36264	in	_	
167-66	36265-36273	patients	_	
167-67	36274-36278	with	_	
167-68	36279-36286	chronic	_	
167-69	36287-36300	schizophrenia	_	
167-70	36301-36303	in	_	
167-71	36304-36307	the	_	
167-72	36308-36313	CATIE	_	
167-73	36314-36319	Trial	_	
167-74	36320-36333	Dopamine-cell	_	
167-75	36334-36348	depolarization	_	
167-76	36349-36354	block	_	
167-77	36355-36357	as	_	
167-78	36358-36359	a	_	
167-79	36360-36365	model	_	
167-80	36366-36369	for	_	
167-81	36370-36373	the	_	
167-82	36374-36385	therapeutic	_	
167-83	36386-36393	actions	_	
167-84	36394-36396	of	_	
167-85	36397-36410	antipsychotic	_	
167-86	36411-36416	drugs	_	
167-87	36417-36427	Olanzapine	_	
167-88	36428-36437	activates	_	
167-89	36438-36441	the	_	
167-90	36442-36445	rat	_	
167-91	36446-36451	locus	_	
167-92	36452-36461	coeruleus	_	
167-93	36461-36462	:	_	
167-94	36463-36465	in	_	
167-95	36466-36470	vivo	_	
167-96	36471-36488	electrophysiology	_	
167-97	36489-36492	and	_	
167-98	36493-36498	c-Fos	_	
167-99	36499-36515	immunoreactivity	_	
167-100	36516-36523	Effects	_	
167-101	36524-36526	of	_	
167-102	36527-36534	chronic	_	
167-103	36535-36546	risperidone	_	
167-104	36547-36549	on	_	
167-105	36550-36557	central	_	
167-106	36558-36571	noradrenergic	_	
167-107	36572-36584	transmission	_	
167-108	36585-36590	Locus	_	
167-109	36591-36600	coeruleus	_	
167-110	36601-36626	norepinephrine-containing	_	
167-111	36627-36634	neurons	_	
167-112	36634-36635	:	_	
167-113	36636-36643	effects	_	
167-114	36644-36652	produced	_	
167-115	36653-36655	by	_	
167-116	36656-36661	acute	_	
167-117	36662-36665	and	_	
167-118	36666-36676	subchronic	_	
167-119	36677-36686	treatment	_	
167-120	36687-36691	with	_	
167-121	36692-36705	antipsychotic	_	
167-122	36706-36711	drugs	_	
167-123	36712-36715	and	_	
167-124	36716-36727	amphetamine	_	
167-125	36728-36735	Chronic	_	
167-126	36736-36752	coadministration	_	
167-127	36753-36755	of	_	
167-128	36756-36766	olanzapine	_	
167-129	36767-36770	and	_	
167-130	36771-36781	fluoxetine	_	
167-131	36782-36791	activates	_	
167-132	36792-36797	locus	_	
167-133	36798-36807	coeruleus	_	
167-134	36808-36815	neurons	_	
167-135	36816-36818	in	_	
167-136	36819-36823	rats	_	
167-137	36823-36824	:	_	
167-138	36825-36837	implications	_	
167-139	36838-36841	for	_	
167-140	36842-36849	bipolar	_	
167-141	36850-36858	disorder	_	
167-142	36859-36866	Effects	_	
167-143	36867-36869	of	_	
167-144	36870-36880	short-term	_	
167-145	36881-36884	and	_	
167-146	36885-36892	chronic	_	
167-147	36893-36903	olanzapine	_	
167-148	36904-36913	treatment	_	
167-149	36914-36916	on	_	
167-150	36917-36926	immediate	_	
167-151	36927-36932	early	_	
167-152	36933-36937	gene	_	
167-153	36938-36945	protein	_	
167-154	36946-36949	and	_	
167-155	36950-36958	tyrosine	_	
167-156	36959-36970	hydroxylase	_	
167-157	36971-36987	immunoreactivity	_	
167-158	36988-36990	in	_	
167-159	36991-36994	the	_	
167-160	36995-36998	rat	_	
167-161	36999-37004	locus	_	
167-162	37005-37014	coeruleus	_	
167-163	37015-37018	and	_	
167-164	37019-37025	medial	_	
167-165	37026-37036	prefrontal	_	
167-166	37037-37043	cortex	_	
167-167	37044-37054	Anatomical	_	
167-168	37055-37065	substrates	_	
167-169	37066-37069	for	_	
167-170	37070-37088	glutamate-dopamine	_	
167-171	37089-37101	interactions	_	
167-172	37101-37102	:	_	
167-173	37103-37111	evidence	_	
167-174	37112-37115	for	_	
167-175	37116-37127	specificity	_	
167-176	37128-37130	of	_	
167-177	37131-37142	connections	_	
167-178	37143-37146	and	_	
167-179	37147-37160	extrasynaptic	_	
167-180	37161-37168	actions	_	
167-181	37169-37181	Interactions	_	
167-182	37182-37189	between	_	
167-183	37190-37200	monoamines	_	
167-184	37200-37201	,	_	
167-185	37202-37211	glutamate	_	
167-186	37211-37212	,	_	
167-187	37213-37216	and	_	
167-188	37217-37221	GABA	_	
167-189	37222-37224	in	_	
167-190	37225-37238	schizophrenia	_	
167-191	37238-37239	:	_	
167-192	37240-37243	new	_	
167-193	37244-37252	evidence	_	
167-194	37253-37262	Modafinil	_	
167-195	37263-37272	modulates	_	
167-196	37273-37281	anterior	_	
167-197	37282-37291	cingulate	_	
167-198	37292-37300	function	_	
167-199	37301-37303	in	_	
167-200	37304-37311	chronic	_	
167-201	37312-37325	schizophrenia	_	
167-202	37326-37342	Characterization	_	
167-203	37343-37345	of	_	
167-204	37346-37349	the	_	
167-205	37350-37370	electrophysiological	_	
167-206	37371-37381	properties	_	
167-207	37382-37384	of	_	
167-208	37385-37391	triple	_	
167-209	37392-37400	reuptake	_	
167-210	37401-37411	inhibitors	_	
167-211	37412-37414	on	_	
167-212	37415-37428	monoaminergic	_	
167-213	37429-37436	neurons	_	
167-214	37437-37446	Psychosis	_	
167-215	37447-37455	pathways	_	
167-216	37456-37464	converge	_	
167-217	37465-37468	via	_	
167-218	37469-37475	D2high	_	
167-219	37476-37484	dopamine	_	
167-220	37485-37494	receptors	_	
167-221	37495-37507	Neurobiology	_	
167-222	37508-37510	of	_	
167-223	37511-37519	dopamine	_	
167-224	37520-37522	in	_	
167-225	37523-37536	schizophrenia	_	
167-226	37537-37544	Reduced	_	
167-227	37545-37555	prefrontal	_	
167-228	37556-37564	activity	_	
167-229	37565-37573	predicts	_	
167-230	37574-37585	exaggerated	_	
167-231	37586-37594	striatal	_	
167-232	37595-37607	dopaminergic	_	
167-233	37608-37616	function	_	
167-234	37617-37619	in	_	
167-235	37620-37633	schizophrenia	_	
167-236	37634-37644	Substantia	_	
167-237	37645-37650	nigra	_	
167-238	37650-37651	/	_	
167-239	37651-37658	ventral	_	
167-240	37659-37668	tegmental	_	
167-241	37669-37675	reward	_	
167-242	37676-37686	prediction	_	
167-243	37687-37692	error	_	
167-244	37693-37703	disruption	_	
167-245	37704-37706	in	_	
167-246	37707-37716	psychosis	_	
167-247	37717-37725	Midbrain	_	
167-248	37726-37736	activation	_	
167-249	37737-37743	during	_	
167-250	37744-37753	Pavlovian	_	
167-251	37754-37766	conditioning	_	
167-252	37767-37770	and	_	
167-253	37771-37781	delusional	_	
167-254	37782-37790	symptoms	_	
167-255	37791-37793	in	_	
167-256	37794-37807	schizophrenia	_	
167-257	37808-37811	The	_	
167-258	37812-37820	ultimate	_	
167-259	37821-37826	model	_	
167-260	37827-37835	organism	_	
167-261	37835-37836	:	_	
167-262	37837-37845	progress	_	
167-263	37846-37848	in	_	
167-264	37849-37861	experimental	_	
167-265	37862-37870	medicine	_	
167-266	37871-37883	Relationship	_	
167-267	37884-37891	between	_	
167-268	37892-37897	locus	_	
167-269	37898-37907	coeruleus	_	
167-270	37908-37917	discharge	_	
167-271	37918-37923	rates	_	
167-272	37924-37927	and	_	
167-273	37928-37933	rates	_	
167-274	37934-37936	of	_	
167-275	37937-37951	norepinephrine	_	
167-276	37952-37959	release	_	
167-277	37960-37966	within	_	
167-278	37967-37976	neocortex	_	
167-279	37977-37979	as	_	
167-280	37980-37988	assessed	_	
167-281	37989-37991	by	_	
167-282	37992-37994	in	_	
167-283	37995-37999	vivo	_	
167-284	38000-38013	microdialysis	_	
167-285	38014-38022	Enhanced	_	
167-286	38023-38037	norepinephrine	_	
167-287	38038-38045	release	_	
167-288	38046-38048	in	_	
167-289	38049-38059	prefrontal	_	
167-290	38060-38066	cortex	_	
167-291	38067-38071	with	_	
167-292	38072-38077	burst	_	
167-293	38078-38089	stimulation	_	
167-294	38090-38092	of	_	
167-295	38093-38096	the	_	
167-296	38097-38102	locus	_	
167-297	38103-38112	coeruleus	_	
167-298	38113-38121	Catching	_	
167-299	38122-38124	up	_	
167-300	38125-38127	on	_	
167-301	38128-38141	schizophrenia	_	
167-302	38141-38142	:	_	
167-303	38143-38150	natural	_	
167-304	38151-38158	history	_	
167-305	38159-38162	and	_	
167-306	38163-38175	neurobiology	_	
